MedImmune Protocol Amendment 4 D9108C00001 (COAST)
Durvalumab and novel oncology therapies 27Jul2021 ; Final
CONFI DENTIAL AND PROPRIETARY 1of 105 Template 18.0A Phase 2, Open -label, Multicenter , Randomized, Multidrug 
Platform Study of Durvalumab Alone or in Combination with 
Novel Agents in Subjects with Locally Advanced, Unresectable, 
Stage III Non -small Cell Lung Cancer (COAST)
Sponsor Protocol Number: D9108C00001
Application Number: IND number 140603
EudraCT number 2018-002931 -35
Investigational Products: Durvalumab (MEDI4736) and novel onco logy 
therapi es (oleclumab [MEDI9447], monalizumab
[IPH2201])
Sponsor: MedImmune, LLC, a wholly owned subsidiary o f 
AstraZeneca PLC
One MedImmune Way
Gaithersburg, Maryland, 20878, USA
Medical Monitor:
 
Phone: 
E-mail: 
Contract Research Organization: ICON Clinical Research Ltd
Protocol History, Date : Original  Protocol , 03Oct2018
Protocol  Amendment 1, 19Nov2018
Protocol  Amendment 2, 07Jan2019
Protocol  Amendment 3, 27 Aug2019
Protocol  Amendment 4, 2 7Jul2021
This document contains trade secrets and commercial information that is privileged or 
confident ial and may not be disclosed without prior authorizat ion from MedImmune.
PPD
PPD
PPD
PPD
MedImmune Protocol Amendment 4 D9108C00001 (COAST)
Durvalumab and novel oncology therapies 27Jul2021 ; Final
CONFI DENTIAL AND PROPRIETARY 2of 105 Template 18.0PROTOCOL SYNOPSIS
TITLE
A Phase 2, Open -label, Multicenter, Randomized, Multidrug Platform Study of Durvalumab Alone or in 
Combination with Novel Agents in Subjects with Locally Advanced, Unresectable, Stage III Non -small Cell 
Lung Cancer (COAST)
HYPOTHESES
Durvalumab in combination with novel agents will demonstrate superior antitumor activity than durvalumab 
alone with an acceptable safety profile in subjects with Stage III non -small cell lung cancer (NSCLC) who have 
not progressed following definitive concurrent chemoradiotherapy (cCRT).
OBJECTIVES and ENDPOINTS
Type Objective Endpoint
Primary
Clinical activityTo compare the antitumor activity of durvalumab 
alone vs durvalumab in combination with novel 
agentsObjective response (OR) per 
Response Evaluation Criteria 
for Solid Tumors version 1.1 
(RECIST v1.1)
Secondary
SafetyTo evaluate the safety and tolerability of 
durvalumab alone and durvalumab in combination 
with novel agentsPresence of adverse events 
(AEs), serious adverse events 
(SAEs), and abnormal 
laborato ry parameters and 
vital signs
Clinical activityTo further compare the efficacy of durvalumab 
alone vs durvalumab in combination with novel 
agentsDuration of response (DoR), 
disease control (DC), 
progression -free survival 
(PFS) at 12 months, and PFS 
per RECIST v1.1 and overall 
survival (OS) 
Pharmacokinetics(a)To describe the pharmacokinetics (PK) of 
durvalumab alone and durvalumab in 
combinatio n with novel agents Concentration of durvalumab 
or novel agents in serum 
(b)To describe the PK of novel agents in 
combinatio n with durvalumab
Immunogenicity(a)To assess the immunogenicity of durvalumab 
alone o r in combination with novel agents Antidrug antibody (ADA) 
incidence of durvalumab or 
novel biologic agents(b)To assess the immunogenicity of novel 
biologic agents in combination with 
durvalumab
MedImmune Protocol Amendment 4 D9108C00001 (COAST)
Durvalumab and novel oncology therapies 27Jul2021 ; Final
CONFI DENTIAL AND PROPRIETARY 3of 105 Template 18.0Type Objective Endpoint
Exploratory
  
 
   
 
 
 
  
 
 
  
 
 
 
  
 
 
  
 
 
 
 
STUDY DESIGN
Study D9108C00001 (COAST) is a Phase 2, open -label, multicenter, randomized, multidrug platform study of 
durvalumab alone or in combination with novel agents. Subjects with unresectable, Stage III NSCLC who have 
not progressed following definitive cCRT are eligible. Subjects will be randomized into the study and initiate 
study treatment within 42 days from the last session of cCRT. Subjects may be treated for up to 12 months. 
Study treatment will be discontinued upon disease progression, unacceptable toxicity, or other reason, eg, 
subject decision or noncompliance with study procedures. Experimental arms may be closed based on results of 
planned interim analyses. New durvalumab combination experimental arms may be adde d based on emerging 
nonclinical and clinical data via protocol amendment. Initially, the study will examine the experimental arms 
comprising durvalumab plus oleclumab (experimental Arm A) and durvalumab plus monalizumab 
(experimental Arm B). Treatment arms may be opened sequentially or in parallel at the discretion of the 
sponsor.
TARGET SUBJECT POPULATION
Unresectable, Stage III NSCLC without progression following definitive cCRT
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
MedImmune Protocol Amendment 4 D9108C00001 (COAST)
Durvalumab and novel oncology therapies 27Jul2021 ; Final
CONFI DENTIAL AND PROPRIETARY 4of 105 Template 18.0TREATMENT GROUPS AND REGIMENS
Control arm (durvalumab monotherapy) : durval umab 1500 mg IV ever y 4weeks (Q4W) ×12 months
Experimental Arm A (durvalumab + oleclumab) : durvalumab IV 1500 mg Q4W ×12 months plus oleclumab 
3000 mg IV every 2 weeks (Q2W) for 2 months then Q4W starting on Cycle 3, Day 1 ×10 months
Experimental Arm B (durvalumab + monalizumab) : durvalumab 1500 mg IV Q4W ×12 months plus 
monalizumab 750 mg IV Q2W × 12months
STATISTICAL METHODS 
Sample size: Up to approximately 60 subjects per experimental treatment arm will be randomized with equal 
ratios to durvalum ab control and each of the open experimental arms. New durvalumab combination 
experimental arms may be added over time and therefore the total number of subjects randomized to the 
durvalumab control arm might be higher than 60 subjects.
Statistical analyse s:
Efficacy
The final efficacy analyses of antitumor activity will be based on the Intent -to-treat (ITT) Population (defined as 
all subjects are randomized). The rates of OR based on RECIST v1.1 will be summarized with 95% confidence 
interval based on the exact binomial distribution. Time -to-event endpoints (DoR, PFS, and OS) will be analyzed 
using the Kaplan -Meier method.
Safety
Safety data, including AEs, SAEs, laboratory evaluations, vital signs, and electrocardiogram results will be 
summarized based on the As -treated Population (defined as all subjects who receive any investigational product 
analy zed according to treatment received). Descriptive statistics will be provided for AEs, SAEs, AE grade 
(severity ), and relatio nship to study drug(s). AEs will b e graded according to the National Cancer Institute 
Common Terminology Criteria for Adverse Events version 5.0. Descriptive statistics will be provided for the 
clinical laboratory results and toxicities.
Pharmacokinetics and Immunogenicity
Only subjects wh o receive at least 1 dose of durvalumab and/or other combination study drug, and provide at 
least 1 post -treatment sample, will be evaluated. 
For each treatment arm, individual durvalumab concentrations will be tabulated with descriptive statistics. 
Addit ionally , for each experimental arm, individual novel agent concentrations will be tabulated with 
descriptive statistics. 
For each treatment arm, the immunogenic potential of durvalumab will be assessed by summarizing the number 
and percentage of subjects who develop detectable ADAs to durvalumab. For experimental arms that include a 
biologic agent, the immunogenic potential of the combination study drug will be assessed by summarizing the 
number and percentage of subjects who develop detectable ADAs to the combination study drug.
Interim analyses: Interim analyses will be done for early evaluation of the safety and clinical activity of the 
experimental arms compared to the control arm. The first interim analysis will be performed once the control 
arm has 30 ITT subjects who have reached the data cu toff criteria (defined as the opportunity to be followed for 
at least 16 weeks at the time of data cutoff). Bayesian predictive probabilities will be used to evaluate clinical 
activity . The disease control rate and objective response rate at Week 16 will b e used for decision -making. 
Enrollment will not be paused for interim analyses.
MedImmune Protocol Amendment 4 D9108C00001 (COAST)
Durvalumab and novel oncology therapies 27Jul2021 ; Final
CONFI DENTIAL AND PROPRIETARY 5of 105 Template 18.0TABLE OF  CONTENTS
PROTOCOL SYN OPSIS ...................................................................................................... 2
LIST OF ABBREVIATION S............................................................................................. 10
1 INTRODUCTION ............................................................................................ 13
1.1 Disease Background ......................................................................................... 13
1.1.1 Immunotherapy ................................................................................................. 13
1.1.1.1 Programmed Cell Death Ligand -1 (PD -L1)....................................................... 13
1.1.1.2 CD73 ................................................................................................................ 14
1.1.1.3 NKG2a ............................................................................................................. 14
1.2 Study  Drug Background.................................................................................... 15
1.2.1 Durvalumab ...................................................................................................... 15
1.2.2 Oleclumab ........................................................................................................ 15
1.2.3 Monalizumab .................................................................................................... 15
1.3 Summary  of Nonclinical Experience ................................................................. 15
1.3.1 Nonclinical Experience -Durvalumab ............................................................... 15
1.3.2 Nonclinical Experience -Oleclumab ................................................................. 15
1.3.3 Nonclinical Experience -Monalizumab ............................................................ 16
1.4 Summary  of Clinical Experience ....................................................................... 16
1.4.1 Clinical Experience -Durvalumab .................................................................... 16
1.4.2 Clinical Experience -Oleclumab Alo ne and in Combinat ion with Durval umab . 17
1.4.3 Clinical Experience -Monalizumab Alone and in Combinat ion with Durval -
umab................................................................................................................. 18
1.5 Rationale for Conducting the Study .................................................................. 18
1.5.1 Rationale for Inclusion of Durvalumab in Co mbination with Oleclumab Arm ...20
1.5.2 Rationale for Inclusio n of Durvalumab in Combination with Monalizumab 
Arm.................................................................................................................. 20
1.6 Benefit -risk and Ethical Assessment ................................................................. 20
1.6.1 Potenti al Benefi ts.............................................................................................. 20
1.6.2 Potenti al Risks .................................................................................................. 21
1.6.2.1 Durv alumab ...................................................................................................... 21
1.6.2.2 Oleclumab ........................................................................................................ 21
1.6.2.3 Monalizumab .................................................................................................... 22
1.6.3 Overall Benefit -Risk ......................................................................................... 23
1.7 Research Hypotheses ........................................................................................ 24
1.7.1 Prim ary Hypothesis .......................................................................................... 24
1.7.2 Secondary  Hypotheses ...................................................................................... 24
2 OBJECTIVES AND ENDPOINTS ................................................................... 24
2.1 Primary Object ive and Associated Endpoint ..................................................... 24
2.1.1 Secondary  Object ives and Associated Endpoints ............................................... 24
2.1.2 Exploratory  Objectives and Associated Endpoints ............................................ 25
3 STUDY DESIGN ............................................................................................. 26
3.1 Descript ion of the Study ................................................................................... 26
MedImmune Protocol Amendment 4 D9108C00001 (COAST)
Durvalumab and novel oncology therapies 27Jul2021 ; Final
CONFI DENTIAL AND PROPRIETARY 7of 105 Template 18.04.3.8 Estimate of Vo lume of Blood to be Collected ................................................... 49
4.4 Study  or Study  Com ponent Suspensio n or Termination ..................................... 49
4.5 Invest igational Product ..................................................................................... 50
4.5.1 Ident ity of Invest igational Product .................................................................... 50
4.5.1.1 Invest igational Product Handling ...................................................................... 51
4.5.1.2 Invest igational Product Inspect ion.................................................................... 52
4.5.1.3 Durvalumab Dose Preparation and Administration ............................................ 52
4.5.1.4 Oleclumab Dose Preparation and Administration .............................................. 53
4.5.1.5 Monalizumab Dose Preparation and Administration ......................................... 53
4.5.1.6 Treatment Administration ................................................................................. 54
4.5.1.7 Moni toring of Dose Administration .................................................................. 55
4.5.1.8 Reporting Product Complaints .......................................................................... 55
4.5.2 Addit ional Study  Medicat ions........................................................................... 55
4.5.3 Labeling ........................................................................................................... 55
4.5.4 Storage ............................................................................................................. 55
4.5.5 Treatment Comp liance ...................................................................................... 56
4.5.6 Accountabilit y.................................................................................................. 56
4.6 Treatment Assignment and Blinding ................................................................. 56
4.6.1 Methods for Assigning Treatment Groups ......................................................... 56
4.6.2 Methods to Ensure Blinding .............................................................................. 57
4.7 Restrictions During the Study  and Conco mitant Treatm ent(s) ........................... 57
4.7.1 Permi tted Concomitant Medicati ons ................................................................. 57
4.7.2 Prohibited Conco mitant Medi cations................................................................ 57
4.8 Statistical Evaluat ion........................................................................................ 58
4.8.1 General Considerations ..................................................................................... 58
4.8.2 Sample Si ze...................................................................................................... 58
4.8.3 Efficacy ............................................................................................................ 59
4.8.3.1 Primary Efficacy  Analysis ................................................................................ 60
4.8.3.2 Secondary  Efficacy  Analyses ............................................................................ 60
4.8.3.3 Exploratory  Analyses ........................................................................................ 60
4.8.4 Safety............................................................................................................... 61
4.8.4.1 Analysis of Adverse Events .............................................................................. 61
4.8.4.2 Analysis of Clinical Laboratory  Parameters ...................................................... 61
4.8.4.3 Analysis of Vital Signs ..................................................................................... 61
4.8.4.4 Analysis of ECOG Performance Status ............................................................. 61
4.8.5 Analysis of Immunogenicit y/Pharmacokinet ics................................................. 61
4.8.6 Analyses of Bio markers .................................................................................... 62
4.8.7 Interim Analysis ............................................................................................... 62
5 ASSESSMENT OF SAFETY ........................................................................... 63
5.1 Definit ion of Adverse Events ............................................................................ 63
5.2 Definit ion of Serious Adverse Events ............................................................... 64
5.3 Definit ion of Adverse Events of Special Interest ............................................... 64
5.3.1 Adverse Events of Special Interest for Durvalumab -containing Regimens ........ 64
5.3.2 Adverse Events of Special Interest Associated with Oleclumab ........................ 66
MedImmune Protocol Amendment 4 D9108C00001 (COAST)
Durvalumab and novel oncology therapies 27Jul2021 ; Final
CONFI DENTIAL AND PROPRIETARY 8of 105 Template 18.05.3.3 Adverse Events of Special Interest Associated with Monalizumab .................... 66
5.4 Recording of Adverse E vents ............................................................................ 66
5.4.1 Time Period for Collect ion of Adverse Events .................................................. 67
5.4.2 Follow-up of  Unreso lved Adverse Events ......................................................... 67
5.4.3 Deaths .............................................................................................................. 67
5.4.4 Adverse Events Based on Signs and Symptoms ................................................ 67
5.4.5 Adverse Events Based on Examinat ion and Tests .............................................. 67
5.4.6 Potenti al Hy’s Law and Hy’s Law ..................................................................... 68
5.4.7 Disease Progressi on.......................................................................................... 68
5.5 Reporting of Serious Adverse Events ................................................................ 69
5.6 Other Events Requiring Immediate Reporting ................................................... 69
5.6.1 Overdose………. .............................................................................................. 69
5.6.2 Pregnancy ......................................................................................................... 70
5.6.2.1 Maternal Exposure ............................................................................................ 70
5.6.2.2 Paternal  Exposure ............................................................................................. 70
5.6.3 Medicat ion Error ............................................................................................... 71
6 STUDY AN D DATA MANAGEMENT ........................................................... 72
6.1 Training of Study  Site Personnel ....................................................................... 72
6.2 Moni toring of the Study .................................................................................... 72
6.2.1 Source Data ...................................................................................................... 73
6.2.2 Study  Agreements ............................................................................................. 73
6.2.3 Archiving of Study  Docum ents......................................................................... 73
6.3 Study  Timetable and End of Study .................................................................... 73
6.4 Data Management ............................................................................................. 73
6.5 Medi cal Moni tor C overage ............................................................................... 74
7 ETHICAL AND REGULATO RY REQUIREMENTS ...................................... 74
7.1 Subject Data Protection ..................................................................................... 74
7.2 Ethics and Regulatory  Review .......................................................................... 74
7.3 Inform ed Consent ............................................................................................. 75
7.4 Changes to the Protocol and Informed Consent Form ........................................ 76
7.5 Audits and Inspect ions...................................................................................... 76
8 REFERENCES ................................................................................................. 77
9 CHANGES TO THE PROTOCOL ................................................................... 83
9.1 Protocol  Amendment 3 ..................................................................................... 83
9.2 Protocol  Amendment 2 ..................................................................................... 85
9.3 Protocol  Amendment 1 ..................................................................................... 85
MedImmune Protocol Amendment 4 D9108C00001 (COAST)
Durvalumab and novel oncology therapies 27Jul2021 ; Final
CONFI DENTIAL AND PROPRIETARY 9of 105 Template 18.0LIST OF TABLES
Table 1 Primary Object ive and Associated Endpoint ............................................ 24
Table 2 Secondary  Object ives and Associated Endpoints ...................................... 24
Table 3 Exploratory  Objectives and Associated Endpoints ................................... 25
Table 4 Criteria for Adequate Organ and Marrow Function .................................. 32
Table 5 Schedule of Screening and Treatment Period Procedures ......................... 37
Table 6 Schedule of Fo llow-up Procedures: Subj ects Who Com pleted Study  
Treatment and Maintain DC, Subjects Who Discontinued Study  Treat-
ment Due to Other Reason Not Related to PD, and Subjects Who Experi-
enced Unconfirmed PD and are Eligible for a Confirmation Scan ............ 40
Table 7 Schedule of Procedures for End of Study  Visi t......................................... 42
Table 8 Ident ification of Invest igational Product .................................................. 50
Table 9 Estimated Differences in ORR Between Experimental and Control Arm 
of 60Subjects Each ................................................................................. 59
Table 10 Criteria of No-Go Decisio ns Based on DCR at 16 Weeks ........................ 63
Table A1 Highly Effective Methods of Contraception ............................................. 88
Table F1 Evaluat ion of Overall Response Using RECIST v1.1 ............................. 103
............................ 104
LIST OF FIGURES
Figure 1 Study  Flow Diagram ................................................................................ 27
Figure 2 Treatment Regimen for Control  Arm  -Durvalumab Monotherapy ........... 27
Figure 3 Treatment Regimen for Arm A -Durvalumab Plus Oleclumab ................ 28
Figure 4 Treatment Regimen for Arm B –Durvalumab Plus Monalizumab ........... 28
LIST OF APPENDICES
Appendix A Contraception Guidance ........................................................................... 87
Appendix B Addit ional Safet y Guidance ..................................................................... 89
Appendix C National Inst itute of Allergy and Infectious Diseases and Food Allergy 
and Anaphylaxis Network Guidance for Anaphylaxis Diagnosis .............. 92
Appendix D Actions Required in Cases of Increases in Liver Biochemistry  and Eval-
uation of  Hy’s Law .................................................................................. 93
Appendix E Genet ic Research ..................................................................................... 98
Appendix F Response Eval uation Cri teria in Solid Tumors Version 1.1 .................... 101
......................... 104
CCI
CCI
CCI
MedImmune Protocol Amendment 4 D9108C00001 (COAST)
Durvalumab and novel oncology therapies 27Jul2021 ; Final
CONFI DENTIAL AND PROPRIETARY 10of 105 Template 18.0LIST OF ABBREVIATION S
Abbreviation or 
Specialized TermDefinition
ADA antidrug antibody
AE adverse event
AESI adverse event of special interest
ALP alkaline phosphatase
ALT alanine aminotransferase
AMP adenosine monophosphate
AST aspartate aminotransferase
ATP adenosine triphosphate
BOR best overall response
CD cluster of differentiation
CI confidence interval
COAST Study D9108C00001
CR complete response
cCRT concurrent chemoradiotherapy
CSR clinical study report
CT computed tomography
CTLA -4 cytotoxic T -lymphocy te-associated antigen -4
DC disease control
DCO data cutoff
DCR disease control rate
DLT dose-limiting toxicity
DoR duration of response
ECG electrocardiogram
ECOG Eastern Cooperative Oncology Group
eCRF electronic case report form
EDC electronic data capture
EOI end of infusion
GCP Good Clinical Practice
HBc hepatitis B core
HBsAg hepatitis B surface antigen
HBV hepatitis B virus
HCV hepatitis C virus
MedImmune Protocol Amendment 4 D9108C00001 (COAST)
Durvalumab and novel oncology therapies 27Jul2021 ; Final
CONFI DENTIAL AND PROPRIETARY 11of 105 Template 18.0Abbreviation or 
Specialized TermDefinition
HIV human immunodeficiency virus
HLA -E major histocompatibility complex E
HR hazard ratio
IB Investigator’s Brochure
ICH International Council for Harmonisation
IEC Independent Ethics Committee
Ig immunoglobulin
imAE immune-mediated adverse event
IRB Institutio nal Review Board
IRR infusion -related reaction
ITT Intent -to-treat
IV intravenous
IXRS interactive voice/web response system
mAb monoclonal antibody
MRI magnetic resonance imaging
NCI CTCAE v5.0Natio nal Cancer Institute Common Terminology Criteria for Adverse Events 
version 5.0
NK natural killer
NSCLC non-small cell lung cancer
OR objective response
ORR objective response rate
OS overall survival
PACIFIC Study D4191C00001 ([STUDY_ID_REMOVED])
PD progressive disease
PD-1 programmed cell death -1
PD-L1 programmed cell death ligand -1
PD-L2 programmed cell death ligand -2
PET positron emission tomography
PFS progression -free survival
PFS-12 progression -free survival 12 -month landmark rate
PI Package Insert
PK pharmacokinetic(s)
PP predictive probability(ies)
CCI
CCI
MedImmune Protocol Amendment 4 D9108C00001 (COAST)
Durvalumab and novel oncology therapies 27Jul2021 ; Final
CONFI DENTIAL AND PROPRIETARY 12of 105 Template 18.0Abbreviation or 
Specialized TermDefinition
PR partial response
Q2W every 2 weeks
Q4W every 4 weeks
RECIST v1.1 Response Evaluation Criteria for Solid Tumors version 1.1
SAE serious adverse event
SD stable disease
SID subject identification
SRC Safety Review Committee
SUV standardized uptake value(s)
T3 triiodothyronine
T4 thyroxine
TBL total bilirubin
TSH thyroid stimulating ho rmone
TV target value
ULN upper limit of normal
US United States
w/v weight per volume
MedImmune Protocol Amendment 4 D9108C00001 (COAST)
Durvalumab and novel oncology therapies 27Jul2021 ; Final
CONFI DENTIAL AND PROPRIETARY 13of 105 Template 18.01 INTRODUCTION
Study  D9108C00001 (COAST) is a plat form study dynamically  assessing the efficacy and 
safet y of durvalumab alone vs durvalumab in co mbinat ion with novel agents in subjects with 
locally advanced, unresectable, Stage III non -small cell  lung cancer (NSCLC). Combinat ion 
treatm ent arm s will  be added via protocol amendment during the course of the study  as novel  
agents of interest become available.
1.1 Disease Background
Lung cancer is the most commo n and l ethal cancer worldwide wit h an estimated 1.8 millio n 
new cases annually result ing in approximately 1.6 millio n deaths ( Torre et al, 2015 ). NSCLC 
represents approximately 85% of all lung cancers and 30% of patients present with Stage III 
disease at diagnosi s (American Cancer Societ y, 2018 ). For pati ents wi th Stage III NSCLC not 
amenable for surgi cal resect ion, the standard treatment is plat inum -based doublet chemother-
apy given concomitant ly wit h radi otherapy  followed by  durv alumab conso lidation. When ad-
ministered after complet ion of concurrent chemoradiotherapy  (cCRT) in pat ients with unre-
sectable NSCLC, durvalumab demo nstrated a better clinical response than placebo, with pro-
longed progression- free survival (PFS; hazard rati o [HR]: 0.51; 95% confidence interval [CI]: 
0.41, 0.63) and overall survival (OS; HR: 0.68; 99.73% CI: 0.47, 0.997, p =0.0025; PACIFIC 
[Study  D4191C00001]; Antoni a et al , 2018 ; Antonia et al, 2017 ). Durval umab showed a me-
dian PFS of 17.2 months compared to 5.6 months in the pl acebo group. However, d espite 
chemoradiotherapy  and durvalumab conso lidation most patients will relapse and eventually 
die from lung cancer. 
1.1.1 Immunotherapy
1.1.1.1 Programmed Cell Death Ligand -1 (PD -L1)
Programmed cell death -1 (PD -1), programmed cell death ligand -1 (PD -L1), and programm ed 
cell death ligand- 2 (PD -L2) are part of a complex system o f receptors and ligands that control 
T-cell act ivation. PD -L1 expressio n helps tum ors evade detection and eliminat ion by the 
immune system ( Juneja et al, 2017 ; Keir et al, 2008 ; Chen and Mellman, 2013 ; Ohaegbulam 
et al, 2015 ). The binding of PD -L1 to PD -1 on activated T cells delivers an inhibitory  signal 
prevent ing T cells fro m killing target tumor cells (Zou and Chen, 2008 ; Zou et al , 2016 ; 
Pardoll, 2012). Monocl onal antibodies (mAbs) targeting PD -1 (nivo lumab, pembr olizumab) 
and PD
-L1 (durvalumab, atezolizumab) have shown evidence of ant itumor activit y and a 
manageable safet y profile in pat ients with NSCLC and have been granted approvals by  the 
United States (US) Food and Drug Administration and/or the European Medic ines Agency for 
the treatment of NSCLC ( Opdivo® US PI, 2018; Keytruda® US PI, 2018; Imfinzi® US PI, 
2018 ; Tecentri q® US PI, 2018 ). 
MedImmune Protocol Amendment 4 D9108C00001 (COAST)
Durvalumab and novel oncology therapies 27Jul2021 ; Final
CONFI DENTIAL AND PROPRIETARY 14of 105 Template 18.01.1.1.2 CD73
Adenosine is a regulatory  autocrine and paracrine factor that accumulates in the tumor 
microenvironment, influencing immune act ivity, angi ogenesis, and metastasi s. Upon apoptoti c 
or necrotic cell death, tumor cells release adenosine triphosphate (ATP) into the extracellular 
space. ATP has been shown to lead to a pro- inflammatory response. To prevent an immune 
over acti vation, tissues express cluster of different iation (CD)39 and CD73 to enzymat ically 
convert ATP to adenosine, which induces a localized immun osuppressive response through 
multiple immune cell t ypes. In the extracellular space, CD39 and CD73 in tandem metabo lize 
ATP to adenosine mo nophosphate (AMP), and AMP to adenosine, respectively, and are a 
major source of extracellular adenosine. Extracellu lar adenosine impairs the proliferat ion and 
effector funct ion of cy totoxi c T lymphocy tes while simul taneously contribut ing to the 
immunosuppressive effects of both regulatory  T cells and myelo id-derived suppressor cells, 
among others ( Vijayan et al, 2017 ). The rate limit ing step in the generation o f extracellular 
adenosine is the dephosphorylat ion of AMP by CD73. 
One mechanism by which tumors may  have evolved to evade the immune system is via 
overexpressio n of CD73. Overexpression o f CD73 has been associated with poor prognosis in 
multiple cancer ty pes ( Inoue et al, 2017 ; Turcotte et al, 2015 ; Vijayan et al , 2017 ). Notably , 
high CD73 expressio n in NSCLC was associated with poor overall survival and recurrence 
free survival in a mult ivariate analysis ( Inoue et al , 2017 ). It is hypothesized that blocking 
CD73 activit y will reduce adenosine production, thus augment ing host and/or immunotherapy 
response to tumor.
1.1.1.3 NKG2a
Major histocom patibilit y complex E (HLA -E) is a non -classical major histocomp atibility 
complex class I m olecule, over -expressed by malignant cells in a variet y of tumor types. 
HLA -E can present antigens to the CD94/NKG2a receptors on the surface o f some ty pes of  
lymphocy tes. Act ivation of CD94/NKG2a receptors induces inhibitory sig nals that suppress 
cytokine secret ion and di rect cy totoxici ty of cytotoxic T lymphocy tes or natural  killer (NK) 
cells against stressed, infected, or “transformed” cells. Such act ivity has been described as a 
possible mechanism in immune escape o f cancer ce lls (Borrego et al , 1998 ;Braud et al, 1998 ). 
Conversely , the bl ockade of  CD94/NKG2a by  an antagoni st mAb restores the response of NK 
cells, enhancing notably their cy totoxi city against tum or cells expressing HLA -E. 
Furtherm ore, bl ocka de of CD94/NKG2a may enhance NK -mediated antibody -dependent 
cellular cy totoxi city (Denis et al, 2017). NK cells can also decrease metastasis through 
immunosurveillance ( López -Soto et al , 2017 ; Malladi et al, 2016 ).
Expressio n of CD94/NKG2a has been documented by subsets of cy totoxi c T lymphocy tes and 
NK cells infiltrat ing solid tumors. CD94/NKG2a appeared to be over -expressed in tumor -
infiltrat ing NK cells as compared to NK cells present in the non -tumoral areas of the same 
tissue or i n the blood. Hy per-expressio n of CD94/NKG2a by infiltrating NK cells appeared to 
MedImmune Protocol Amendment 4 D9108C00001 (COAST)
Durvalumab and novel oncology therapies 27Jul2021 ; Final
CONFI DENTIAL AND PROPRIETARY 15of 105 Template 18.0be associ ated wi th a diminished cy totoxi c potenti al (Sheu et al, 2005; Mamessier et al, 2011 ; 
Platonova et al , 2011 ) and has been documented in a variet y of solid tum ors including 
NSCLC, colorectal, ovarian, endo metrial, pancreatic, and prostate cancers ( Aparicio -Pagés et 
al, 1991 ; Goode n et al, 2011 ; Iannone et al, 2015 ; Pardoll, 2012; Pasero et al , 2015 ; Peng et al , 
2014 ; Tarle et al , 1993 ; Zeestraten et al, 2014 ). In addit ion, expressio n of HLA -E has been 
shown to correlate with a poor outcome in co lorectal , ovari an, or endom etrial carcinoma ( Guo 
et al, 2015 ; Emens et al, 2017 ; Goode n et al, 2011 ;Versl uis et al , 2017 ).
1.2 Study Drug Background
1.2.1 Durvalumab
Durvalumab is a human immunoglobulin (Ig) G1 kappa mAb that blocks the interaction of 
PD-L1 (but not PD -L2) with PD- 1 on T cells and CD80 (B7.1) on immune cells, and is 
engineered to reduce antibody -dependent cell -mediated cy totoxici ty and com plement 
activat ion. Refer to the current durvalum ab Invest igator’s Brochure (IB) for details. 
1.2.2 Oleclumab
Oleclumab (MEDI9447) is a human IgG1 lambda mAb that select ively binds to CD73 and 
inhibits adenosine production as well as leads to a reduction in CD73 expression through 
internalizat ion (Geoghegan et al, 2016; Hay et al , 2016 ). It contains a triple mutation in the 
heavy chain constant region for reduced effector funct ion. The enzymat ic blockade of CD73 
and decreased expressio n caused by binding of o leclumab to CD7 3 may lead to increased 
antitumor immuni ty. Refer to the current oleclumab IB for details.
1.2.3 Monalizumab
Monalizumab (IPH2201) is a humanized mAb o f the IgG -4 subt ype produced in Chinese 
hamster ovary  cells. It has a non -depleting and purely blocking activit y directed wi th high 
affinit y and specificit y against the CD94/NKG2a subunit of the heterodimeric inhibitory  
CD94/NKG2a receptor expressed by subsets of NK cells, activated αβ CD8+ T cells and 
γδ-Tcells. By suppressing the inhibitory signal transduced by CD94/NKG2a, m onalizumab 
enhances the ant itumor functions, including cytolytic act ivity of these immune effector cells . 
Refer to the current monalizumab IB for details.
1.3 Summary of Nonclinical Experience
1.3.1 Nonclinical Experience -Durvalumab
Refer to the curre nt durvalumab IB for a complete summary of nonclinical experience.
1.3.2 Nonclinical Experience -Oleclumab
No ol eclumab -related adverse effects were noted in CD -1 mice (5 -week, repeat intravenous 
[IV] bol us dose, once every  4 days, total  9 doses) at doses up to 200 mg/kg or in cyno molgus 
MedImmune Protocol Amendment 4 D9108C00001 (COAST)
Durvalumab and novel oncology therapies 27Jul2021 ; Final
CONFI DENTIAL AND PROPRIETARY 16of 105 Template 18.0monkeys (5 -week, repeat IV 30 -minute infusion dose, once weekly, total 5 doses) at doses up 
to 300.7 mg/kg in Good Laboratory  Practi ce toxicity  studi es. Addit ionally , no oleclumab -
related effects on electrocardiogram (ECG), bloo d pressure, or behavioral examinat ions were 
observed in the 5- week cyno molgus monkey study. The no -observed -adverse -effect -level was 
200 m g/kg/dose in CD -1 mice and 300.7 mg/kg/dose in cyno molgus monkeys. Refer to the 
current oleclumab IB for a complete su mmar y of nonclinical experience.
1.3.3 Nonclinical Experience -Monalizumab
The nonclinical safet y profiling of monalizumab has not identified any  safety  issues. Vari ous 
human in vit ro biological assays testing acute pharmacological effects identified no 
non-target -related or potentially target -related safety  issues. No toxicit ies were observed in 
cyno molgus monkeys after 13 weeks of dosing of up to 150 mg/kg weekly. The highest dose 
(150 m g/kg) resul ted in approximately  18 weeks of full  CD94/ NKG2a receptor sa turati on. In 
humans, monalizumab binds select ively to CD94/ NKG2a A receptors. In monkeys, 
monalizumab binds with equal affinit y to the activating CD94/NKG2c receptor in addit ion to 
the inhibitory  CD94/ NKG2a receptor. Thi s is m ost likely the reason why it ha s been 
impossible to observe effects comparable to those seen in humans in funct ional in vitro assays 
with cyno molgus vs human cells. Further risk assessment of long -term blocking of the 
CD94/ NKG2a receptor was therefore performed wit h a surrogate anti -mouse NKG2a antibody  
that has been used to demonstrate in vitro antitumor efficacy with mouse cells. In toxico logy 
studi es, mice were dosed subcutaneously  every second day  for up to 26 weeks at doses up to 
50 m g/kg. As wi th the cyno molgus monkey studies, the toxicity studies in mice did not 
ident ify any safet y issues. Refer to the current monalizumab IB for a complete summary o f 
nonclinical experience.
1.4 Summary of Clinical Experience
A co mplete summary  of clinical experience, including safet y, efficacy , and pha rmacokineti cs 
(PK), for durvalumab, oleclumab, and mo nalizumab can be found in the current IB of each 
respective agent.
1.4.1 Clinical Experience -Durvalumab
To date, durvalumab has been given to more than 6,000 subjects as part of ongoing studies 
either as m onotherapy  or in combinat ion with other anti cancer agents. In m onotherapy  clinical 
studi es, the m ost comm on adverse events (AEs; ≥ 20%) included fat igue (32%), cough (23%), 
decreased appet ite, dy spnea (21% each), and nausea (20%). Approximately 9% of subject s 
discontinued durvalumab due to an AE. The majorit y of treatm ent-related AEs were 
manageable, with dose delays, symptomat ic treatment, and in the case of events suspected to 
have an immune basis, the use of established treatment guidelines for immune -medi ated 
toxicity (see Secti on 3.1.3 ).
MedImmune Protocol Amendment 4 D9108C00001 (COAST)
Durvalumab and novel oncology therapies 27Jul2021 ; Final
CONFI DENTIAL AND PROPRIETARY 17of 105 Template 18.0In the PACIFIC study , 68% (322/475) of subjects with unresectable, Stage III NSCLC without 
progression after cCRT treated with durvalumab reported a treatment -related AE, with 
fatigue (13%), hy pothy roidism  (11%), di arrhea (10%), pneumonit is (9%), rash (8%), pruritus 
(7%), hy perthy roidism, asthenia, dyspnea, decreased appetite, nausea (6% each), and cough 
(5%) being t he most commo n. Grade 3 or 4 AEs were reported in 30% (142/475) of subjects, 
with pneum onia (4%), pneum onitis or radiation pneumonit is, anemia (3% each), and dyspnea 
(2%) reported in > 1% of subjects ( Antonia et al , 2017 ). 
In PACIFIC, durvalumab treatment for 12 months demonstrated superior PFS and OS in 
comparison to pl acebo (Secti on 1.1; Antoni a et al , 2018 ; Antoni a et al , 2017 ).
1.4.2 Clinical Experience -Oleclumab Alone and in Combination with 
Durvalumab
As of the data cutoff (DCO) date of 09Jan2018, 116 adult subjects with advanced solid tumors 
have received oleclumab either as monotherapy ( 42 subjects) or in combinat ion with 
durvalumab (74 subjects) during the dose -escalation or dose- expansio n phases o f the 
first-time- in-human Phase 1 Study D6070C00001. 
Following ol eclumab m onotherapy , 55% (23/42) of subjects reported a treatment -related AE , 
with fatigue (17%), nausea, and anemia (10% each) being the most commo n. Grade 3 or 4 
AEs were reported in 45% (19/42) of subjects, with ascites (12%), acute kidney injury, 
hyperglycemia, hyponatremia, and hypotensio n (5% each) reported in more than 1 subject. 
Three deaths occurred in subjects treated with oleclumab monotherapy  (1due to small 
intestinal obstruction and 2 due to disease under treatment); none were considered related to 
oleclumab.
Following ol eclumab plus durvalumab co mbinat ion therapy , 47% (35/74) of subjects reported 
a treatment -related AE, with fat igue (14%), increased aspartate aminotransferase (AST), 
diarrhea, and py rexia (8% each), increased blood alkaline phosphatase (ALP; 7%), increased 
alanine aminotransferase (ALT), decreased appe tite, and vomi ting (5% each) being the most 
commo n. Grade 3 or 4 AEs were reported in 53% (39/74) of subjects, with increased ALP 
(8%), anemia, increased ALT, increased AST, and increased gamma glutamyl transferase 
(5% each) reported in at least 5% of subj ects. Six deaths occurred in subjects treated with 
oleclumab plus durvalumab (1 each due to renal failure, vomit ing, respiratory  failure; 2 due to 
pneumo nia; and 1 due to disease under treatment); none of the deaths were considered related 
to study  treatm ent.
Efficacy data fro m 42 response -evaluable subjects treated with o leclumab plus durvalumab in 
the dose -expansio n phase (including subjects with colorectal  cancer [n = 21], pancreatic 
adenocarcino ma [n = 20], and NSCLC [n = 1]) showed an object ive respons e rate (ORR; 
MedImmune Protocol Amendment 4 D9108C00001 (COAST)
Durvalumab and novel oncology therapies 27Jul2021 ; Final
CONFI DENTIAL AND PROPRIETARY 18of 105 Template 18.0confirmed and unconfirmed) of 7.1% (3/42 subjects; 95% CI: 1.5%, 19.5%) and a disease 
control  rate (DCR; 8 weeks) of 16.7% (7/42 subjects; 95% CI: 7.0%, 31.4%).
1.4.3 Clinical Experience -Monalizumab Alone and in Combination with 
Durvalumab
The saf ety and tol erabilit y as well as single -dose and m ultiple-dose PK and pharmacodynamic 
properties of monalizumab were init ially invest igated in subjects with active rheumatoid 
arthri tis (Study  NN8765- 3658). In this first study  (com pleted), 68 subjects receiv ed 
monalizumab monotherapy  with maximum  tested dose l evels o f 10 m g/kg during IV infusio n 
(single dose) and 4.0 mg/kg fo llowing subcutaneous administrations (in single and mult iples 
doses), wi th a favorable safety  profile. 
Monalizumab is now being develop ed for the treatment of various hematologic and so lid 
malignancies as monotherapy  or in combinat ion with other drugs. As of 30Apr2018, a total of 
315 subjects have been treated with mo nalizumab in 7 hematology /onco logy studi es wi th 
multiple doses up to 10 mg/kg or 750 mg IV. Most of the reported AEs were Grade 1 or 2, 
with no obvi ous dose rel ationship. The most commo n (≥ 10%) AEs considered related to 
monalizumab monotherapy  were headache (23%), nausea (18%), fat igue (16%), vomit ing 
(15%), anorexia (11%), d iarrhea, abdo minal pain, and sore throat (10% each). There was no 
death related to study  treatm ent. 
In Study  D419NC00001, as of 30Apr2018, 154 subjects were exposed to monalizumab and 
durvalumab combinat ion therapy  in a dose -escalation (12 subjects) or do se-expansio n 
(139 subjects) phase. Overall, 62% (95/154) of subjects reported a treatment -related AE, with 
diarrhea, fati gue (10% each), asthenia, py rexia (8% each), hy pothy roidism , nausea (7% each), 
decreased appet ite (6%), and pruritus (5%) being the mos t comm on. Grade 3 or 4 AEs were 
reported in 43% (66/154) of subjects, with anemia (7%) reported in at least 5% of subjects. 
Three deaths occurred ( 2 due to intestinal obstructions and 1 due to bipo lar disorder); none of 
the deaths were considered related to study  treatm ent.
Of 39 evaluable subjects with microsatellite- stable col orectal  cancer in the dose -expansio n 
phase of Study  D419NC00001, 3 (8%) subjects had a partial response (PR) and 11 (28%) 
subjects had stable disease (SD; Segal  et al , 2018 ).
1.5 Rationale for Conducting the Study
Current standard of care for patients with unresectable, Stage III NSCLC includes cCRT 
followed by durvalumab maintenance for 12 months. When administered after complet ion of 
cCRT in patients with unresectable NSCLC, durvalumab demo nstrated improved PFS 
(HR:0.51; 95% CI: 0.41, 0.63) and OS (HR: 0.68; 99.73% CI: 0.47, 0.997, p = 0.0025) vs 
MedImmune Protocol Amendment 4 D9108C00001 (COAST)
Durvalumab and novel oncology therapies 27Jul2021 ; Final
CONFI DENTIAL AND PROPRIETARY 19of 105 Template 18.0placebo (PACIFIC study; Antonia et al, 2018). Durvalumab showed a median PFS of 
17.2 months co mpared to 5.6 months in the placebo group.
Furtherm ore, ORR might be an appropriate endpoint to assess antitumor activit y when sub-
jects are randomized after cCRT. In the PACIFIC study, ORR fo llowing cCRT com pleted 
prior to stud y drug treatm ent was 50.5% in the durvalumab group and 49.8% in the placebo 
group ( Antonia et al , 2017 ). Following s tudy drug treatm ent, ORR was higher in the durval-
umab than the pl acebo group (28.5% vs 16.0%, respectively). Previous studies assessing the 
role of conso lidation or maintenance strategies in subjects with NSCLC treated with CRT 
were consistently negat ive, and no differences in ORR were seen between the placebo and ex-
perimental  arms (Ahn et al, 2015 ; Kelly et al, 2008 ). Together, these data suggest that ORR is 
an appropriate endpo int to assess the ant itumor activit y in a signal finding study  where sub-
jects with unresectable Stage III NSCLC are randomiz ed after com pleting cCRT.
Despite these therapeutic advances, unresectable, Stage III NSCLC remains a condit ion with a 
high ri sk of  relapse and morbidit y. Further improvement in clinical outcomes in this pat ient 
popul ation with a high unmet m edical  need ma y be achieved through combinat ion therapy  of 
durvalumab with other immune modulators or anticancer therapies. Several ongo ing studies 
are exploring durvalumab and/or other immunotherapies for the treatment of Stage III NSCLC 
(CT03519971, [STUDY_ID_REMOVED], NCT03 217071, and [STUDY_ID_REMOVED]). 
The pl atform study  design permit s a dynamic assessment of durvalumab combinat ion 
experimental arms. Experimental arms may be closed based on results of planned interim 
analyses. New experimental arms may be added via protocol amendment (see Section 1.6.3 ). 
Potenti al new candidate study  drugs to be evaluated in combinat ion with durvalumab in this 
platform study  must have a k nown mechanism of action that could be addit ive or synergist ic 
with durvalumab, an established recommended dose in combination wit h durvalumab with an 
acceptable safet y profile, and preliminary  evidence of clinical activit y in combinat ion with 
durvalumab i n a so lid tumor setting. As a starting point, oleclumab and monalizumab meet 
these cri teria (see Section 1.5.1 and Section
 1.5.2 , respectively), and will be used in 
combinat ion with durval umab in the init ial experimental arms of this plat form study . Thus, at 
the outset, the study  will examine th e clinical act ivity and safet y of durvalumab pl us 
oleclumab, durvalumab plus monalizumab, and durvalumab alone in subjects with 
unresectable, Stage III NSCLC who have not progressed after cCRT. 
Given this plat form study  uses randomizat ion and a perpetual control  arm, it may requi re 
adapti ons over time as the standard of care in pat ients with unresectable, Stage III NSCLC 
evolves in order to safeguard the best interests of the pat ients participating in this study . 
Potenti al protocol  modificat ions may includ e changes in the definit ion of curative intent 
cCRT, inclusio n of durvalumab as part of the cCRT treatment plan, or the duration/schedule 
MedImmune Protocol Amendment 4 D9108C00001 (COAST)
Durvalumab and novel oncology therapies 27Jul2021 ; Final
CONFI DENTIAL AND PROPRIETARY 20of 105 Template 18.0of durvalumab maintenance. Rationale and supporting evidence for any  changes to the current 
protocol  design will be addressed via protocol amendment.
1.5.1 Rationale for Inclusion of Durvalumab in Combination with Oleclumab 
Arm
 
 
 
 
 
 
 
 
 
 
1.5.2 Rationale for Inclusion of Durvalumab in Combination with 
Monalizumab Arm
 
 
 
 
1.6 Benefit -risk and Ethical Assessment
The study  will be perform ed in accordance with ethical principles that have their origin in the 
Declaration of Helsinki and are consistent with Internat ional Council for Harmonisat ion 
(ICH)/Good Clinical Practice (GCP), and applicable regulatory  requi rements. More detailed 
inform ation about the known and expec ted benefi ts and risks and reasonably  expected AEs of 
durvalumab and each novel onco logy therapy  may be found in the respect ive IB for each 
molecule.
1.6.1 Potential Benefits
Most patients with unresectable, Stage III NSCLC will relapse and die fro m lung cancer 
despite aggressive cCRT, with a 5 -year survival of approximately 15% ( Curran et al, 2011 , 
CCI
CCI
MedImmune Protocol Amendment 4 D9108C00001 (COAST)
Durvalumab and novel oncology therapies 27Jul2021 ; Final
CONFI DENTIAL AND PROPRIETARY 21of 105 Template 18.0Aupérin et al , 2010 ). Recently, results from the PACIFIC study  dem onstrated that durv alumab 
maintenance for 12 months improved PFS and OS in comparison to placebo, with a favorable 
safet y profile ( Antoni a et al , 2018 ; Antoni a et al , 2017 ).
This protocol will allow patients with unresectable, Stage III NSCLC without progression 
after cCRT to receive durvalumab and potentially  achieve s urvival benefit as demonstrated in 
the PACIFIC study  (Antoni a et al , 2018 ; Antoni a et al , 2017 ). Further improvement in clinical 
outcom es in this pati ent popul ation with a high unmet medical need may be achieved through 
combining novel therapies wit h durvalumab. Selection of the combinat ion novel agen ts will  
be based on nonclinical and clinical data supporting a potentially favorable interaction wit h 
durvalumab in this patient populat ion, wi th a well -tolerated and m anageable safet y profile.
1.6.2 Potential Risks
1.6.2.1 Durvalumab
Durvalumab may boost endogenous imm une responses leading to undesired AEs. Most 
adverse drug reactions seen with durvalumab include, but are not limited to, diarrhea/co litis, 
pneumo nitis/interst itial lung disease, endocrinopathies (ie, events of hypophysit is, adrenal 
insufficiency, hyper - and hypo-thy roidism , and ty pe I di abetes m ellitus), hepat itis/increases in 
transaminases, nephrit is/increases in creatinine, pancreat itis/increases in amylase and lipase, 
rash/dermat itis, myocardi tis, my ositis/polymyo sitis, other rare or less frequent infla mmatory  
events including neurotoxicit ies, infusio n-related reactions (IRRs), hy persensi tivity react ions, 
and infections/serious infect ions.
For informat ion on all ident ified and potential risks with durvalumab alo ne or i n combinat ion 
with other ant icancer therapi es ref er to the current versio n of the durvalumab IB.
1.6.2.2 Oleclumab 
As of 09Jan2018, a total of 42 subjects with advanced solid tumors have received o leclumab 
monotherapy  during the dose -escalat ion phase of the first time -in-human Phase 1 
Study D6070C0 0001. No dose -limit ing toxicit ies (DLTs), treatment -related SAEs, or 
treatm ent-related deaths were ident ified. Fo llowing oleclumab m onotherapy , 55% (23/42) of 
subjects reported a treatment -related AE, with fat igue, nausea, and anemia being the most 
commo n (≥ 10%). Addit ionally, some potential risks for the abrogation of CD73 act ivity 
caused by  oleclumab treatm ent have been suggested fro m clinical findings in individuals wit h 
CD73 deficiency and findings in CD73 -deficient mice. Those potential risks include arteri al 
calcificat ions, arterial ischemic disorder, thrombosis, and increased microvascular 
perm eabili ty, and potenti al risks include jo int calcificat ions. Other important potential risks
associ ated wi th the administrati on of  mAbs include IRRs, anaphylaxi s, hypersensit ivity or 
allergic reactions, and immune co mplex disease. Addit ional potential risks associated with any 
IV administration are localized infect ion, redness, swelling, pain, and indurat ion at the 
administration site. 
MedImmune Protocol Amendment 4 D9108C00001 (COAST)
Durvalumab and novel oncology therapies 27Jul2021 ; Final
CONFI DENTIAL AND PROPRIETARY 22of 105 Template 18.0Given the mode of action of o leclumab, and the potential risks for durvalumab, the theoretical 
risk associ ated wi th removing the inhibit ion of adenosine on the microenvironment favors 
increased ant itumor immuni ty when combined wi th durvalumab as well as th e risk of 
emergence of autoimmune phenomena. As of 09Jan2018, a total of 74 subjects with advanced 
solid tumors have received o leclumab in co mbinat ion with durvalumab in 
Study D6070C00001. No DLTs or treatment -related deaths were ident ified. Fo llowing 
oleclumab plus durvalumab co mbinat ion therapy , 47% (35/74) of subjects reported a 
treatm ent-related AE, with fat igue, increased AST, diarrhea, pyrexia, increased blood ALP, 
increased ALT, decreased appetite, and vo miting being the most commo n (≥ 5%). Grade 3 o r 
4 AEs were reported in 53% (39/74) of subjects, wit h increased ALP, anemia, increased ALT, 
increased AST, and increased gamma glutamyl transferase reported in at least 5% of subjects. 
Overall, durvalumab plus oleclumab and oleclumab alo ne have been well tolerated to date. 
See Secti on 1.4.2 for a detailed descript ion of AEs reported in Study D6070C00001. 
For informat ion on safet y and potential ris ks wi th oleclumab, refer to the current oleclumab 
IB. See Section 5.3.2 for adverse events of special interest (AESIs) associated with oleclumab.
1.6.2.3 Monalizumab 
As of 30Apr2018, a total o f 315 subjects have been treated with monalizumab in 
hematol ogy/onco logy studi es. Most of the reported AEs were Grade 1 or 2, with no obvious 
dose rel ationship. The most frequent ( ≥ 10%) AEs considered related to monal izumab 
monotherapy  were headache, nausea, fatigue, vomit ing, anorexia, diarrhea, abdo minal pain, 
and sore throat. There were no treatment -related deaths in any o f the studi es. 
Given the mode of action of mo nalizumab, and the potential risks for durvalumab , the 
theoreti cal risk associ ated when m onalizumab is combined with durvalumab may be an 
increased risk of emergence of autoimmune phenomena. However, no such potential risks 
have been ident ified during the conduct of the development program. As o f 30Apr20 18, 
154subjects were exposed to monalizumab and durvalumab combinat ion therapy . Overall, 
62% (95/154) of subjects reported a treatment -related AE, with diarrhea, fat igue, asthenia, 
pyrexia, hypothy roidism , nausea, decreased appetite, and pruritus being th e most comm on 
(≥5%). Grade 3 or 4 AEs were reported in 43% (66/154) of subjects, with anemia reported in 
at least 5% of subjects. No deaths were considered related to study  treatm ent.
Given the mode of action of mo nalizumab, however, there are theoretical risks that m ay arise 
when mo nalizumab is used in co mbinat ion with durvalumab. The theoretical risk associated 
with inhibit ing NKG2a favors increased ant itumor immuni ty when combined wi th 
durvalumab as well as the risk of emergence of autoimmune phenomena. These risks include 
adverse effects on the immune system, increased risk of infect ion, acute generalized or 
delayed hypersensit ivity react ions, immunogenicit y, local inject ion-site reacti ons and AEs 
associ ated wi th the bl ocking effect on CD94/NKG2a recept ors. 
MedImmune Protocol Amendment 4 D9108C00001 (COAST)
Durvalumab and novel oncology therapies 27Jul2021 ; Final
CONFI DENTIAL AND PROPRIETARY 23of 105 Template 18.0Overall, durvalumab plus monalizumab and monalizumab alo ne have been well tolerated to 
date. See Section 1.4.3 for a description o f AEs report ed in monalizumab m onotherapy  and 
durvalumab combinat ion therapy  studies. 
For informat ion on safet y and potential risks wit h mo nalizumab, refer to the current 
monalizumab IB.
1.6.3 Overall Benefit- Risk
While durvalumab administered after complet ion of cCRT in p atients with unresectable 
NSCLC has demo nstrated improved clinical benefit over placebo, further improvement in 
clinical outcomes may  be achieved through combinat ion therapy  of durvalumab wi th novel 
therapi es such as ol eclumab or m onalizumab. Clinical and nonclinical data to date have shown 
an acceptable safety  profile for oleclumab and mo nalizumab in co mbinat ion with durvalumab. 
The design of the current study  aims to minimize potential risks to subjects and include the 
protocol  inclusion and exclusio n criteria, restri ctions on conco mitant m edicat ion during the 
study , safet y monitoring (incl uding review of all safet y, PK, and other relevant data by  the 
Safety Review Co mmit tee [SRC]), toxi city managem ent gui delines, study  stopping cri teria, 
and rules and pr ocedures to add new durvalumab combinat ion treatment arms. Specific 
intensive safet y monitoring is in place for those risks deemed to be most likely  for durvalumab 
alone and for each of the durvalumab combinat ion therapi es.
Further design elements aim to s pecifically minimize the risks for subjects allocated to a 
durvalumab combinat ion experimental arm. Any  new combinat ion treatment arm must adhere 
to the following elements: 
A rati onale for addi tive or synergist ic act ivity of the potenti al new candidate agent in 
combinat ion with durval umab based on i ts mechanism of act ion and/or supported by  
nonclinical or clinical evidence.
An established recommended co mbinat ion dose for the novel agent in combinat ion with 
durvalumab with an acceptable safet y profile for the target populat ion in this study .
Descript ion of the safet y profile and AESIs for the novel agent alone and/or in 
combinat ion with durval umab based on previous Phase 1 expansio n cohorts or 
Phase 2 studi es. 
Preliminary evidence of clinical act ivity of the novel  agent in combinat ion with 
durvalumab in a so lid tumor setting.
Requi rement of a protocol amendment and respective healt h authorit y and local 
Institutional Review Board (IRB)/Independent Ethics Committee (IEC) approvals prior to 
implement ing any n ew experimental arm.
Updated informed consent form with relevant info rmation on the new durvalumab 
combinat ion experimental arm.
MedImmune Protocol Amendment 4 D9108C00001 (COAST)
Durvalumab and novel oncology therapies 27Jul2021 ; Final
CONFI DENTIAL AND PROPRIETARY 24of 105 Template 18.0Overall, the benefit -risk assessment for this Phase 2 platform study  is acceptable.
1.7 Research Hypotheses
1.7.1 Prim ary Hypothesis
Durvalumab in co mbinat ion with novel agents will dem onstrate superior ant itumor activit y 
than durvalumab alo ne in subjects with unresectable, Stage III NSCLC who have not 
progressed fo llowing definit ive cCRT.
1.7.2 Secondary Hypotheses
Durvalumab alone or in co mbinat ion with novel  agents will  dem onstrate an acceptable safet y 
profile in subjects with Stage III NSCLC who have not progressed fo llowing definit ive cCRT. 
2 OBJECTIVES AND ENDPOINTS
Overall study  objectives and endpo ints applicable across treatment arms a re presented below.
Each combinat ion experimental arm will evaluate these objectives based on the respective 
novel agent. Secondary  immunogenicit y object ive (b) is applicable only to novel bio logic 
agents ( Table 2). 
2.1 Primary Objective and Associated Endpoint
Table 1 Primary Objective and Associated Endpoint
Type Objective Endpoint
Clinical activityTo compare the antitumor activity of durvalumab 
alone vs durvalumab in combination with novel 
agents  OR per RECIST v1.1
OR = objective response; RECIST v1.1 = Response Evaluation Criteria for Solid Tumors version 1.1.
2.1.1 Secondary Objectives and Associated Endpoints
Table 2 Secondary Objectives and Associated Endpoints
Type Objective Endpoint
SafetyTo evaluate the safety and tolerability of durvalumab 
alone and durvalumab in combination with novel 
agentsPresence of AEs, SAEs, and 
abnormal laboratory parameters 
and vital signs
Clinical activityTo further compare the efficacy of durvalumab alone 
vs durvalumab in combination with novel agentsDoR, DC, PFS -12, and PFS per 
RECIST v1.1 and OS 
Pharmacokinetics(a)To describe the PK of durvalumab alone and 
durvalumab in combination with novel agents Concentration of durvalumab or 
novel agents in serum (b)To describe the PK of novel agents in combination 
with durvalumab
MedImmune Protocol Amendment 4 D9108C00001 (COAST)
Durvalumab and novel oncology therapies 27Jul2021 ; Final
CONFI DENTIAL AND PROPRIETARY 26of 105 Template 18.03 STUDY DESIGN
3.1 Description of the Study
3.1.1 Overview
COAST is a Phase 2, open -label, m ulticenter, randomized, mult idrug pl atform study  of 
durvalumab alone or in co mbination wit h novel agents in subjects with locally advanced, 
unresectable, Stage III NSCLC. 
The study  will evaluate the clinical act ivity and s afety  of durval umab al one or in combinat ion 
with novel  agents in subjects with Stage III NSCLC who have not progressed fo llowing 
definit ive cCRT ( Figure 1). Subj ects will be randomized into the study  and ini tiate study  
treatm ent wi thin 42 days from the last sessio n of cCRT. Informat ion on subject randomizat ion 
and sample size is provided in Section 4.6.1 and Section 4.8.2 , respectively. Up to 
approximately  80 si tes gl obally  will participate in this study . 
Subjects m ay be treated for up to 12 m onths. Study  treatm ent will  be discont inued upon dis-
ease progression, unacceptable toxicit y, or other reason, eg, subject decisio n or noncompli-
ance wi th study  procedures. Overall, all subjects cont inuing in the study must adhere to the 
study  procedures for up to 5 y ears (from  rando mization) provided they achieve disease control 
(DC) and remain disease free. Subjects who have experienced PD will be fo llowed for sur-
vival. 
All subjects will be fo llowed for survival unt il the end of the study  as per the time points 
shown in Table 6. After com pleting the 5 -year post -randomization study  period, all  subjects 
included into any  treatm ent arm  may be contacted annually for survival unt il 5 years after the 
final subject is rando mized into the study  or until the sponsor stops the study , whichever 
occurs first. The platform nature of the study  allows an individ ual experimental  arm to be 
perm anent ly closed while the overall COAST study  remains open.
New durvalumab combinat ion experimental arms may be added based on emerging 
nonclinical and clinical data via protocol amendment (see Section 1.6.3 ). Interim fut ility 
analyses will be performed using Bayesian predict ive probabilit y (PP; see Section 4.8.7 ).
MedImmune Protocol Amendment 4 D9108C00001 (COAST)
Durvalumab and novel oncology therapies 27Jul2021 ; Final
CONFI DENTIAL AND PROPRIETARY 27of 105 Template 18.0Figure 1 Study Flow Diagram
cCRT = concurrent chemoradiotherapy; ECOG PS = Eastern Cooperative Oncology Group Performance Status; 
NSCLC = no n-small cell lung cancer.
Treatment arms may be opened sequentially or in parallel. Randomization will be stratified by histology 
(adenocarcinoma vs non -adenocarcinoma). 
Enrollment to combination experimental arms may be stopped if planned interim analysis shows safety concerns 
orlack of efficacy. New combination experimental arms may be added based on emerging nonclinical and 
clinical data via a protocol amendment.
3.1.2 Treatm ent Regimen
Subjects will be rando mized to a treatment arm and may remain on study treatment for up to 
12 m onths. Study  treatm ent will be di scontinued upon disease progression, unacceptable 
toxicity, or other reason. See Section 4.1.6 for informat ion on di scont inuat ion of study  drug 
for individual subjects.
3.1.2.1 Durvalumab Control Arm
Figure 2presents the treatment regimen for the durvalumab mo notherapy  control arm. 
Figure 2 Treatment Regimen for Control Arm -Durvalumab Monotherapy 
D = durvalumab; IV = intravenous; Q4W = every 4 weeks.
aSubjects in the control arm will receive durvalumab 1500 mg IV Q4W on Day 1 of each cycle.
3.1.2.2 Experimental Arm A –Durvalumab Plus Oleclumab
Subjects rando mized to Arm A will receive durvalumab in co mbinat ion with oleclumab as 
presented in Figure 3. 

MedImmune Protocol Amendment 4 D9108C00001 (COAST)
Durvalumab and novel oncology therapies 27Jul2021 ; Final
CONFI DENTIAL AND PROPRIETARY 28of 105 Template 18.0Figure 3 Treatment Regimen for Arm A -Durvalumab Plus Oleclumab 
D = durvalumab; IV = intravenous; O = oleclumab; Q2W = ever y 2 weeks; Q4W = ever y 4 weeks.
aSubjects in Arm A will receive durvalumab 1500 mg IV Q4W on Day 1 of each cycle, and oleclumab 
3000 mg IV Q2W (Day 1 and Day 15) for Cycle 1 and Cycle 2 then Q4W starting on Cycle 3, Day 1. 
On day s when both durvalumab and oleclumab are administered, olec lumab will be administered first. 
3.1.2.3 Experimental Arm B –Durvalumab Plus Monalizumab
Subjects rando mized to Arm B will receive durvalumab in co mbinat ion with monalizumab as 
presented in Figure 4. 
Figure 4 Treatment Regimen for Arm B –Durvalumab Plus Monalizumab 
D = durvalumab; IV = intravenous; M = monalizumab; Q2W = ever y 2 weeks; Q4W = ever y 4 weeks.
aSubjects in Arm B will receive durvalumab 1500 mg IV Q4W on Day 1 of each cycle, and monalizumab 
750mg IV Q2W on Days 1 and 15 of each cycle. 
On day s when both durvalumab and monalizumab are administered, durvalumab will be administered first.
3.1.3 Managemen t of Study Medication Related Toxicities 
The fo llowing general guidance should be fo llowed for m anagement of toxi cities. 
1Next cy cle administration can be delayed or discontinued 
2In the absence of clear alternat ive et iology, all events shoul d be consider ed potenti ally 
immune mediated 
3In the event that an AE is considered related only to durvalumab or the combination novel 
therapy , both agents must be delayed 
If unsure how to m anage a subject, please contact the study  medical  monitor to discuss 
individual cases. Treatment for toxicit ies shoul d be init iated prior to discussio n with the study  
medical mo nitor.
Dose m odificat ions are not allowed.
Guidelines for the management of immune -mediated reactions, infusio n-related reacti ons, and 
non-immune -mediated reacti ons for durval umab alone or in combinat ion with the novel  

MedImmune Protocol Amendment 4 D9108C00001 (COAST)
Durvalumab and novel oncology therapies 27Jul2021 ; Final
CONFI DENTIAL AND PROPRIETARY 29of 105 Template 18.0immunotherapies are provided in the Toxicit y Managem ent Gui delines. These guidelines have 
been prepared by the sponsor to assist the investigator in the exercise of his/her clinical 
judgment in treati ng these ty pes of  toxicities. Follo wing the guidelines is expected, but 
changes due to local site procedures are allowed according to the physician’s judgement. 
The m ost current version of the Toxicit y Management Guidelines is to be maintai ned wi thin 
the Site Master File. 
3.1.4 Safety Review Committee
An SRC will conduct safet y reviews of all enro lled subjects at least twice a year .The SRC 
may make recommendat ions regarding continuat ion, modificati on, or terminat ion of any  study  
arm for safet y concerns. They  may request addi tional data (eg, clinical efficacy ) as needed. 
Addit ional safet y reviews m ay be conducted at the discret ion of the SRC.
An SRC will consist of the following:
The sponsor study  Medical Monitor, or delegate
Global Safet y Physic ian, or delegate
Study  Stati stician
Principal Invest igators, or delegates, fro m a subset of active investigat ional sites. The 
number of sponsor representatives will not exceed the number of Principal Invest igators.
External physician not associated with th e conduct of the study  (SRC Chairperson)
The Clinical Pharmaco logy Scientist, Patient Safety Scient ist, Clinical Operations 
Representative, and other delegates may also be invited as appropriate. Other internal and 
external experts may be consulted by  theSRC as necessary . The membership, roles, 
responsibilit ies, and details on the process flow/communicat ion plan are provi ded in the SRC 
Charter.
3.2 Rationale for Dose, Population, and Endpoints
3.2.1 Dose Rationale
3.2.1.1 Durvalumab 
Based on available PK and safet y data f or wei ght-based doses of durvalumab 10 mg/kg Q2W 
and 20 m g/kg Q4W and simulated PK data for a fixed dose of durvalumab 1500 mg Q4W, the 
fixed -dose regimen was predicted to provide comparable exposure to the body  weight-based 
dosing regimens. Durvalumab has a flat exposure -response (efficacy and safet y) relationship. 
Based on all the observed and simulated data, a fixed dosing regimen of 1500 mg Q4W was 
predi cted to provide similar efficacy and safet y profiles as the body  weight -based dosing 
regimens. As det ailed in the durvalumab IB, a fixed dose of 1500 mg Q4W is being used in 
MedImmune Protocol Amendment 4 D9108C00001 (COAST)
Durvalumab and novel oncology therapies 27Jul2021 ; Final
CONFI DENTIAL AND PROPRIETARY 30of 105 Template 18.0numerous ongoing studies. Therefore, a fixed dosing regimen of 1500 mg Q4W was selected 
in this study . 
For addi tional details on the nonclinical and clinical data that informed durva lumab dose 
select ion, see the durvalumab IB.
3.2.1.2 Oleclumab
The ol eclumab regimen of 3000 mg Q2W × 4 doses and then Q4W was selected based on data 
from the Phase 1 Study  D6070C00001. In that study, o leclumab doses of 5, 10, 20, and 
40mg/kg Q2W were examined bo th as a monotherapy  and in combinat ion with durvalumab 
10 m g/kg Q2W. Ol eclumab was well tol erated and there were no observed DLTs either as 
monotherapy  or in co mbinat ion with durvalumab. Addit ionally , both ol eclumab and 
durvalumab exposures in co mbinat ion were com parable to m onotherapy  exposures. The 
oleclumab 40 m g/kg Q2W dose was selected for evaluat ion with durvalumab 10 m g/kg Q2W 
in the dose -expansio n phase of that study . 
A fixed dose of oleclumab 3000 mg Q2W × 4 doses is current ly being explored based on 
simulat ions that oleclumab might achieve similar exposures to th ose observed with the 
40 mg/kg Q2W dose schedule. The subsequent Q4W schedule at 3000 mg is predicted to 
resul t in adequate l ong-term exposures wi th median trough concentration above the e stimated 
CD73 saturating concentration of approximately 40 μg/mL (100 -fold of est imated Michaelis -
Menten constant from the population PK model) to maintain optimal CD73 saturation at 
steady  state.
3.2.1.3 Monalizumab
The m onalizumab dose of 750 mg Q2W was selecte d based on the available clinical safet y, 
tolerabilit y, efficacy, and PK data from the ongoing Phase 1 Study  D419NC00001. In that 
study , monalizumab doses of 22.5, 75, 225, and 750 mg Q2W and 750 mg Q4W were 
examined in co mbinat ion with durvalumab 1500 mg Q4W. Monalizumab was well tolerated 
in all dose -escalat ion cohorts, and no DLTs were observed. The mo nalizumab 750 mg Q2W 
dose was identified for evaluation wit h durvalumab 1500 mg Q4W in the dose- expansio n 
phase of the study .
3.2.2 Rationale for Study Population
Patients wi th unresectable, Stage III NSCLC who have not progressed after cCRT will be 
considered for enrollment into the study . These characteri stics defined the patient populat ion 
in the Phase 3 PACIFIC study  that showed superiority  of durvalu mab maintenance over 
placebo (see Secti on 1.5). Aligning wit h the PACIFIC target population provides support for 
use of a durvalumab control arm as the com parator for evaluat ing novel durvalumab 
combinat ions.
MedImmune Protocol Amendment 4 D9108C00001 (COAST)
Durvalumab and novel oncology therapies 27Jul2021 ; Final
CONFI DENTIAL AND PROPRIETARY 31of 105 Template 18.03.2.3 Rationale for Endpoints
The primary  object ive of this platform study  is to com pare the clinical act ivity of durvalumab 
alone vs durval umab in combinat ion with novel agents. The overall study  goal is early 
ident ificat ion of novel durvalumab co mbinat ions that are more active than durvalumab alo ne 
in the treatment of patients with unresectable, Stage III NSCLC who have not progressed after 
cCRT. The classical efficacy endpo ints of PFS and OS require long evaluat ion peri ods, eg, the 
ongoing PACIFIC study  showed an interim median PFS of 17.2 months fo llowing a 3 -year 
follow-up (Antonia et al , 2018 ).The current study  will use obj ective response (OR) per 
Response Evaluat ion Cri teria for Solid Tum ors versi on 1.1 (RECIST v1.1), which is a 
widespread outcom e measure in Phase 1- 2 studi es, as the primary  endpoint to provi de an 
earlier measure of antitumor activit y. A difference in ORR between the durvalumab 
monotherapy  arm and the novel combinat ions arms i s believed to be clinically  meaningful  as 
responses to immunotherapies can be sustained over time and might relate to the overall PFS 
benefit. Clinical ac tivity will be further assessed by  secondary  endpoints routinely used in 
oncol ogy studi es, including duration of response (DoR), DC, PFS -12, and PFS based on 
RECIST v1.1, and OS.
The safet y and tol erabilit y of each study  treatment will be assessed by  the s tandard safet y 
endpo ints, including AEs, SAEs, laboratory  parameters, vi tal signs, and other standard clinical 
param eters.
4 MATERIALS AND METHOD S
4.1 Subjects
4.1.1 Number of Subjects
Up to approximately 60 subjects per experimental treatment arm will be randomized w ith 
equal  ratios to durval umab control  and each of the open experimental arms. New durvalumab 
combinat ion experimental arms may  be added over time following protocol -specific 
guidelines (see Sect ion1.6.3 ) and therefore the total number of subjects randomized to the 
durvalumab control arm might be higher than 60 subjects. Details regarding the specifics of a 
new co mbinat ion arm  will be provi ded via pr otocol amendment. See also Section 4.6.1 for 
potenti al changes to the rando mizat ion scheme and changes to overall study  enrollment in the 
control  arm and the combination experimental arms during the study .
4.1.2 Inclusion Criteria
Subjects m ust m eet all of the fo llowing cri teria:
1Written inform ed consent and any  locally requi red authori zation obtained fro m the 
subject pri or to performing any  protocol -related procedures, including screening 
evaluat ion
2Age 18 y ears or ol der
MedImmune Protocol Amendment 4 D9108C00001 (COAST)
Durvalumab and novel oncology therapies 27Jul2021 ; Final
CONFI DENTIAL AND PROPRIETARY 32of 105 Template 18.03Body  weight ≥ 35 kg
4Subjects m ust have histol ogically  or cy tologically docum ented NSCLC who present with 
locally advanced, unresectable, Stage III disease
5Subjects m ust have com pleted, wi thout progressing, definit ive cCRT within 42 days prior 
to being rando mized into the study :
Definit ive radiotherapy  refers to a total  dose ≥ 60 Gy  at 1.8 Gy  per f raction or 
bioequivalent dose
Concurrent chemotherapy  refers to a pl atinum -based doublet
The final chem otherapy  administrati on m ust end pri or to, or concurrently wit h, the 
final dose of radiat ion
6Subjects m ust have at l east one previously  irradiated tum or lesion that can be measured 
by RECIST v1.1 (RECIST v1.1 guidelines permit previously irradiat ed lesio ns to be 
considered measurable if defined in the protocol [see Section 3.1.3 in Eisenhauer et al, 
2009 ])
7Provisio n of tumor tissue sample, when available, fro m original diagnosis obtained before 
initiation of chemoradiotherapy  (tumor ti ssue blo ck or unstained slides are acceptable; 
refer to La boratory  Manual  for details)
8Life expectancy  ≥ 12 weeks 
9Eastern Cooperative Oncology  Group (ECOG) Performance Status of 0 or 1
10Adequate organ and marrow funct ion as defined in Table 4:
Table 4 Criteria for Adequate Organ and Marrow Function
Parameter Value
HematologicalHemoglobina≥9.0 g/dL (5.59 mmol/L)
Absolute neutrophil counta≥1.0 × 109/L (1000 per mm3)
Platelet counta≥100 × 109/L (100,000 per mm3)
HepaticTotal bilirubin≤ 1.5 × ULN in the absence of Gilbert’s syndrome
≤ 3 × ULN if the patient has Gilbert’s syndrome
Alanine transaminase and 
aspartate transaminase≤ 2.5 × ULN
RenalCalculated creatinine 
clearanceb ≥40 mL/minute
ULN = upper limit normal.
aHematological criteria cannot be met with ongoing or recent blood transfusions (within 14 days prior to 
the scheduled first dose of study treatment) or require growth factor support (within 21 days prior to the 
scheduled first dose of study treatment).
bAs determined by Cockcroft -Gault (using actual body weight; Cockcroft and Gault, 1976 ) or 24-hour 
urine creatinine clearance.
11Females of childbearing potential and non -sterilized male subjects with female partners of 
childbearing potential must use effective methods of contraception fro m screening to 
180days after the final dose of study  treatm ent (see Appendix A)
MedImmune Protocol Amendment 4 D9108C00001 (COAST)
Durvalumab and novel oncology therapies 27Jul2021 ; Final
CONFI DENTIAL AND PROPRIETARY 33of 105 Template 18.04.1.3 Exclusion Criteria
Any of the fo llowing woul d exclude the subject from participat ion in the study :
1Involvement in the planning and/or conduct of the study (appli es to both sponsor staff 
and/or staff at the study  site)
2Concurrent enrollment in another clinical study , unless i t is an observat ional 
(non-intervent ional) clinical study  or during the follow -up peri od of  an intervent ional 
study
3Mixed small cell and non -small cell lung cancer histology  
4 Current or prior use of immunosuppressive medication within 14 days before the first 
dose of study  drug. The following are except ions to this criterion:
Intranasal, inhaled, topical steroids, or local steroid injections (eg , intra -articular 
inject ion)
Systemic corti costeroi ds at physio logic doses not to exceed 10 mg/day of prednisone 
or its equivalent
Steroi ds as prem edicati on for hypersensi tivity reacti ons (eg, CT scan premedicat ion)
5Prior exposure to any  anti-PD-1, ant i-PD-L1, or anti -cytotoxi c T-lymphocy te-associ ated 
antigen-4 (CTLA -4) ant ibody  for the treatm ent of NSCLC
6Any unreso lved toxicit y Nat ional Cancer Inst itute Commo n Termino logy Criteria f or 
Adverse Events versio n 5.0 (NCI CTCAE v5.0) > Grade 2 from the prior chemoradiat ion 
therapy
7Subjects with history  of ≥ Grade 2 pneumo nitis from prior chemoradiat ion therapy
8Subjects with a history  of venous thrombosis within the past 3 months.
9Subjects with history  of myocardial  infarcti on, transient i schemic attack, or str oke in the 
past 6 m onths.
10Congest ive heart failure ≥ Class 3 based on New York Heart Associat ion Funct ional 
Classificat ion
11Major surgi cal procedure (as defined by  the investigator) wi thin 28 days prior to the first 
dose of study  drug  
12Active or prior docume nted autoimmune or inflammatory  disorders (including 
inflammatory  bowel  disease [eg, colit is or Crohn's disease], divert iculitis [wit h the 
exception of diverticulosis], systemic lupus ery thematosus, Sarcoi dosis syndro me, or 
Wegener syndro me [granulo matos is with polyangiit is, Graves' disease, rheumatoid 
arthri tis, hypophysit is, uveit is, etc]). The fo llowing are exceptions to this criterion:
Subjects with vit iligo or alopecia
Subjects with hypothy roidism  (eg, f ollowing Hashimoto syndrome) stable on 
horm one replacement 
Any chronic skin condit ion that does not require systemic therapy
Subjects with celiac disease controlled by diet alone
13History  of active primary immunodeficiency 
MedImmune Protocol Amendment 4 D9108C00001 (COAST)
Durvalumab and novel oncology therapies 27Jul2021 ; Final
CONFI DENTIAL AND PROPRIETARY 34of 105 Template 18.014Active infection including tubercul osis, hepat itis B, hepatit is C, or human 
immunodeficiency  virus (HIV)
15History  of allogenic organ transplantation
16Known allergy  or hy persensi tivity to study  drug form ulation(s)
17QTcF interval ≥ 470 m s
18Uncontrolled intercurrent illness, including but not limited to, ongoing or active infect ion, 
symptom atic congestive heart failure, uncontrolled hypertensio n, unstable angina 
pectori s, cardi ac arrhy thmia, intersti tial lung disease, seri ous chronic gastrointestinal 
condi tions associ ated wi th diarrhea, or psychiatric illness/social situat ions that would
limit compliance wit h study  requi rement, substantially  increase risk of incurring AEs or 
compromise the abilit y of the pati ent to give wri tten informed consent
19Receipt of live attenuated vaccinat ion within 30 days pri or to study  entry  
20History  of another primary malignancy except for:
Malignancy  treated wi th curative intent and with no known active disease ≥ 5 y ears 
before the first dose of study  drug and of l ow potent ial risk for recurrence
Adequately treated non -melanoma skin cancer or lent igo maligna wi thout evi dence 
of disease
Adequately treated carcinoma in situ without evidence o f disease
21Females who are pregnant, lactating, or intend to become pregnant during their 
participat ion in the study
4.1.4 Subject Enrollment and Randomization
Study  parti cipat ion begins (i e, a subject i s “enrolled”) once written informed consent is 
obtained. Once informed consent is obtained, a subject ident ificat ion (SID) number will be 
assigned by  a central  system  (ie, an interactive voice/web response system [IXRS]), and the 
screening evaluat ions m ay begin to assess study  eligibilit y (inclusio n/exclusio n) cri teria. The 
SID number will be used to ident ify the subject during the screening process and throughout 
study  participati on, if applicable. 
A master log of all consented subje cts will be m aintained at the site and will document all 
screening failures (ie, subjects who are consented but do not meet study  eligibilit y criteria and 
are not randomized), including the reason(s) for screening failure.
Subjects who fail to meet the inc lusion/exclusio n criteria (ie, screening failures) should not be 
rando mized or receive study treatment. Further details regarding rando mizat ion are detailed in 
Secti on 4.6.1 .
4.1.5 Withdrawal from  the Study
Subjects are free to withdraw their consent to participate in the study  (study  treatm ent and 
assessments) at any  time, wi thout prej udice to further treatment. All study  drug(s) shoul d be 
MedImmune Protocol Amendment 4 D9108C00001 (COAST)
Durvalumab and novel oncology therapies 27Jul2021 ; Final
CONFI DENTIAL AND PROPRIETARY 35of 105 Template 18.0returned by the subject. If a subject withdraws from further participat ion in the study, then no 
further study  visits or data coll ection shoul d take place. 
4.1.6 Discontinuation of Investigational Product
An individual subject in any o f the treatm ent arm s will  not receive any further study  drug if 
any of the fo llowing occur in the subject in quest ion:
1Withdrawal o f consent 
2Any toxicit y/AE that in the opinio n of the invest igator and/or the sponsor, warrants 
discontinuat ion of further dosing
3Any AE that meets criteria for discontinuation as defined in the Toxicit y Management 
Guidelines (see Section 3.1.3 )
4Pregnancy or intent to beco me pregnant (Section 5.6.2 )
5Delay of  more than 56 days from the last administration of study  drug to the next planned 
dose
6Confirmation o f disease progressi on (Secti on 4.3.1 )
7Unconfirmed disease progre ssion and invest igator determinat ion that the subject is not 
eligible for a confirmat ion scan (Sect ion 4.3.1 )
8Initiation of  alternative anticancer t herapy 
9Intercurrent illness or medical condit ion, in the judgment of the investigator and/or the 
sponsor warrants discont inuat ion of further dosing 
Subjects who are permanent ly discont inued fro m receiving study  treatment will be fo llowed 
for protocol -specified assessments, including fo llow-up of any  AEs, unless consent i s 
withdrawn from  further study  parti cipat ion (Section 4.1.5 ), disease progressi on, the subject 
starts alternat ive treatment/clinical study, or the subject is lost to follow -up. All  subjects will 
be followed for survival unt il the end of the study  unless consent is withdrawn fro m further 
study  participati on.
4.1.7 Replace ment of Subjects
Subjects will not be replaced.
4.1.8 Withdrawal of Informed Consent for Data and Biological Samples
MedImmune ensures that biological samples are returned to the source or destroyed at the end 
of a specified period as described in the informed consent.
If a subject wi thdraws consent to the use of donated bio logical samples, the sam ples will  be 
disposed of/destroy ed, and the acti on documented. If samples are already analyzed, 
MedImmune is not obliged to destroy  the resul ts of this research. As collect ion of th e 
biological  samples (except for the optional tumor biopsy at screening and on -treatm ent, and 
optional blood sam ple at screening for germline DNA) is an integral part of the study , if a 
MedImmune Protocol Amendment 4 D9108C00001 (COAST)
Durvalumab and novel oncology therapies 27Jul2021 ; Final
CONFI DENTIAL AND PROPRIETARY 36of 105 Template 18.0subject decides to withdraw consent to the use of donated bio logical s amples, then the subject 
will also be wit hdrawn from further study  parti cipati on.
The Principal Invest igator:
Ensures subject’s wit hdrawal o f informed consent to the use of donated samples is 
notified immediately to MedImmune.
Ensures that bio logical sampl es from that subject, if stored at the study  site, are 
immediately  identified, disposed of/destroy ed, and the action documented.
Ensures the organizat ion(s) ho lding the samples is/are informed about the withdrawn 
consent immediately and that samples are di sposed of/destroy ed, the acti on docum ented 
and the signed document returned to the study  site.
Ensures that the subject and MedImmune are informed about the sample disposal.
MedImmune ensures the organizat ions holding the samples is/are informed about the
withdrawn consent immediately and that samples are disposed of/destroy ed and the act ion 
docum ented and returned to the study  site.
4.2 Schedule of Study Procedures
The schedule of study  procedures outlined in this section, with the exception o f study  drug 
administration that is treatment -arm specific, will be fo llowed for all  treatm ent arms. 
The study  drug treatm ent regimens for the control arm and each combinat ion experimental 
arm are presented in Section 3.1.2 . 
4.2.1 Enroll ment/Screening and Treatment Periods
Table 5shows all procedures to be conducted during the screening and treatment periods.
MedImmune Protocol Amendment 4 D9108C00001 (COAST)
Durvalumab and novel oncology therapies 27Jul2021 ; Final
CONFIDENTIAL AND PROPRIETARY 37of 105 Template 18.0Table 5 Schedule of Screening and Treatment Period Procedures
ProcedureScreeningTreatment Period: Up to 12 Months
28-day Cycles
Day -28 to 
Day -1Cycle 1 Cycle 2 Cycle 3 Cycle 4 Cycle 5 through Cycle 13
Day 1Day 1 
(± 3 days)Day 1
(± 3 days)Day 1 
(± 3 days)Day 1
(± 3 days)
Written informed consent X
Demographics X
Medical history aX
Verify  eligibility  criteria X
Physical examination X X X X X X
Vital signs X X X X X X
ECG bX
ECOG performance status X X X X X X
Tumo r specimen cX X (optional) c
Serum chemistry X X dX X X X
Hematology X X dX X X X
Urinaly sis X As clinically indicated
Thyroid functio n tests eX X dX X X X
Pregnancy test fX X X X X X
Coagulation parameters X
Hepatitis B and C; HIV gX
Concomitant medications X X X X X X
Assessment of AEs/SAEs X X X X X X
Disease assessment (scans) X hX 
(within 7 days)Cycle 5 then every 2 cycles
(within 7days)
MedImmune Protocol Amendment 4 D9108C00001 (COAST)
Durvalumab and novel oncology therapies 27Jul2021 ; Final
CONFIDENTIAL AND PROPRIETARY 38of 105 Template 18.0Table 5 Schedule of Screening and Treatment Period Procedures
ProcedureScreeningTreatment Period: Up to 12 Months
28-day Cycles
Day -28 to 
Day -1Cycle 1 Cycle 2 Cycle 3 Cycle 4 Cycle 5 through Cycle 13
Day 1Day 1 
(± 3 days)Day 1
(± 3 days)Day 1 
(± 3 days)Day 1
(± 3 days)
Brain MRI (preferred) or CT Xh
PET scanCycle 7 only  
(within 7 days of Day 1)
 
 
 
Serum for PK X (predose & EOI)iX (predose)jCycle 7 and Cycle 11 only 
(predose)j
Serum for ADA X (predose)kX (predose)kCycle 7 and Cycle 11 only 
(predose)k
Study drug administration lAccording to each study drug-specific regimen 
ADA = antidrug antibody; AE = adverse event; β-hCG = beta human chorionic gonadotropin; CT = computed tomography ;  
ECG = electrocardiogram; ECOG = Eastern Cooperative Oncology Group; EOI = end of infusion; HBc = hepatitis B core; HBs = hepa titis B surface; HBsAg
= hepatitis B surface antigen; HBV = hepatitis B virus; HCV = hepatitis C vir us; HIV = human immunodeficiency virus; MRI = magnetic resonance imaging; 
PET = positron emission tomography; PK = pharmacokinetics; SAE = serious adverse event; T3 = triiodothyronine; T4 = thyroxine ; TSH = thyroid 
stimulating hormone.
Note: All safety lab oratory  results must be reviewed by the investigator or physician designee prior to administration of any study treatment.
aDiagnosis of active tuberculosis is defined by compatible clinical evaluation (medical history and physical examination), rad iograph ic findings, and 
tuberculosis testing in line with local practice.
bIn cases when the first ECG shows clinically significant abnormalities, including a QTcF value ≥ 470 ms, 2 additional ECGs should be obtained over a 
brief period (eg, 30 minutes) to confirm the finding based on the average of all 3 manually overread ECGs by a medically qualified delegate.
CCI
CCI
MedImmune Protocol Amendment 4 D9108C00001 (COAST)
Durvalumab and novel oncology therapies 27Jul2021 ; Final
CONFIDENTIAL AND PROPRIETARY 39of 105 Template 18.0Table 5 Schedule of Screening and Treatment Period Procedures
ProcedureScreeningTreatment Period: Up to 12 Months
28-day Cycles
Day -28 to 
Day -1Cycle 1 Cycle 2 Cycle 3 Cycle 4 Cycle 5 through Cycle 13
Day 1Day 1 
(± 3 days)Day 1
(± 3 days)Day 1 
(± 3 days)Day 1
(± 3 days)
cTumo r tissue sample, when available, from the original diagnosis and before initiation of chemoradiotherapy will be collected at screening, per inclusion 
criterion. Optional fresh tumor tissue specimens may be collected after completion of chemoradiotherapy during screening and o n treatment at the time of 
the PET/CT (Cycle 7). Additional on -treatment fresh tumor tissue specimens may be collected at the inves tigator’s discretion as clinically indicated for 
correlative biomarker studies. See Section 4.3.7.4 .
dIf screening laboratory assessments are perfor med within 3 days prior to Day 1, they do not need to be repeated at Day 1.
eTSH, T3, and T4. If TSH is normal, then T3 or T4 is not required. Free T3/free T4 are preferred over total T3/total T4.
fFemales of childbearing potential are required to have a pre gnancy test within 7 days prior to the first dose of study treatment. A urine or serum pregnancy 
test is acceptable; if urine test is equivocal or positive then serum β -hCG testing should be performed for confirmation. 
gActive hepatitis B, hepatitis C, and HIV infections are defined by positive serologic test. Subjects positive for HBV infection are eligible if findings are 
compatible with past or resolved infection (HBsAg negative, anti -HBc positive and anti -HBs positive) or due to vaccination (HBsAg negat ive, anti -HBc 
negative and anti -HBs positive). Subjects positive for HCV antibody are eligible only if polymerase chain reaction is negative for HCV RNA.
hScreening disease assessment and brain MRI or CT must be performed after completion of chemoradiothera py. 
iIn combination arms, PK predose (within 1 hour prior to dosing) and EOI (within 15 minutes post-EOI) samples will be collected according to the 
administration time of each study drug. For example: PK predose Agent 1 collected →Agent 1 administration →PK EOI Agent 1 collected →PK 
predose Agent 2 collected →Agent 2 administration →PK EOI Agent 2 collected.
jIn combination arms, at visits when predose samples only are required, PK samples will be collected within 1 hour prior to ad ministration of the first 
study drug only. For example: PK predose Agent 1 and Agent 2 collected →Agent 1 administration →Agent 2 administration.
kIn combination arms, ADA samples will be collected within 1 hour prior to administration of the first study drug only. For ex ample: ADA predose 
Agent 1 and Agent 2 collected →Agent 1 administration →Agent 2 administration.
lTreatment regimens are described in Section 3.1.2.
MedImmune Protocol Amendment 4 D9108C00001 (COAST)
Durvalumab and novel oncology therapies 27Jul2021 ; Final
CONFIDENTIAL AND PROPRIETARY 41of 105 Template 18.0Table 6 S chedule of Follow -up Procedures: Subjects Who Completed Study 
Treatment and Maintain DC, Subjects Who Discontinued Study 
Treatment Due to Other Reason Not Related to PD, and Subjects 
Who Experienced Unconfirmed PD and are Eligible for a 
Confirmation Scan
Time since Cycle 1 Day 1 ≤ 12 Months > 12 to ≤ 24 Months > 24 to 60 Months
Follow -up based on previous 
scheduled visitEvery 8 Weeks
(± 3 days)Every 12 Weeks
(± 7 days)Every 6 Months
(± 4 weeks)
Procedure
Serum for ADA10 months post 
Cycle 1 Day  1 onlyMonth 15 only
Survival status (if visits are 
discontinued, this may be done 
via telephone contact) cX X X
ADA = antidrug antibody; AE = adverse event; ; DC = disease control; 
ECOG = Eastern Cooperative Oncology Group; PD = progressive dise ase; PK = pharmacokinetics; SAE = 
serious adverse event; T3 = triiodothyronine; T4 = thyroxine; TSH = thyroid stimulating hormone.
aTSH, T3, and T4. If TSH is normal, then T3 or T4 is not required. Free T3/free T4 are preferred over 
total T3/total T4.
bConcomitant medications and AEs/SAEs will be collected up to 12 months post Cycle 1 Day 1, 
regardless of whether the subject discontinued treatment. Following the first 12 months, concomitant 
medications and AEs/SAEs will be collected up to 3 months post l ast dose of study treatment, if 
applicable.
cSubjects may be contacted for survival status ever y 12 mo nths beyond 60 months post Cycle 1 Day 1, 
until the end of the entire study, unless the subject withdraws consent from further participation in the 
study.
4.2.3 End of Study
Table 7presents procedures for the end of study  visit for all  subjects. End of study  visit will 
be perform ed when a subject discont inues study  due to a confirmed PD, or a subject 
experienced an unconfirmed PD but is not eligible for a confirmat ion scan, or after 60 months 
of follow-up for subjects who achieve DC and remain disease free, or at the last study  visit for 
subjects who discont inue study  due to reason not related to PD.
Subjects who discont inue treatment due to any reason, including confirmed PD or init iation of 
alternat ive anticancer therapy, will be fo llowed for survival according to the timepo ints in 
Table 6(every  8 weeks up to 12 m onths post Cy cle 1 Day  1, every  12 weeks from  >12 to 
≤24 m onths, and every  6 months f rom > 24 to 60 m onths post Cy cle 1 Day  1) unless the 
subject wi thdraws consent from further participat ion in the study . After 60 m onths, subjects 
may be contacted for survival every  12 m onths until the end of the ent ire study .
CCI
MedImmune Protocol Amendment 4 D9108C00001 (COAST)
Durvalumab and novel oncology therapies 27Jul2021 ; Final
CONFIDENTIAL AND PROPRIETARY 44of 105 Template 18.0 
4.3.1.2 Disease assessment by PET 
Local  changes and the presence of distal metastasis will be assessed by  posi tron emissi on 
tomography  (PET). The methods for assessing metabolic update by  PET are s ummarized 
below ( Plathow et al , 2011 ).
PET requires measurement of the metabo lically active lesio ns and background area. The 
FDG -distribut ion is rated visually and quanti ﬁed as standardized uptake values (SUV).
Any focal tracer uptake in lesio ns wit h SUV peak at least 1.5- fold greater than liver 
SUV mean is considered metastatic in absence of any alternat ive explanat ion. If liver is 
abnorm al, primary tu mor lesio n shoul d have uptake at least 2.0 -fold greater than SUV 
mean of blood pool in descending thoracic aorta.
For each lesion suspicious for malignancy in PET/CT, the site -based localizat ion (lymph 
nodes, l ung, liver, adrenal gland, brain, other viscera, and bone) is recorded.
These parameters can be recorded as exploratory  data on up to 5 m easurable target 
lesions, ty pically  the 5 hottest l esions, which are typically the largest, and no more than 
2per organ. Tumor size of these lesio ns can be determin ed per RECIST v1.1.
Addit ional SUV measures including SUV mean, SUV peak or volumetric informat ion 
may be measured to assess suspicious lesio ns.
4.3.2 Medical History, Physical Examination, Electrocardiogram , and Vital 
Signs 
Medical History
Medical history  will be co llected at screening. Based on findings fro m medical history , 
ongoing current condit ions will be given a baseline grade according to the procedure for AEs. 
Increases in severit y of pre-exist ing condit ions during the study  will be considered AEs, wit h 
resol ution occurring when the grade returns to the pre -study  grade or bel ow.
Physical Examinations
Physical examinat ions will be performed according to the schedules in Sect ion4.2. A 
complete physical examinat ion will be performed at screening and should include assessments 
of the head, ey es, ears, nose, and throat, respiratory , cardi ovascular, gastrointestinal, 
musculoskeletal, neuro logical, psych iatric, derm atological, hematol ogic/lymphat ic, endocrine 
system s, and wei ght to 0.1 kg; and height (at screening only). Abbreviated symptom -directed 
physical examinat ions will be conducted at subsequent visits post dosing. 
Vital Signs
CCI
MedImmune Protocol Amendment 4 D9108C00001 (COAST)
Durvalumab and novel oncology therapies 27Jul2021 ; Final
CONFIDENTIAL AND PROPRIETARY 45of 105 Template 18.0Vital signs (blood pressure and pulse rate) will be measured according to the schedules in 
Secti on4.2. For all vital sign measurements, subjects should rest for at l east 10 minutes in a 
supine or semi -recumbent posi tion, and all vital sign measurements should be taken prior to 
any blood draws or other procedures whenever possible.
ECG
Resting 12 -lead ECGs will be recorded at screening and as clinically indicated throu ghout the 
study  as presented in Section 4.2. ECGs shoul d be obtained after the subject has been in a 
supine posit ion for 5minutes and recorded while the subject remains in that position.
In cases when the first ECG shows clinically significant abnormalit ies, including a QTcF 
value ≥ 470 ms, 2 addit ional 12 -lead ECGs should be obtained over a brief period (eg, 
30minutes) to confirm the finding ba sed on the average of all 3 manually  overread ECGs by  a 
medically qualified delegate.
4.3.3 Clinical Laboratory Tests
A Laboratory  Manual will be provided to the sites that specifies the procedures for collect ion, 
processing, storage, and shipment of samples, as well as laboratory  contact information, 
specific to this clinical research study . 
Clinical laboratory  safet y tests, including serum pregnancy tests, will be performed in a 
licensed clinical laboratory . Urine pregnancy  tests may be perform ed at the si te using a 
licensed test (dipst ick). Abnormal laboratory result s should be repeated using a serum 
pregnancy test as soon as possible (preferably wit hin 24 to 48 hours). 
The fo llowing clinical laboratory  tests will  be perform ed (see Section 4.2for the schedule of 
tests): 
Serum Chemistry
•Albumin •Gamma -glutamyl transferase
•Amylase •Glucose
•ALP •Lactate dehydrogenase
•ALT •Lipase
•AST •Magnesium
•Bicarbonate •Potassium
•Blood urea nitrogen / urea •Sodium
•Calcium•Total bilirubin (TBL; direct bilirubin should be obtained 
if TBL is > ULN)
•Chloride •Total protein
•Creatinine • C-reactive protein
ULN = upper limit of normal
MedImmune Protocol Amendment 4 D9108C00001 (COAST)
Durvalumab and novel oncology therapies 27Jul2021 ; Final
CONFIDENTIAL AND PROPRIETARY 46of 105 Template 18.0Note: Tests for AST, ALT, ALP, and TBL must be conducted concurrently and assessed concurrently.
Hematology
• Absolute lymphocyte count • Platelet count
• Absolute neutrophil count • White blood cell count
• Hemoglobin
Urinalysis
• Blood
• Protein
Pregnancy Test (females of childbearing potential only)
• Urine hCG
• Serum β -hCG (or required if a urine hCG is equivocal or positive)
β-hCG = beta -human chorionic gonadotropin; hCG =human chorionic gonadotropin.
Other Safety Tests
• Coagulation tests: activated partial t hromboplastin time and international normalized ratio. If international 
normalized ratio is not available the sites may substitute a prothrombin time.
• Tuberculosis: Diagnosis of active tuberculosis is defined by compatible clinical evaluation (medical his tory 
and physical examination), radiographic findings, and tuberculosis testing in line with local practice.
• Hepatitis B, hepatitis C, and HIV: Active hepatitis B, hepatitis C, and HIV infections are defined by 
positive serologic test. Subjects positive fo r HBV infection are eligible if findings are compatible with past 
or resolved infection (HBsAg negative, anti -HBc positive and anti -HBs positive) or due to vaccination 
(HBsAg negative, anti -HBc negative and anti -HBs positive). Subjects positive for HCV ant ibody are 
eligible only if polymerase chain reaction is negative for HCV RNA.
• Thyroid functio n tests: TSH, T3, and T4. If TSH is normal, then T3 or T4 is not required. Free T3/free T4 
are preferred over total T3/total T4.
HBc = hepatitis B core; HBsAg = hepatitis B surface antigen; HBV = hepatitis B virus; HCV = hepatitis C 
virus; T3 = triiodothyronine; T4 = thyroxine; TSH = thyroid stimulating hormone.
4.3.4 Pharmacokinetic Evaluation and Methods
Blood sam ples will be collected to evaluate PK in serum of dur valumab when administered 
alone or in combinat ion with novel agents. Addit ionally , PK in serum  of novel agents admin-
istered in combinat ion with durvalumab will be evaluated. Novel agents include oleclumab 
and mo nalizumab. See Section 4.2for collect ion time points. Evaluations will be performed 
using a validated immunoassay.
In combinat ion arms, at visits when predose and end of infusion (EOI) sample s are required, 
PK predose (within 1 hour prior to dosing) and EOI (within 15 minutes post -EOI) samples 
will be co llected according to the administration time of each study drug. For example: 
MedImmune Protocol Amendment 4 D9108C00001 (COAST)
Durvalumab and novel oncology therapies 27Jul2021 ; Final
CONFIDENTIAL AND PROPRIETARY 47of 105 Template 18.0PKpredose Agent 1 collected → Agent 1 administration → PK EOI A gent 1 collected → PK 
predose Agent 2 collected → Agent 2 administration → PK EOI Agent 2 collected.
In combinat ion arms, at visits when predose samples only are required, PK samples will be 
collected within 1 hour prior to administration of the first study  drug only . For example: PK 
predose Agent 1 and Agent 2 collected → Agent 1 administration → Agent 2 administration.
4.3.5 Immunogenicity Evaluation and Methods
Blood sam ples will be collected to evaluate ant idrug antibody (ADA) responses to durval-
umab when administered alone or in combinat ion with novel  agents. Addi tionally, ADA re-
sponses to novel bio logic agents administered in combinat ion with durvalumab will be evalu-
ated. Novel/bio logic agents include oleclumab and monalizumab. See Section 4.2for collec-
tion time poi nts. Eval uations will be performed using a validated immunoassay . Tiered anal-
yses will be performed to include screening, confirmatory , and ti ter assay  com ponents, and the 
positive-negat ive cut points will be statist ically determined from drug -naive validat ion sam-
ples. Sam ples may  be utilized for further characterizat ion of the ADA response, including pos-
sible assessment of neutralizing antibody .
In combinat ion arms, ADA samples will be collected within 1 hour prior to administration o f 
the first study  drug only. For example: ADA predose Agent 1 and Agent 2 collected → 
Agent 1 administration → Agent 2 administration.
4.3.6 Genetic Evaluations a nd Methods
See Appendix Efor informat ion regarding genet ic research.
4.3.6.1 Collection of Genetic Samples
If the subject agrees to participate in the opt ional genet ic research study, a blood sample will 
be co llected. Participat ion is optional. Subjects who do not wish to participate in the genet ic 
research may st ill part icipate in the study . 
The blood sample for genet ic research will be obtained fro m the subjects at screening. If for 
any reason the sample is not drawn at screening, it may be taken at any  visit unt il the last 
study  visit. Only  one sample shoul d be co llected per subject for genetics during the study.
In the event of DNA extraction failure, a replacement genet ic blood sample may be requested 
from the subject. Si gned informed consent will be required to obtain a replacement sample un-
less it was included in the original consent.
Samples will  be collected, l abelled, stored and shipped as detailed in the Laboratory  Manual.
MedImmune Protocol Amendment 4 D9108C00001 (COAST)
Durvalumab and novel oncology therapies 27Jul2021 ; Final
CONFIDENTIAL AND PROPRIETARY 48of 105 Template 18.04.3.6.2 Storage and Destruction of Genetic Samples
The processes adopted for the coding and storage of samples for genet ic analysis are im-
portant to maintain subject confident iality. Sam ples will  be stored for a m aximum  of 15years 
or as per l ocal regul ations from the date of the l ast subject’s l ast vi sit, after whi ch they will be 
destroy ed. DNA is a finite resource that may be used up during analyses. The results of any 
further analyses will be reported either in the CSR itself or as an addendum, or separately in a 
scientific report or publicat ion.
No personal details identifying the individual will be available to MedImmune or designated 
organi zations working wit h the DNA.
4.3.7
 
4.3.7.1
4.3.7.2
 
4.3.7.3
 
4.3.7.4
 
 
CCI
CCI
CCI
CCI
CCI
CCI
CCI
MedImmune Protocol Amendment 4 D9108C00001 (COAST)
Durvalumab and novel oncology therapies 27Jul2021 ; Final
CONFIDENTIAL AND PROPRIETARY 49of 105 Template 18.0screening (Day  -28 to Day  -1) and on treatm ent at the time o f the PET/CT (Cy cle 7). Addi -
 
 
4.3.7.5 Storage, Re -use, and Destruction of Biological Samples
Samples will  be stored for a m aximum  of 15 y ears or as per l ocal regul ations from the date of 
the last subject’s last visit, after which they  will be destroy ed. The results of this bio marker 
research will be reported either in the clinical study report (CSR) itself or as an addendum, or 
separately  in a scient ific report or publicat ion. The results of this bio marker research may be 
pooled wi th biomarker data from  other studi es wi th the study  drug to generate hy potheses to 
be tested in future research.
4.3.8 Estim ate of Volume of Blood to be Collected
A total o f no m ore than 36.8 mL of blood will be required for all screening tests. No more 
than 59.0 mL of blood will be drawn at any  visit during the treatm ent peri od. During the fo l-
low-up peri od, no m ore than approximately  34.5 mL of blood will be collected at any visit. 
The total volume to be collected will depend on the treatment arm, central laboratory  used, 
and length of a subject’s participat ion in the study . The Laboratory  Manual may  be referenced 
for test vol ume specifics.
4.4 Study or Study Component Suspension or Termination
MedImmune reserves the right to temporarily suspend or permanent ly terminate this study  or 
component of the study  at any  time. The reasons for temporarily suspending or permanently 
terminating the study  may include but are not limit ed to the fo llowing: 
1The incidence or severit y of AEs in this or other studies indicates a potential health 
hazard to subjects
2Subject enrollment is unsat isfactory
3Non-compliance that might significant ly jeopardize the validit y or integri ty of the study  
4Sponsor decisio n to terminate development of durvalumab or any  of the combinat ion 
study  treatm ents for this indicat ion
5Sponsor decisio n to terminate the study  or any  treatm ent arm  based on a pl anned fut ility 
analysis and/or recommendat ion from SRC (Section 4.8.7 and Section 3.1.4 , respectively)
CCI
MedImmune Protocol Amendment 4 D9108C00001 (COAST)
Durvalumab and novel oncology therapies 27Jul2021 ; Final
CONFIDENTIAL AND PROPRIETARY 50of 105 Template 18.0If MedImmune determines that temporary  suspension or permanent terminat ion of the study  
or com ponent of the study  is requi red, MedImmune will discuss the reasons for taking such 
action wi th all parti cipat ing invest igators (or head of the medical inst itution, where applica-
ble). When feasible, MedImmune will provide advance notice to all participat ing inves tigators 
(or head of the medical inst itution, where applicable) of the impending act ion.
If the study  or com ponent of the study  is suspended or terminated for safet y reasons, MedIm-
mune will prompt ly inform all invest igators, heads of the medical institutions (where applica-
ble), and/or inst itutions conduct ing the study. MedImmune will also prompt ly inform  the rel e-
vant regulatory  authori ties of  the suspensio n/terminat ion alo ng with the reasons for such ac-
tion. Where required by  applicable regulat ions, the invest igator or head of the medical inst itu-
tion m ust inform  the IRB/IEC prom ptly and provide the reason(s) for the suspensio n/termina-
tion. If the study  or com ponent of the study  is suspended for safet y reasons and it is deemed 
appropriate by  MedImmu ne to resume the study  or com ponent of the study , approval  from the 
relevant regul atory  authori ties (and IRBs/IECs when applicable) will be obtained prior to re-
suming the study .
4.5 Investigational Product 
4.5.1 Identity of Investigational Product
For all the treat ment arms, control  arm and each combinat ion experimental arm, MedImmune 
will provide the investigators with study  drug ( Table 8) using designated distr ibution centers. 
Table 8 Identification of Investigational Product 
Investigational Product Provider Concentration and Formulation as Supplied
Durvalumab (MEDI4736) MedImmuneSupplied as a vialed liquid solution containing 
500mg(nominal) durvalumab per vial. The solution 
contains 50 mg/mL durvalumab, 26 mM 
histidine/histidine HCl, 275 mM trehalose dihydrate, 
and 0.02% (w/v) polysorbate 80, at pH 6.0 and 
density  of 1.054 g/mL. The nominal fill volume is 
10.0 mL.
Oleclumab (MEDI9447) MedImmuneSupplied as a vialed liquid solution containing 
500mg (nominal) oleclumab. The solution contains 
50mg/mL oleclumab, 25 mM histidine/histidine HCl, 
240 mM sucrose, 0.03% (w/v) polysorbate 80, at 
pH6.0. The nominal fill volume is 10.0 mL.
MedImmune Protocol Amendment 4 D9108C00001 (COAST)
Durvalumab and novel oncology therapies 27Jul2021 ; Final
CONFIDENTIAL AND PROPRIETARY 51of 105 Template 18.0Table 8 Identification of Investigational Product 
Investigational Product Provider Concentration and Formulation as Supplied
Monalizumab (IPH2201) MedImmuneSupplied as a vialed lyophilized powder containing 
375 mg (nominal) monalizumab per vial. The powder 
is to be reconstituted with 7.4 mL WFI. After 
reconstitution, the vial contains 50 mg/mL
monalizumab, 20 mM histidine /histidine 
hydrochloride, 220 mM sucrose, 0.03% (w/v) 
polysorbate 80, pH 6.0
DP = drug product; DS = drug substance; HCl = hydrochloride; WFI = Water for Injection; w/v = weight per 
volume.
Durvalumab is supplied in 10R vials as a sterile, clear to opalescent, col orless to slightly yel-
low liquid, free from or practically free fro m visible parti cles at a concentrati on of  50mg/mL.
Oleclumab is supplied in 10R vials as a sterile, clear to opalescent, colorless to y ellow liqui d, 
that may  contain a few w hite to off -white transl ucent parti cles at a concentrati on of  
50mg/mL.
Monalizumab is supplied in 20R vials as a vialed lyophilized powder with dried powder visi-
ble on the vial wall. The reconst ituted drug product is a clear to opalescent and colorless to
yellow liquid, that may  contain som e translucent or whi te to off -white inherent parti cles at a 
concentration of 50 mg/mL.
Durvalumab, oleclumab, and mo nalizumab vials are stored at 2°C to 8°C (36°F to 46°F) and 
must not be frozen. Drug products should be kept in ori ginal  packaging unt il use to prevent 
prolonged light exposure.
Each invest igational product kit has a unique number that is printed on all labels wit hin the kit 
(ie, the outer carton label and the label o f each container within the carton). Each carton and 
vial is labeled with the same unique number.
Commercially available 0.9% (weight per volume [w/v]) saline or 5% (w/v) dextrose will be 
supplied by  each si te.
4.5.1.1 Investigational Product Handling
The invest igator’s or site’s designated invest igational product m anager is required to maintain 
accurate investigat ional product accoun tabilit y records. Upon complet ion of the study , copi es 
of investigational product accountabilit y records will be returned to MedImmune. All unused 
investigat ional products wi ll be returned to a MedImmune authorized depot or disposed of 
upon authorizat ion by MedImmune according to the invest igational site policy. 
MedImmune Protocol Amendment 4 D9108C00001 (COAST)
Durvalumab and novel oncology therapies 27Jul2021 ; Final
CONFIDENTIAL AND PROPRIETARY 52of 105 Template 18.04.5.1.2 Investigational Product Inspection
Each vial selected for dose preparation should be inspected. See Section 4.5.1 for a descript ion 
of investigational product presentation. 
If there are any defects noted with the invest igational product, the invest igator and sit e moni-
tor should be notified immediately. Refer to the Product Complaint sect ion (Section 4.5.1.8 ) 
for further instructi ons.
4.5.1.3 Durvalumab Dose Prepar ation and Administration
The dose of durvalumab for administration must be prepared by  the investi gator’s or si te’s 
designated invest igational product manager using asept ic technique. 
Total  time fro m needle puncture of a durvalumab vial to start of admini strati on shoul d not ex-
ceed: 
24 hours at 2°C to 8°C (36°F to 46°F)
4 hours at room temperature 
A dose of 1500 mg will be administered using an IV bag containing 0.9% (w/v) saline or 
5%(w/v) dextrose, with a final durvalumab concentration ranging from 1 to 15 mg/mL, and 
delivered through an IV administration set with a 0.2 -or 0.22 -μm filter. Add 30 .0 mL of dur-
valumab (ie, 1500 mg of durvalumab) to the IV bag. The IV bag size should be selected such 
that the final concentration is within 1 to 15 mg/mL. Mix the bag by  gent ly inverting to ensure 
homogeneit y of the dose in the bag. 
Standard infusio n time is 1 hour, however if there are interruptions during infusion, the total 
allowed infusio n time should not exceed 8 hours at room temperature. 
For experimental arms that require administration of durvalumab and the combinat ion study  
drug on the same day , the total  infusio n time for both study  drugs shoul d not exceed 8 hours at 
room  temperature. 
Do not co -administer other drugs through the same infusio n line. 
Flush the IV line wit h a vo lume of IV diluent equal to the priming vo lume of the infusio n set 
used after the contents of the IV bag are fully administered, or complete the infusio n accord-
ing to inst itutional policy to ensure the full dose is administered. 
If eit her preparation time or infusio n time exceeds the time limit s, a new dose must be pre-
pared fro m new vials. Durvalumab does not contain preservat ives, and any unused portion 
must be discarded.
MedImmune Protocol Amendment 4 D9108C00001 (COAST)
Durvalumab and novel oncology therapies 27Jul2021 ; Final
CONFIDENTIAL AND PROPRIETARY 53of 105 Template 18.04.5.1.4 Oleclumab Dose Preparation and Administration
The dose of oleclumab for administration must be prepared by  the invest igator’s or site’s des-
ignated inves tigational product manager using aseptic technique. 
Total  time fro m needle puncture of the oleclumab vial to the start of administration should not 
exceed:
24 hours at 2°C to 8°C (36°F to 46°F)
4 hours at room temperature
If preparation t ime exceeds the time limit s a new dose must be prepared from new vials. Ole-
clumab does not contain preservat ives, and any unused portion must be discarded.
No incompat ibilities between oleclumab and polyvinylchloride or polyolefin IV bags have 
been observed.
A dose of 3000 mg will be administered using an IV bag containing 0.9% (w/v) saline with a 
final o leclumab concentration of 1.5 to 30 mg/mL, and delivered through an IV administration 
set wi th a 0.2 -or 0.22 -μm filter. Mix the bag by gent ly invert ing to ensure homog eneity dose 
in the bag.
Standard infusio n time for oleclumab is 1 hour; however, if there are interruptions during infu-
sion, the total  allowed time shoul d not exceed 4 hours at room temperature. If this duration is 
met, then the remainder of the dose shoul d be abandoned and should not be completed with a 
second prepared dose.
On days when both oleclumab and durvalumab are administered, durvalumab infusio n will 
start no less than 15 minutes after the end of o leclumab infusion. See Section 4.5.1.3 for dur-
valumab administration. In the event that on day s when both ol eclumab and durvalumab are 
administered there are interruptions during infusio n for eitheroleclumab and/or durvalumab, 
the total infusio n duration for both study  drugs shoul d not exceed 8 hours. Of the total 8- hour 
infusio n duration, a maximum o f 4 hours may correspond to oleclumab infusio n.
Do not co -administer other drugs through the same in fusio n line.
4.5.1.5 Monalizumab Dose Preparation and Administration
The dose of monalizumab for administration must be prepared by the investigator’s or site’s 
designated invest igational product manager using asept ic technique. 
Slowly  add 7.4 m L of sterile Water for Inject ion by t ilting the vial to one side such that the 
liquid stream is directed along the vial wall and not direct ly onto the lyophilized cake. Gent ly 
swirl the sol ution until all so lids are disso lved. Do not shake or vigorously agitate the vial. 
MedImmune Protocol Amendment 4 D9108C00001 (COAST)
Durvalumab and novel oncology therapies 27Jul2021 ; Final
CONFIDENTIAL AND PROPRIETARY 54of 105 Template 18.0Visually inspect the solut ion to ensure that the ent ire con tent of the ly ophilized cake is com -
pletely reconst ituted. The reconstituted solut ion shoul d appear cl ear to opal escent. A thin layer 
of bubbles on the surface of the liquid is normal. 
Monalizumab sh ould be protected from direct sunlight during preparation and handling. Total 
time fro m start of reconstitution to the start of monalizumab administration should not exceed: 
24 hours at 2°C to 8°C (36°F to 46°F)
4 hours at room temperature
No incompat ibilities between monalizumab and polyo lefin, polyethylene, polypropylene, or 
polyvinyl chloride IV bags have been observed. 
A dose of 750 mg will be administered using an IV bag containing 0.9% (w/v) saline or 
5%(w/v) dextrose, with a final m onalizumab concentrati on of  1 to 20 m g/mL, and delivered 
through an IV administration set with a 0.2- or 0.22 µm  filter. Add 15.0 mL of monalizumab 
(ie, 750 m g of monalizumab) to the IV bag. The IV bag size should be selected such that the 
final concentrat ion is within 1 to 20 mg/mL. Mix the bag by gent ly invert ing to ensure ho mo-
geneit y of the dose in the bag.
Standard monalizumab infusio n time is 1 hour, however if there are interruptions during infu-
sion, the total  allowed infusi on time shoul d not exceed 8 hours at room temperature. The infu-
sion rate shoul d not be changed unless necessary  to manage acute reactions. 
On days when both durvalumab and mo nalizumab are administered, durvalumab will be ad-
ministered first. See Section 4.5.1.3 for durval umab treatm ent administrati on. 
Monalizumab infusio n will start no less than 15 minutes after the end of the durvalumab infu-
sion. 
In the event that there are interruptions during infusion for either durvalumab and/or monali-
zumab on days when both durvalumab and monalizumab are administered, the total infusio n 
durati on for both study  drugs shoul d not exceed 8 hours. Of the total 8 -hour infusio n duration, 
a maxim um of 4 hours m ay correspond to durvalumab infusion. Do not co- administer other 
drugs through the same infusio n line.
4.5.1.6 Treatment Administration
The first day  of dosing is considered Day 1. 
No specific premedication is required for durvalumab, oleclumab, o r monalizumab. Details of 
any premedicat ion or conco mitant m edicat ion given to m anage or prevent AEs should be rec-
orded on the electronic case report form (eCRF).
MedImmune Protocol Amendment 4 D9108C00001 (COAST)
Durvalumab and novel oncology therapies 27Jul2021 ; Final
CONFIDENTIAL AND PROPRIETARY 55of 105 Template 18.0A physician must be present at the site or immediately available to respond to emergencies 
during all administrations of invest igational product. Fully  functional resuscitat ion facilities 
shoul d be available.
4.5.1.7 Monitoring of Dose Administration 
Subjects will be mo nitored during and after infusion(s) of invest igational product(s). Vital 
signs will b e measured according to the schedules described in Section 4.2.1 .
As wi th any biologic product, allergic react ions to dose administration are possible. Therefore, 
appropriate drugs and medical equipment to treat acute anaphylact ic react ions must be imme-
diately available, and study  personnel must be trained to recognize and treat anaphylaxis.
4.5.1.8 Reporting Product Complaints
Any defects with the inve stigational product must be reported immediately to AstraZeneca 
Product Qualit y Complaints by the site with further notificat ion to the site monitor. All defects 
will be co mmunicated to AstraZeneca and invest igated further with Product Qualit y Com-
plaints. During the investigat ion of the product complaint, all invest igational product must be 
stored at labeled condit ions unless otherwise instructed.
AstraZeneca contact informat ion for reporti ng product com plaints:
E-mail:
Phone:
Website: 
Mail: AstraZeneca
Attn: 
,
4.5.2 Additional Study Medications
No other study  medicat ions are specified for use in this clinical protocol.
4.5.3 Labeling
Labels for the investigational product will be prepared in accordance wit h Good Manufactur-
ing Practice and local regulatory  guidelines. Label text will be translated into local languages, 
as requi red.
4.5.4 Storage
All invest igational products should be stored in a secure and dry  place. Vi als o f investigational 
product for parenteral administration should be stored at 2°C to 8°C (36°F to 46°F; refriger-
ated) and must not be frozen. Invest igational product supplied as oral tablet sh ould be stored 
PPD
PPD
PPD
PPD
PPD
PPD
MedImmune Protocol Amendment 4 D9108C00001 (COAST)
Durvalumab and novel oncology therapies 27Jul2021 ; Final
CONFIDENTIAL AND PROPRIETARY 56of 105 Template 18.0at 15°C to 30°C (59°F to 86°F). Drug product should be kept in secondary packaging unt il use 
to prevent excessive light exposure.
4.5.5 Treatm ent Compliance
Invest igational product is administered by study  site personnel, who will mo nitor com plian ce.
4.5.6 Accountability
The invest igator’s or site’s designated invest igational product manager is required to maintain 
accurate investigat ional product accoun tabilit y records. Upon complet ion of the study , copi es 
of investigational product accountabilit y recor ds will be returned to MedImmune. All unused 
investigat ional product will be returned to a MedImmune -authori zed depot or di sposed of 
upon authorizat ion by MedImmune.
4.6 Treatment Assignment and Blinding
4.6.1 Methods for Assigning Treatment Groups
Once confirmed th at the subject m eets eligibilit y criteria, an IXRS will randomize the subject 
to a treatment arm according to the randomizat ion scheme. 
A rando mization method with dynamically changing rando mizat ion rati os will be em ployed to 
account for fluctuation in th e number of treatm ent arm s open for enrollment over the course of 
the study . Rando mization will be stratified by hist ology  (adenocarcino ma vs non -adenocarci -
noma). The rando mizat ion scheme will use an equal ratio to all study  treatm ent arms open for 
enrollment (eg, if experimental arms are opened sequent ially, an experimental  arm is 
added/closed, or enrollment in an experimental arm is suspended). Addit ionally , the f ollowing 
considerations regarding rando mizat ion will apply: 
If there is no experimental arm open for enrollment, then enrollment will be paused. Any 
subject who had consented previously and was in screening when the experimental arm(s) 
was closed due to safet y concerns may  be allowed to enter into the study  but m ust be 
allocated to the control ar m. 
Once the control arm enro lls 60 subjects, a subsequent randomization scheme may be 
initiated to optimize the number of subjects allocated to control arm. 
At any point during the study , the control  arm will have no l ess than a 33% chance to be 
rando mized in co mpar ison to the active experimental arm that has the lowest 
rando mizat ion rati o in the study . 
Study  treatm ent m ust be administered wi thin 3 days after the treatment arm is assigned. If 
there is a delay in the administration o f study  treatment suc h that i t will not be administered 
within the specified t imeframe, the study monitor must be notified immediately.
MedImmune Protocol Amendment 4 D9108C00001 (COAST)
Durvalumab and novel oncology therapies 27Jul2021 ; Final
CONFIDENTIAL AND PROPRIETARY 57of 105 Template 18.04.6.2 Methods to Ensure Blinding
This study  is not blinded.
4.7 Restrictions During the Study and Concomitant Treatment(s)
The investigator must be inf ormed as soon as possible about any  medicat ion taken from the 
time of screening until the final study  visit. Any conco mitant m edicat ion(s), including herbal 
and natural preparat ions, taken during the study  will be recorded in the eCRF.
4.7.1 Perm itted Concomitan t Medications
Invest igators may prescribe concomitant medicat ions or treatments deemed necessary to pro-
vide adequate prophylactic or supportive care except for those medications ident ified as pro-
hibited in Sect ion4.7.2 .
4.7.2 Prohibited Concomitant Medications
Subjects m ust be instructed not to take any  medicati ons, including over- the-counter products, 
without fi rst consul ting wi th the investi gator. The following conco mitant m edicat ions are pro-
hibited:
Any invest igational anticancer therapy
Any concurrent chemotherapy, radiotherapy  (except palliat ive radiotherapy), 
immunotherapy , biologic or horm onal therapy for cancer treatment. Concurrent use of 
horm ones for noncancer -related condi tions (eg, insulin for diabetes and hormone 
replacement therapy ) is acceptable.
Immunosuppressive medications including, but not limited to systemic corticosteroids at 
doses exceeding 10 mg/day of prednisone or equivalent, meth otrexate, azathioprine, and 
tumor necrosis factor -alpha blockers. The fo llowing are exceptions:
Use of immunosuppressive medicat ions for the m anagement of invest igational 
product -related AEs or in subjects with contrast allergies is acceptable. 
Use of inh aled, intranasal, or topical corticosteroids is permitted. 
Temporary  courses of corti costeroi ds for treatm ent of underlying or concurrent 
illness or in the setting of palliat ive radiotherapy may  be permitted upon discussio n 
with the m edical m onitor.
Live attenuated vaccines during the study  through 180 day s after the l ast dose of study  
drug
Herbal and natural remedies should be avo ided
MedImmune Protocol Amendment 4 D9108C00001 (COAST)
Durvalumab and novel oncology therapies 27Jul2021 ; Final
CONFIDENTIAL AND PROPRIETARY 58of 105 Template 18.04.8 Statistical Evaluation
4.8.1 General Considerations
Tabular summaries will be presented by treatment group. Categorical data wi ll be summarized 
by the number and percentage of subjects in each category . Continuous variables will be sum-
marized by descript ive statistics. Addit ional details of statist ical analyses will  be described in 
the stati stical analysis plan.
The Intent -to-treat (ITT) Population includes all subjects who are randomized. Subjects will 
be analyzed according to their rando mized treatment group.
The As -treated Popul ation includes all subjects who receive any invest igational product. Sub-
jects will be analyzed accordi ng to the treatm ent they  actually  receive.
The Response -evaluable Populat ion includes subjects from the As -treated Popul ation who 
have a baseline disease assessment, have the opportunit y to be fo llowed for at l east 16 weeks 
at the time of the DCO (ie, dose d at l east 16 weeks prior to the time of the DCO), and either 
has at l east one post -baseline disease assessment and/or discontinued treatment due to death or 
disease progressi on.
4.8.2 Sample Size
Subjects will be rando mized to the durvalumab monotherapy control arm and combinat ion 
therapy  experimental  arms. The sample size of 60 subjects per experimental arm is not de-
signed to m ake explicit power and Ty peI error considerations for a hy pothesis test. It is pri-
marily chosen to obtain a preliminary assessment of a ntitumor activit y with a certain degree of 
preci sion.
Table 9shows est imated differences in ORR between an experimental arm and the control 
arm along with 2-sided 95% exact CIs with a sample size of 60 subjects each. Sixty subjects 
per treatment arm provides a 95% CI with reasonable width (approximately ± 18%) for the es-
timated ORR difference between a durvalumab combinat ion experimental arm and the dur val-
umab control  arm. For a 20% increase in ORR in any  durvalumab combinat ion experimental 
arm over durval umab control arm (50% vs 30%, respect ively), the lower limit of the 95% CI 
for the difference between these arms is 1%, which is greater than 0%, sugge sting that the dur-
valumab co mbinat ion experimental arm will have a higher ORR than the durvalumab control 
arm with 95% confi dence.
MedImmune Protocol Amendment 4 D9108C00001 (COAST)
Durvalumab and novel oncology therapies 27Jul2021 ; Final
CONFIDENTIAL AND PROPRIETARY 59of 105 Template 18.0Table 9 Estimated Differences in ORR Between Experimental and Control Arm 
of 60 Subjects Each 
Number of Responders (ORR)
Difference (%) in ORR
(2-sided 95% Exact Confidence Interval)Experimental Arm
(n60)Control Arm
(n60)
24 (40%) 18 (30%) 10% ( -9%, 28%)
27 (45%) 18 (30%) 15% ( -4%, 33%)
30 (50%) 18 (30%) 20% (1%, 38%)
33 (55%) 18 (30%) 25% (6%, 42%)
ORR = objective response rate.
4.8.3 Efficacy
The final efficacy analyses will be based on the ITT Populat ion defined in Sect ion 4.8.1 . Re-
sponse will be summarized and compared between the experimental arm and control arm. 
Time -to-event data will be summarized using the Kaplan -Meier estimates. The following effi-
cacy endpoint s will be analyzed. Each experimental arm will be co mpared to the control arm. 
There will be no formal co mparisons between any  experimental  arms. RECIST v1.1 will be 
used as primary  analysis for all endpoints when applicable. Localized post -radiation chang es 
which affect lesio n sizes may  occur and there m ay be high l evels o fnecrosi s/fibrosis with lit-
tle or no active tumor in recent ly irradiated l esions. However, accepting these limit ations in 
this pat ient populat ion with prior curati ve radi ation, treatm enttheprior irradiated lesio ns may 
be considered measurable and selected as target lesio ns providing they fulfill the other criteria 
for measurabilit y. More details will be provided in the statist ical analysis plan.
Best overall response (BOR), defined as t he best response (in the order of complete 
response [CR], PR, SD, PD, and not evaluable) among all overall responses recorded 
from randomization unt il progression, or the last evaluable disease assessment in the 
absence of PD prior to the init iation o f subsequent ant icancer therapy  or discont inuat ion 
from the study , whichever occurs first. The BOR of CR or PR must be confirmed, which 
means a response of CR/PR is recorded at 1 visit and confirmed by repeat imaging not 
less than 28 days (4 weeks) after the vi sit when the response was first observed with no 
evidence of progression between the init ial and CR/PR confirmat ion visit.
OR, defined as BOR of confirmed CR or confirmed PR according to RECIST v1.1. 
DC, defined as BOR of confirmed CR, confirmed PR, or SD based on RECIST v1.1. 
Disease control  rate (DCR) at 16 weeks is defined as a BOR of confirmed CR, confirmed 
PR or having SD with duration of SD last ing 16 weeks.
DoR, defined as the time fro m the first docum entati on of a subsequent ly confirmed OR to 
the first docum entati on of  a disease progressi on according to RECIST v1.1 or death due 
to any  cause, whichever occurs first. Only subjects who have achieved OR (confirmed CR 
or confirmed PR) will be evaluated for DoR.
MedImmune Protocol Amendment 4 D9108C00001 (COAST)
Durvalumab and novel oncology therapies 27Jul2021 ; Final
CONFIDENTIAL AND PROPRIETARY 60of 105 Template 18.0PFS, defined as the time fro m rando mization until the first documentation of disease 
progression according to RECIST v1.1 or death due to any  cause, whichever occurs first, 
regardl ess of whether the subject receives subsequent ant icancer therapy prior to 
progression. Subjects who are alive progress ion free at the time of DCO will be censored 
on the date of their last evaluable tumor assessment. PFS- 12 will be est imated using the 
Kaplan -Meier m ethod. 
4.8.3.1 Primary Efficacy Analysis
The primary  efficacy  endpoint i s OR per RECIST v1.1. ORR is defined as th e proporti on of  
subjects wi th OR. The 2 -sided 95% CI for ORR will be estimated using the exact bino mial 
distribut ion. In addit ion, the unconfirmed ORR which is defined as the proportion of subjects 
who achieved a BOR of confirmed/unconfirmed CR or confirme d/unconfirmed PR will be 
presented along with its CI. An est imate of the difference in ORR between the experimental 
arm and the control arm will be reported. Comparison of treatment arms for ORR will be ob-
tained fro m the Chi -square or Fi sher’s exact test.
4.8.3.2 Secondary Efficacy Analyses
Secondary  efficacy endpo ints include DoR, DC, PFS, and OS. Analyses o f secondary  end-
points will be performed as fo llows.
DoR according to RECIST v1.1 will be analyzed using the Kaplan -Meier m ethod for 
those subjects with OR in t he corresponding analysis populat ions. The m edian of DoR 
with 95% CI will be estimated based on the Kaplan -Meier curves.
The DCR according to RECIST v1.1 is defined as the proportion of subjects with DC. 
The 2 -sided 95% CI of DCR will be provided using an exact probabilit y method. DCR at 
16 weeks will be estimated along with the 2 -sided 95% CI. 
PFS according to RECIST v1.1 will be analyzed using the Kaplan -Meier m ethod. The 
median PFS with 95% CI will be est imated based on the Kaplan -Meier curves. PFS -12 
will be estimated based on the Kaplan -Meier curves along with their 95% CIs when 
applicable. An estimate of the difference in PFS -12 between an experimental arm and the 
control  arm will be reported. Comparison of treatment arms for PFS -12 will be performed 
under complementary  log-log transformat ion of the Kaplan -Meier est imates of PFS -12 
(Klein et al, 2007 )
OS will be analyzed using the Kaplan -Meier m ethod. The median OS with 95% CI will 
be est imated based on the Kaplan -Meier curves. The 1- year OS rates will be estimated 
based on the Kaplan -Meier curves along wit h their 2 -sided 95% CI when applicable.
4.8.3.3 Exploratory Analyses
 
CCI
MedImmune Protocol Amendment 4 D9108C00001 (COAST)
Durvalumab and novel oncology therapies 27Jul2021 ; Final
CONFIDENTIAL AND PROPRIETARY 61of 105 Template 18.0 
4.8.4 Safety
Safety analyses will be based on the As -treated Popul ation defined in Sect ion 4.8.1 .
4.8.4.1 Anal ysis of Adverse Events
Summary  statistics will be provided for AEs, SAEs, and AE grade, severit y, and rel ationship 
to study  drug(s). AEs will be graded according to NCI CTCAE v5.0 and coded using system 
organ class and preferred term using the Medical Dict ionary for Regulatory  Activities pre-
ferred term . Specific AEs will be counted once for each subject when calculat ing rates, but 
will be all presented in total in subject list ings.
4.8.4.2 Analysis of Clinical Laboratory Parameters
Summary  statistics will be provi ded for clinical laboratory  parameters, physical examinat ions, 
vital signs, and ECG. Laboratory  abnorm alities wi th toxicity grades according to the 
NCI CTCAE v5.0 will be derived and summarized.
Laboratory  parameters will be assessed at baseline as we ll as throughout the study . Frequen-
cies of  maximum observed grade will be presented for each laboratory  param eter as well as 
the rates of subjects with Grade 3 -4 toxi cities. A shift tabl e, presenting the 2 -way frequency  
tabul ation for baseline and post -baseline grade at scheduled t ime of evaluat ion as well as the 
worst post -baseline grade, will be provided for clinical laboratory tests. Also, laboratory pa-
rameters will be assessed by present ing tables containing information related to 2 -grade (or 
greater) l aboratory  shifts.
4.8.4.3 Analysis of Vital Signs
Descript ive statistics will be provided for the vital signs measurements and changes fro m 
baseline by scheduled time of evaluat ion and by treatment arm including the maximum and 
minimum post -baseline values. 
4.8.4.4 Analy sis of ECOG Performance Status 
Descript ive statistics will be provided for the ECOG Performance Status assessments and 
changes fro m baseline by scheduled time of evaluation and by treatment arm.
4.8.5 Analysis of Immunogenicity/Pharmacokinetics 
Immunogenicity
Only subjects who receive at least 1 dose of durvalumab and/or other combinat ion study  drug, 
and provide at least 1 post -treatm ent sam ple, will  be evaluated. For each treatment arm, the 
immunogenic potential of durvalumab will be assessed by summarizing th e number and per-
centage of subjects who develop detectable ADAs to durvalumab. For experimental arms that 
CCI
MedImmune Protocol Amendment 4 D9108C00001 (COAST)
Durvalumab and novel oncology therapies 27Jul2021 ; Final
CONFIDENTIAL AND PROPRIETARY 62of 105 Template 18.0include a bio logic agent, the immunogenic potential of the combinat ion study  drug will be as-
sessed by summarizing the number and percentage of subject s who develop detectable ADAs 
to the combinat ion study  drug. 
The impact of ADAs on PK and safet y will be assessed if data allow. Samples confirmed posi-
tive for ADAs may  also be evaluated for neutralizing antibody act ivity.
Pharmacokinetics 
Only subjects who receive at least 1 dose of durvalumab and/or other combinat ion study  drug, 
and provide at least 1 post -treatm ent sam ple, will  be evaluated. For each treatment arm, indi-
vidual durvalumab concentrations will be tabulated with descript ive statist ics. Addi tionally, 
for each experimental arm, individual novel agent concentrations will be tabulated with de-
scriptive statist ics. 
Non-compartmental  PK data analysis will be performed from each treatment arm with sched-
uled PK sam ple collect ion where data allow. Re levant descript ive statist ics of non -compart-
mental  PK parameters will be provided and may  include: area under the concentration -time 
curve, observed maximum concentration, clearance, and terminal half -life.
4.8.6 Analyses of Biomarkers
Descript ive statistics wil l be the primary  method for the bio marker analyses (see Section 4.3.7
for a descri ption of the exploratory  biomarkers). Depending on the nature of the data, geomet-
ric mean and other appropriate statist ical summaries might be used as well.
Summaries and analyses for exploratory  biomarkers m ay be reported outside the CSR in a 
separate report.
4.8.7 Interim Analysis
Interim analyses will be conducted during t he course of the study  to eval uate the clinical activ-
ity and safet y of any experimental arm in comparison with the control arm. The results of the 
interim analyses may  be used for internal program decisio n and/or potential interact ions with 
regul atory  agen cies on future development. The first interim analysis will be performed once 
the control arm has 30 ITT subjects who have reached the data cutoff criteria (defined as the 
opportunit y to be followed for at least 16 weeks at the time o f data cutoff). The DC R at Week 
16 will be used for No -Go decisio n, and ORR may be used for early Go decisio n. Enrollment 
will not be paused for interim analyses. 
Bayesian PP will be used to evaluate clinical act ivity (Lee and Liu, 2008). Table 10illustrates 
the sam ple algori thm to m ake a No -Go decisio n based on DCR at 1 6weeks at the interim 
analysis when the control arm and an experimental arm each have 30 subjects. If an early  No-
Go deci sion is made, enro llment to the corresponding experimental arm will be stopped. In 
MedImmune Protocol Amendment 4 D9108C00001 (COAST)
Durvalumab and novel oncology therapies 27Jul2021 ; Final
CONFIDENTIAL AND PROPRIETARY 63of 105 Template 18.0this study , we assume a target value (TV) of ΔDCR a t 16 weeks as 15%, where ΔDCR is the 
difference in DCR between an experimental arm and control arm.
An experimental arm will meet the No- Go criteria if the probabilit y that the true ΔDCR is 
larger than TV is less than 10%, ie, Prob.(True ΔDCR > 0.15) < 0.1 0. A No -Go decisio n 
will be made at an interim analysis if the PP of meeting the No -Go criteria given observed 
data i s greater than 95%, ie, PP[Prob.(ΔDCR > 0.15) < 0.10)] > 0.95.
Table 10 Criteria of No -Go Decisions Based on DCR a t 16Weeks 
Number of Subjects with DCR at 16 weeks in 
Control ArmNumber of Subjects with DCR at 16 weeks in 
Experimental Arm
10 ≤ 7
11 ≤ 8
12 ≤ 8
13 ≤ 9
14 ≤ 10
15 ≤ 11
16 ≤ 12
17 ≤ 13
18 ≤ 14
19 ≤ 15
20 ≤ 16
21 ≤ 17
22 ≤ 19
23 ≤ 20
24 ≤ 21
25 ≤ 23
26 ≤ 24
27 ≤ 26
28 ≤ 28
29 ≤ 29
30 ≤ 30
DCR = disease control rate.
5 ASSESSMENT OF SAFETY
5.1 Definition of Adverse Events
An AE is the development of any untoward medical occurrence in a subject or clinical study  
subject administered a medicinal product and which does not necessarily have a causal rela-
tionship wi th this treatm ent. An AE can therefore be any  unfavorable and unintended sign (eg, 
an abnormal laboratory  finding), symptom (eg, nausea, chest pain), or disease temporally as-
sociated wi th the use of a m edicinal product, whether or not considered related to the medici-
nal product.
MedImmune Protocol Amendment 4 D9108C00001 (COAST)
Durvalumab and novel oncology therapies 27Jul2021 ; Final
CONFIDENTIAL AND PROPRIETARY 64of 105 Template 18.0The term  AE is used to include both serious and non -serious AEs and can include a deteriora-
tion of  a pre -exist ing medical occurrence. An AE may occur at a ny time, including run -in or 
washout periods, even if no study  treatm ent has been administered. 
Elect ive treatment or surgery or preplanned treatment or surgery  (that was scheduled prior to 
the subject being enro lled into the study ) for a docum ented pre -existing condit ion that di d not 
worsen from baseline is not considered an AE (serious or nonserious). An untoward medical 
event occurring during the prescheduled elect ive procedure or routinely scheduled treatment 
shoul d be recorded as an AE or SAE.
5.2 Definit ion of Serious Adverse Events
An SAE is any  AE that:
Results in death
Is immediately life -threatening
Requi res inpat ient hospi talizat ion or prolongat ion of exist ing hospi talizati on 
Results in persistent or significant disabilit y/incapacit y 
Is a congenita l anomaly/birth defect in o ffspring of the subject
Is an important medical event that may jeopardize the subject or may require medical 
intervent ion to prevent one of the outcomes listed above
Medical or scient ific judgment should be exercised in deciding whether expedited reporting is 
appropriate in this situation. Examples of medically important events are intensive treatment 
in an em ergency room  or at hom e for allergic bronchospasm, blood dy scrasias, or convulsio ns 
that do not result in hospitalizat ions; or devel opment of drug dependency or drug abuse.
5.3 Definition of Adverse Events of Special Interest
An AESI is one of scientific and medical interest specific to understanding of the invest iga-
tional product and m ay requi re close m onitoring and rapi d commun ication by the invest igator 
to MedImmune. An AESI may be serious or nonserious. The rapid reporting of AESIs allows 
ongoing surveillance of these events in order to characterize and understand them in associa-
tion wi th the use of this invest igational produc t.
5.3.1 Adverse Events of Special Interest for Durvalumab -containing 
Regim ens
AESIs for durvalumab include but are not limited to events with a potential inflammatory  or 
immune -mediated mechanism and which may require more frequent monitoring and/or inter-
ventions such as steroids, immunosuppressants, and/or hormone replacement therapy . These 
AESIs are being closely  monitored in clinical  studies wi th durvalumab mo notherapy  and co m-
binat ion therapy . An imAE is defined as an AE that is associated with drug exposure and is 
MedImmune Protocol Amendment 4 D9108C00001 (COAST)
Durvalumab and novel oncology therapies 27Jul2021 ; Final
CONFIDENTIAL AND PROPRIETARY 65of 105 Template 18.0consistent with an immune -mediated m echanism of action and where there is no clear alter-
nate eti ology. Serol ogic, immunol ogic, and histo logic (biopsy ) data, as appropri ate,should be 
used to support an imAE diagnosis. Appropriate efforts should be m ade to rule out neoplast ic, 
infect ious, m etabo lic, toxin, or other etio logic causes of the imAE.
If the invest igator has any quest ions determining whether an AE is an imAE, the invest igator 
shoul d prom ptly contact the Study  Physician. 
AESIs observed with durvalumab include:
Diarrhea/coli tis and intestinal perforations
Pneumo nitis
Hepati tis
Endocrinopathies (ie, events of hypophysit is/hypopituitarism, ty pe 1 di abetes m ellitus, 
adrenal insufficiency , and hyper -and hypothy roidism )
Rash/dermat itis
Nephrit is
Pancreat itis
Myocardi tis
Myositis/polymyosit is
Neuropathy /neurom uscular toxicit y (eg, Guillain- Barré and myasthenia gravis)
Immune com plex mediated diseases
The immune system can respond to foreign mAbs by producing human -anti-human 
antibodies, which may r esult in formation of immune co mplexes and their deposit ion in 
blood vessels, jo ints, and glo meruli causing symptomat ic disease (eg, vasculit is, 
glomerulonephri tis, arthri tis). Subj ects who experience an AE suspected to be immune -
complex related and wi th confirmed presence of ADAs will discont inue treatment. Other 
inflammatory  responses that are rare/less frequent with a potential immune- mediated 
etiology include, but are not limited to, pericardit is, sarcoidosis, uveit is and other events 
involving the ey e,skin, hematol ogical  and rheumatol ogical events.
In addit ion, IRRs and hypersensit ivity/anaphylact ic reactions wit h a different underlying phar-
maco logical et iology are al so consi dered AESIs. Anaphylaxis and IRRs have so me co mmo n 
manifestations and may  be difficult to di stinguish from each other. IRRs are commo nly ob-
served during or shortly after the first time of exposure to therapeutic mAbs delivered through 
IV infusio n. These react ions are less co mmo n following subsequent exposures. Unlike IRRs, 
anaphyla xis is a rare allergic mediated event, usually  occurring after subsequent exposure to 
an ant igen, and it is most commonly acco mpanied by severe systemic, skin and/or mucosal re-
actions. The invest igator is advised to carefully examine adverse react ions obse rved during or 
shortly  after drug i nfusi on, and consider the above -mentioned facts pri or to m aking a final di-
agnosis. For the invest igator’s convenience and to facilitate consistency in judgments, a copy 
MedImmune Protocol Amendment 4 D9108C00001 (COAST)
Durvalumab and novel oncology therapies 27Jul2021 ; Final
CONFIDENTIAL AND PROPRIETARY 66of 105 Template 18.0of the Nati onal Institute of Allergy  and Infect ious Disease and Food and Allergy Anaphylaxis 
Network guidance for anaphylaxis diagnosis is provided in Appendix C.
Further informat ion on all those risks (eg, presenting symptoms) can be found in the current 
versio n of the durvalumab IB. More specific guidelines for their evaluat ion and treatment are 
described in detail in the Toxicit y Management Guidelines (see Sect ion 3.1.3 ). These guide-
lines have been prepared by the sponsor to assist the invest igator in the exercise of his/her 
clinical judgment in treating these t ypes of toxicit ies. These guidelines apply  to AEs consid-
ered causally related to the study  drug/study  regimen by  the reporting Invest igator.
5.3.2 Adverse Events of Special Interest Associate d with Oleclumab
Cardiac Chest Pain, Transient Ischemic Attack, and Thromboembolism
AEs of cardiac chest pain, transient ischemic attack, and thromboembo lism are of special in-
terest due to oleclumab potential risks o f arteri al calcificat ions, arterial isch emic disorder, and 
thrombosis. Because of this potential risk, poten tial subjects wi th a history  of venous throm -
bosis in the prior 3 months, or my ocardial  infarcti on, stroke, or transient ischemic attack in the 
prior 6 m onths are not eligible (see Section 4.1.3 ). These events require urgent medical man-
agem ent, which shoul d be perform ed according to consensus guidelines developed by the 
American Heart Associat ion or appropriate local standards o f care.
Edema
Edem a (eg, pulmo nary or peri pheral) i s regarded as AESI due to oleclumab potential risks of 
increased microvascular permeabilit y. For subjects who develop ≥ Grade 3 edema, doses 
shoul d be omi tted ( Section 3.1.3 ), and therapy  may be discontinued at the discretion of the in-
vestigator.
5.3.3 Adverse Events of Special Interest Associated with Monalizum ab
There are no ident ified AESIs associated with monalizumab that are not included in the AESIs 
for durvalumab -containing regimens (see Section 5.3.1 ).
5.4 Recording of Adverse Events
AEs will be recorded on the eCRF using a recognized medical term or diagnosis that accu-
rately  reflects the event. AEs will be assessed by the invest igator for severit y, relationship to 
the invest igational product, possible etiologies, and whether the event meets criteria of an 
SAE and therefore requires immediate notificat ion to MedImmune (see Sect ion 5.5). See Sec-
tion5.2for the definit ion of SAEs and 0for guidelines on assessment of severit y and relati on-
ship. 
If an AE evo lves into a condi tion that m eets the regulatory  defini tion of  “seri ous,” i t will be 
reported on the SAE Report Form.
MedImmune Protocol Amendment 4 D9108C00001 (COAST)
Durvalumab and novel oncology therapies 27Jul2021 ; Final
CONFIDENTIAL AND PROPRIETARY 67of 105 Template 18.05.4.1 Time Period for Collection of Adverse Events
AEs and SAEs will be co llected fro m time of signature of informed consent up to 12 months 
post Cy cle 1 Day  1, regardl ess of whether the subject discont inued treatment. Following the 
first 12 m onths post Cycle 1 Day  1, AEs and SAEs will be collected up to 3 months post l ast 
dose of study  treatm ent, if applicable.
5.4.2 Follow- up of Unresolved Adverse Events
Any AEs that are unresolved during the end of study  visit or when a subject has consented to 
study  participati on may be foll owed up by  the investi gator for as l ong as medically indicated, 
but without further recording in the eCRF. The sponsor retains the right to request addit ional 
inform ation for any  subject wi th ongoing AE(s)/SAE(s) at the end of the study , if judged nec-
essary .
5.4.3 Deaths
All deaths that occur during the study , incl uding the protocol -defined fo llow-up peri od m ust 
be reported as follows:
Death cl early  the resul t of disease progressi on shoul d be reported and documented in the 
eCRF but should not be reported as an SAE.
Where death is not due (or not clearly  due) to di sease progressi on, the AE causing the 
death m ust be reported as an SAE within 24 hours fo llowing invest igator awareness of the 
event. The report should contain a co mment regarding the co -involvement of disease 
progression, if appropriate, and sho uld assi gn main and contributory  causes of death.
Deaths with an unknown cause should always be reported as an SAE. A post -mortem 
(autopsy ) may be helpful in the assessment of the cause of death, and if performed a copy  
of the post -mortem results should be forwarded to MedImmune representative(s) within 
the usual timeframes (refer to Section 5.5for addi tional information).
5.4.4 Adverse Events Based on S igns and Symptoms
All AEs spontaneously reported by  the subject or reported in response to the open question 
from the study  site staff: ‘Have you had any health problems since the previous visit/you were 
last asked?’ , or revealed by observat ion will be collected and recorded in the eCRF. When 
collect ing AEs, the recording of diagnoses is preferred (when possible) to recording a list of 
signs and symptoms. However, if a diagnosis is known and there are other signs or symptoms 
that are not generally part o f the diagnosis, the diagnosis and each sign or symptom will be 
recorded separately.
5.4.5 Adverse Events Based on Examination and Tests
The results from the protocol -mandated laboratory tests and vital signs will be summarized in 
the CSR. An abnormal laboratory finding (including ECG finding) that requires medical inter-
vention by the invest igator, or a finding judged by the invest igator as medically significant 
MedImmune Protocol Amendment 4 D9108C00001 (COAST)
Durvalumab and novel oncology therapies 27Jul2021 ; Final
CONFIDENTIAL AND PROPRIETARY 68of 105 Template 18.0shoul d be reported as an AE. If clinical sequelae are associated with a laboratory  abnormalit y, 
the diagnosi s or m edical condit ion should be reported (eg, renal failure, hematuria) not the la-
boratory  abnorm ality (eg, el evated creatinine, urine red blood cell increased).
If deteri oration in a laboratory  value/vi tal sign i s associ ated wi th clinical signs and symptom s, 
the sign or symptom  will be reported as an AE and the associated laboratory  resul t/vital sign 
will be considered as addit ional informat ion. Wherever possible, the reporting invest igator 
shoul d use the clinical rather than the laboratory  term  (eg, anemia vs low hemoglo bin value). 
In the absence of clinical signs or symptoms, clinically relevant deteriorations in non -man-
dated param eters shoul d be reported as AE(s).
Any new or aggravated clinically relevant abnormal medical finding at a physical exa minat ion 
as com pared wi th the baseline assessment will be reported as an AE.
5.4.6 Potential Hy’s Law and Hy’s Law
Cases where a subject shows elevat ions in liver biochemistry  may require further evaluat ion 
and occurrences o f AST or ALT ≥ 3 × ULN together with T BL ≥ 2×ULN will need to be re-
ported as SAEs. Please refer to Appendix Dfor further instructi on on cases of increases in 
liver biochemistry  and e valuat ion of Hy’s Law.
5.4.7 Disease Progression
Disease progressi on can be considered as a worsening of a subject’s condit ion attributable to 
the disease for which the invest igational product is being studied. It may  be an increase in the 
severit y of the diseas e under study  and/or increases in the symptoms o f the disease. The devel-
opment of a new m etastasis or progression of exist ing m etastasis rel ated to the primary cancer 
under study  shoul d not be considered an AE. Death clearly result ing fro m disease progress ion 
shoul d not be reported as an SAE (see reporting guidelines in Section 5.4.3 ).
The term  disease progression should not be reported as an AE or S AE, however, medically 
significant individual events and/or laboratory  abnorm alities associated wi th disease progres-
sion (see definit ion of disease progression above) that fulfill the AE or SAE definit ion shoul d 
be reported.
New Cancers
The development of a new cancer should be regarded as an SAE. New cancers are those that 
are not the primary reason for the administration of the invest igational product and have been 
ident ified after the subject’s inclusio n in the study . New m etastati c lesi on(s) of the subj ect’s 
known cancer should not be reported as a new cancer.
MedImmune Protocol Amendment 4 D9108C00001 (COAST)
Durvalumab and novel oncology therapies 27Jul2021 ; Final
CONFIDENTIAL AND PROPRIETARY 69of 105 Template 18.05.5 Reporting of Serious Adverse Events
All SAEs have to be reported, whether or not considered causally related to the invest igational 
product, or to the study  procedure(s). All SAEs will be recorded in the eCRF.
If any SAE occurs in the course of the study , then investi gators or other si te personnel must 
inform  the appropri ate sponsor representative(s) wit hin 1 day, ie, immediately but no later 
than 24 hours after beco ming aware of the event.
The desi gnated study  representati ve works wi th the investigator to ensure that all the neces-
sary informat ion is provided to the sponsor’s patient safet y data entry  site wi thin 1 calendar 
day of initial receipt for fatal  and life -threatening events and wit hin 5 cal endar days of init ial 
recei pt for all other SAEs.
For fatal  or life -threatening AEs where important or relevant informat ion is missing, active 
follow-up is undertaken immediately . Invest igators or other site personnel inform sponsor rep-
resentatives of any  follow-up inform ation on a previously reported SAE within 1 calendar 
day, ie, immediately but no l ater than 24 hours after becoming aware of the event.
Once the invest igators or other site personnel indicate an AE is serious in the electronic data 
capture (EDC) sy stem , an autom ated em ail alert is sent to inform the designated sponsor rep-
resentative(s).
If the EDC system is not available, then the investigator or other study  site personnel  reports 
an SAE to the appropriate sponsor representative by  telephone. The sponsor representative 
will advise the investigator/study  site personnel how to proceed. 
Thereference docum ent for defini tion of  expectedness/listedness is the IB for the study  drug.
5.6 Other Events Requiring Immediate Reporting
5.6.1 Overdose
An overdose is defined as a subject receiving a dose of invest igational product in excess of 
that specified in the IB, unless otherwise specified in this protocol.
An overdose with associated AEs is recorded as the AE diagnosis/symptoms on the 
relevant AE m odules in the eCRF and on the Overdose eCRF module.
An overdose without associated AEs is only reported on the Overdose eCRF module.
If an overdose on any study  drug occurs during the course of the study , then the invest igator 
or other si te personnel should inform appropriate sponsor representatives immediately , but no 
later than 24 hours after becoming aware of the event.
MedImmune Protocol Amendment 4 D9108C00001 (COAST)
Durvalumab and novel oncology therapies 27Jul2021 ; Final
CONFIDENTIAL AND PROPRIETARY 70of 105 Template 18.0The designated sponsor representative works with the invest igator to ensure that all relevant 
inform ation is provided to the sponsor’s Patient Safet y data entry  site.
For overdoses associated with an SAE, the standard reporting timelines appl y; see Sect ion 5.5. 
For other overdoses (ie, those not associated with an AE or SAE), reporting must occur within 
30 day s.
5.6.2 Pregnancy 
All pregnancie s and outcom es of  pregnancy  should be reported to the sponsor except if the 
pregnancy is discovered before the subject has received any  study  drug.
Females of childbearing potential must have a negative pregnancy test result at screening to be 
enrolled in the study  and treated with study  drug. 
5.6.2.1 Maternal Exposure
If a subject beco mes pregnant during the course of the study, invest igational product should be 
discontinued immediately .
Pregnancy itself is not regarded as an AE unless there is a suspicio n that t he invest igational 
product under study  may have interfered with the effectiveness of a contraceptive medicat ion. 
Congenital abnormalit ies/birth defects and spontaneous miscarriages should be reported and 
handled as SAEs. Elective abortions without complica tions shoul d not be handled as AEs. The 
outcom e of all pregnancies (spontaneous miscarriage, elective terminat ion, ectopic pregnancy, 
norm al birth or congeni tal abnorm ality) shoul d be fo llowed up and documented even if the 
subject was discont inued from the study .
If any pregnancy  occurs during the course of the study , then the investigator or other site per-
sonnel will inform the appropriate sponsor representatives wit hin 1 day, ie, immediately but 
no later than 24 hours after becoming aware of the event.
The designated study  representati ve works wi th the invest igator to ensure that all relevant in-
formation is provided to the sponsor’s patient safety data entry  site wi thin 1 or 5 cal endar days 
for SAEs (see Section 5.5) and wi thin 30 days for all other pregnancies.
The same timelines apply when outcome informat ion is available.
The pregnancy reporting module in the eCRF is used to report the pregnancy  and the preg-
nancy outcome module is used to report the outcome of the pregnancy.
5.6.2.2 Paternal Exposure
Pregnancy of the subject’s partners is not considered to be an AE. However, the outcome of 
all pregnancies (spontaneous miscarriage, elective termination, ect opic pregnancy, normal 
MedImmune Protocol Amendment 4 D9108C00001 (COAST)
Durvalumab and novel oncology therapies 27Jul2021 ; Final
CONFIDENTIAL AND PROPRIETARY 71of 105 Template 18.0birth or congenital abnormalit y), occurring from the date of the first dose until 90 days after 
the last dose should, if possible, be fo llowed up and docum ented.
5.6.3 Medication Error
For the purposes of this clinical study  a medicat ion error is an unintended failure or mistake in 
the treatment process for a study  drug that ei ther causes harm  to the subject or has the poten-
tial to cause harm  to the subject. 
A medicat ion error is not lack of efficacy o f the drug, but rather a human -or process -related 
failure while the drug is in control of the study  site staff or subj ect.
Medicat ion error includes situat ions where an error: 
Occurred
Was i dentified and intercepted before the subject r eceived the drug
Did not occur, but circumstances were recognized that could have led to an error
Examples of events to be reported in clinical studies as medication errors:
Drug name confusio n (ie, instead of receiving the investigational product, the su bject 
received a drug that has a similar -sounding name)
Dispensing error, eg, medicat ion prepared incorrectly, even if it was not actually given to 
the subject
Drug not administered as indicated, eg, wrong route or wrong site of administration
Drug not tak en as indicated, eg, tablet disso lved in water when it should be taken as a 
solid tablet 
Drug not stored as instructed, eg, kept in the refrigerator when it should be at room 
temperature 
Wrong subject received the medicat ion (excluding IXRS errors)
Wrong drug administered to subject (excluding IXRS errors)
Examples of events that do not require reporting as medicat ion errors in clinical studies:
Errors related to or resulting fro m IXRS -including those which lead to one of the above 
listed events that w ould otherwi se have been a medicat ion error 
Subject accidentally missed drug dose(s), eg, forgot to take medicat ion
Accidental  overdose (will be captured as an overdose)
Subject failed to return unused medicat ion or em pty packaging
Errors related to backg round and rescue medicat ion 
MedImmune Protocol Amendment 4 D9108C00001 (COAST)
Durvalumab and novel oncology therapies 27Jul2021 ; Final
CONFIDENTIAL AND PROPRIETARY 72of 105 Template 18.0Medicat ion errors are not regarded as AEs, but AEs may occur as a consequence of the medi-
cation error. 
If a medicat ion error occurs in the course of the study , then the Invest igator or other site per-
sonnel informs the appropr iate MedImmune representatives within 1 day, ie, immediately but 
no later than 24 hours of when he or she beco mes aware of it.
The designated MedImmune representative works with the Invest igator to ensure that all rele-
vant informat ion is completed wi thin 1 or 5 cal endar day s if there i s an SAE associated with 
the medicat ion error (see Section 5.5) and wi thin 30 day s for all other m edicat ion errors. Me d-
ication errors should be reported using a Medication Error Report Form.
6 STUDY AND DATA MANAG EMENT
6.1 Training of Study Site Personnel
Before the first subject is entered into the study , a MedImmune representative will review and 
discuss the requirements of the protocol and related documents with the invest igational staff 
and also train them in any study -specific procedures and system(s) utilized.
The Principal Invest igator will ensure that appropriate training relevant to the study is given to 
all of these s taff, and that any  new informati on relevant to the perform ance of this study  is for-
warded to the staff invo lved.
The Principal Invest igator will maintain a record of all individuals invo lved in the study  
(medical, nursing, and other staff).
6.2 Monitoring of t he Study
During the study , a MedImmune representative will have regular contacts with the study  site, 
including visits to:
Provi de inform ation and support to the invest igator(s)
Confirm that facilit ies remain acceptable
Confirm that the invest igational tea m is adhering to the protocol, that data are being 
accurately and timely recorded in the eCRFs, that bio logical  samples are handled in 
accordance with the Laboratory  Manual  and that study  drug accountabilit y checks are 
being performed
Perform  source data v erification (a comparison of the data in the eCRFs with the subject’s 
medical records at the hospital or practice, and other records relevant to the study ) 
including verificat ion of informed consent of participat ing subjects. This will require 
direct acces s to all ori ginal  records for each subject (eg, clinic charts)
MedImmune Protocol Amendment 4 D9108C00001 (COAST)
Durvalumab and novel oncology therapies 27Jul2021 ; Final
CONFIDENTIAL AND PROPRIETARY 73of 105 Template 18.0Ensure withdrawal of informed consent to the use of the subject’s bio logical  samples is 
reported and bio logical  samples are i dentified and disposed of/destroyed accordingly, and 
the acti on is d ocum ented, and reported to the subject.
The MedImmune representative will be available between visit s if the invest igator(s) or other 
staff at the center needs information and advice about the study  conduct.
6.2.1 Source Data
Refer to the Clinical Study  Agreement for location of source data.
6.2.2 Study Agreements
The Principal Invest igator at each center should comply wit h all the terms, condit ions, and ob-
ligations of the Clinical Study  Agreement, or equivalent, for this study . In the event of any  in-
consistenc y between this protocol and the Clinical Study  Agreement, the terms of this proto-
col shall  prevail wi th respect to the conduct of the study  and the treatm ent of subjects and in 
all other respects, not relating to study conduct or treatment of subjects, the terms of the Clini-
cal Study  Agreement shall prevail.
Agreements between MedImmune and the Principal Invest igator must be in place before any 
study -related procedures can take place, or subjects are enrolled.
6.2.3 Archiving of Study Documents
The invest igator f ollows the principles outlined in the Clinical Study  Agreement.
6.3 Study Timetable and End of Study
An individual subject will be considered to have completed the study if the subject was fol-
lowed through thei r last protocol -specified visit/assessment, regard less of the number of doses 
of investigational product that was received. 
Subjects will be considered not to have co mpleted the study  if consent was withdrawn or the 
subject was lost to fo llow-up (see Secti on 4.1.5 and Section 4.1.6 ).
The end o f the study  (“study  com pletion”) is defined as the date of the last protocol -specified 
visit/assessment (including telephone contact) for the last subject in the study . This date will 
be 5 y ears after the final subject is entered into the study  or when the sponsor stops the study , 
whichever occurs first. 
6.4 Data Management 
Data m anagement will be performed by MedImmune Data Management staff or other party
according to the Data Management Plan.
MedImmune Protocol Amendment 4 D9108C00001 (COAST)
Durvalumab and novel oncology therapies 27Jul2021 ; Final
CONFIDENTIAL AND PROPRIETARY 74of 105 Template 18.0An EDC system will be used for data collect ion and query  handling. The investigator will en-
sure that data are recor ded in the eCRFs as specified in the study  protocol  and in accordance 
with the eCRF instructions provided.
The invest igator ensures the accuracy, completeness, and timeliness of the data recorded and 
of the provisio n of answers to data queries according to the Clinical Study  Agreement. The in-
vestigator will sign the completed eCRFs. A copy  of the com pleted eCRFs will be archived at 
the study  site.
6.5 Medical Monitor Coverage
Each subject will be provided wit h contact information for the Principal Invest igator. In addi-
tion, each subject will receive a toll -free number intended to provide the subject’s physician 
access to a medical mo nitor 24 hours a day , 7 days a week in the event of an emergent situa-
tion where the subject’s healt h is deemed to be at risk. In th is situation, when a subject pre-
sents to a m edical facilit y where the treating physician or health care provider requires access 
to a physician who has knowledge of the invest igatio nal product(s) and the clinical study  pro-
tocol  and the Principal Invest igator is not available, the treating physician or health care pro-
vider can contact a medical mo nitor through this system , which i s managed by  a thi rd party  
vendor.
7 ETHICAL AND REGULATO RY REQUIREMENTS
7.1 Subject Data Protection
Each subject will be assigned a SID to ensure that personally ident ifiable informat ion is kept 
separate from the study  data. Subj ect data that are rel evant to the study , eg, dem ographic in-
formation, physical or mental healt h condit ion, diagnosis, com orbidities, laboratory  test re-
sults, etc will only be co llected with the subject’s informed consent. The informed consent 
form will incorporate (or, in some cases, be acco mpanied by a separate document incorporat-
ing) wording that describes how subject data will be collected, used, and distributed in com-
pliance wit h relevant data protection and privacy legislation. Data (clinical and bio logical 
sample) fro m this study  may be used and m ay be combined with results fro m other studi es for 
additional scientific -related research, based on agreement from the subject as defined in the 
inform ed consent form .
7.2 Ethics and Regulatory Review
The IRB/IEC responsible for each site must review and approve the final study  protocol , in-
cluding the final versio n of the informed consent form and any  other wri tten inform ation 
and/or materials to be provided to the subjects. The IRB/IEC must also approve all advertising 
used to recruit subjects for the study . The investigator is responsible for submitt ing these doc-
uments to the applicable IRB/IEC and distribut ing them to the study site staff.
MedImmune Protocol Amendment 4 D9108C00001 (COAST)
Durvalumab and novel oncology therapies 27Jul2021 ; Final
CONFIDENTIAL AND PROPRIETARY 75of 105 Template 18.0The opinio n of the IRB/IEC must be given in writ ing. The invest igator must provide a copy of 
the wri tten approval  to MedImmune before enrollment of any  subject into the study . 
MedImmune should approve any substant ive modificat ions to the informed consent form that 
are needed to meet local requirements.
If required by  local regulat ions, the protocol must be re -approved by  the IRB/IEC annually.
Before the study  is initiated, MedImmune will ensure that the national regulatory  authori ty in
each country  has been notified and their approval has been obtained, as required. MedImmune 
will provide safet y updates/reports according to local requirements, including suspected unex-
pected serious adverse reactions where relevant, to regulatory  authori ties, IRB/IEC, and prin-
cipal invest igators.
Each Principal Investigator is responsible for providing reports of any serious and unexpected 
adverse drug reactions from any other study  conducted wi th the invest igational product(s) to 
the IRB/IEC. MedImmune w ill provide this information to the Principal Investigator so that 
he/she can meet these reporting requirements.
7.3 Informed Consent
Inform ed consent of each subject will be obtained through a written and verbal explanat ion 
process that addresses all elements required by ICH/GCP. MedImmune will develop a core 
inform ed consent form  for use by  all invest igators in the clinical study. MedImmune must ap-
prove any  modificati ons to the informed consent form that are needed to meet local require-
ments.
The Principal Invest igator(s) at each center will:
Ensure each subject is given full and adequate oral and written information about the 
nature, purpose, possible risk and benefit of the study
Ensure each subject is notified that they  are f ree to discont inue from the stud y at any  time
Ensure that each subject is given the opportunit y to ask questi ons and all owed time to 
consider the information provided
Ensure each subject provides signed and dated info rmed consent before conducting any 
procedure specifically  for the study
Ensure the original, signed informed consent form(s) is/are stored in the Invest igator’s 
Study  File
Ensure a copy  of the signed informed consent form is given to the subject
Ensure that any  incentives for subjects who participate in the study  as well  as any 
provi sions for subjects harmed as a consequence of study  parti cipat ion are described in 
the informed consent form that is approved by an IRB/IEC
MedImmune Protocol Amendment 4 D9108C00001 (COAST)
Durvalumab and novel oncology therapies 27Jul2021 ; Final
CONFIDENTIAL AND PROPRIETARY 76of 105 Template 18.07.4 Changes to the Protocol and Informed Consent Form
Study  procedures will not be changed without the mutual agreement of the Principal Invest i-
gator and the sponsor. Any changes must be documented in a study  protocol  amendment. 
For a substantial change to the protocol, MedImmune will distribute amended versions of the 
protocol  to the Principal Invest igator(s). B efore implementation, amended protocols must be 
approved by  relevant IRB/IEC (see Section 7.2) and reviewed as per local regulatory  authori ty 
requi rements. The IRB/IEC must also approve revisions to the informed consent form, adver-
tising, and any  other wri tten inform ation and/or materials result ing from the change to the pro-
tocol .
Any non -substant ial changes will be communicated to or approved by  each IRB/IEC and local 
regul atory  authori ty per l ocal requi rements.
7.5 Audits and Inspections
Authori zed representatives of MedImmune, a regulatory  authori ty, or an IRB/IEC m ay 
perform  audi ts or i nspect ions at the center, including source data verificat ion. The purpose of 
an audit or inspect ion is to sy stematically and independent ly examine all study- related 
activit ies and documents, to determine whether these activit ies were conducted, and data were 
recorded, analyzed, and accurately  reported according to the pr otocol , GCP, gui delines of the 
ICH, and any applicable regulatory  requi rements. The invest igator will contact MedImmune 
immediately  if contacted by  a regulatory  agency about an inspect ion at the site.
MedImmune Protocol Amendment 4 D9108C00001 (COAST)
Durvalumab and novel oncology therapies 27Jul2021 ; Final
CONFIDENTIAL AND PROPRIETARY 77of 105 Template 18.08 REFERENCES
Ahn et al, 2015
Ahn JS, Ahn YC, Kim JH, Lee CG, Cho EK, Lee KC, et al. Mult inational randomized Phase 
III tri al with or wi thout conso lidation chemotherapy using docetaxel and cisplatin after con-
current chemoradiat ion in inoperable Stage III non -small-cell lung cancer: KCSG -LU05 -04. J 
Clin Onco l. 2015;33(24):2660 -6.
American Cancer Society, 2018
American Cancer Societ y. Cancer Facts & Figures 2018 . Atlanta: American Cancer Societ y; 
2018. Available at: https://www.cancer.org/research/cancer -facts-statistics/all -cancer -facts -
figures/cancer -facts -figures -2018.html
Antonia et al, 2017
Antoni a SJ, Villegas A, Daniel D, Vincente D, Murakami S, Hui R, et al. Durvalumab after 
chemoradiotherapy  in Stage III non -small-cell lung cancer. New Engl J Med. 
2017;377(20):1919 -29.
Antonia et al, 2018
Antoni a SJ, Villegas A, Daniel D, Vincente D, Murakami S, Hui R, et al. Overall survival 
with durvalumab after chemoradiotherapy  in stage III NSCLC. New Engl J Med. 2018. Epub 
ahead of print. Available at: https://www.nejm.org/doi/10.1056/NEJMoa1809697. Published 
25Se p2018. Accessed 25Sep2018.
Aparicio -Pagés et al, 1991
Aparicio -Pagés MN, Verspaget HW, Peña AS, Lamers CB. Natural  killer cell act ivity in 
patients wi th adenocarcinom a in the upper gastrointestinal tract. J Clin Lab Immunol. 
1991;35(1):27 -32.
Aupérin et al , 2010
Aupérin A, Le Pechoux C, Rolland E, Curran WJ, Furuse K, Fournel P, et al. Meta -analysis o f 
concomitant versus sequential radiochemotherapy in locally advanced non -small cell lung 
cancer. J Clin Onco l. 2010;28:2181 -90.
Borrego et al, 1998
Borrego F, Ulbrecht M, Weiss EH, Coligan JE, Brooks AG. Recognit ion of human 
histocompat ibilit y leukocy te ant igen (HLA) -E complexed wit h HLA class I signal sequence -
derived peptides by CD94/NKG2 confers protection fro m natural  killer cell -mediated lysis. J 
Exp Med. 1998;187(5):813 -8.
Braud et al, 1998
Braud VM, Allan D, O’Callaghan CA, Söderström K, D’Andrea A, Ogg GS, et al. HLA -E 
binds to natural killer cell receptors CD94/NKG2a, B and C. Nature. 1998;391(6669):795 -9.
MedImmune Protocol Amendment 4 D9108C00001 (COAST)
Durvalumab and novel oncology therapies 27Jul2021 ; Final
CONFIDENTIAL AND PROPRIETARY 78of 105 Template 18.0Chen and Mellman, 2013
Chen DS, Mellman I. Onco logy meets immunol ogy: the cancer -immunit y cycle. Immunit y. 
2013;39(1):1 -10. 
Cockcroft and Gault, 1976
Cockcroft DW, Gault MH. Prediction of creat inine clearance fro m serum  creat inine. Nephron. 
1976;16(1):31 -41.
Curran et al, 2011
Curran WJ Jr, Paulus R, Langer CJ, Ko maki R, Lee JS, Hauser S, et al. Sequential vs 
concurrent chemoradiat ion for stage III non -small cell lung cancer: randomized phase III trial 
RTOG 9410. J Natl Cancer Inst. 2011;103(19):1452 -60.
Denis et al, 2017
Denis C, Brezar V, Arnoux T, Lopez J, Caillet C, Chanuc F, et al. Combined blo ckade of 
PD-L1 and NKG2A checkpo ints enhances ant i-tumor CD8+ T cell response. Poster A130. 
Third CRI -CIMT -EATI -AACR International Cancer Immunotherapy  Conference. Available 
at: http://www.innate -pharma.co m/sites/default/files/poster_cri -cimt-eati-
aacr_2017_a0_mona.pdf
Eisenhauer et al, 2009
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response 
evaluat ion criteria in solid tum ours: revi sed RECIST gui deline (versio n 1.1). Eur J Cancer. 
2009;45(2):228 -47.
Emens et al, 2017
Emens LA, Ascierto PA, Darcy  PK, Demaria S, Eggermont AMM, Redmo nd WL, et al. 
Cancer immunotherapy : Opportuni ties and challenges in the rapidly  evolving clinical 
landscape. Eur J Canc er. 2017;81:116-29.
Geoghegan et al, 2016
Geoghegan JC, Diedrich G, Lu X, Rosenthal K, Sachsenmeier KF, Wu H, et al. Inhibit ion of 
CD73 AMP hydrolysis by  a therapeut ic antibody with a dual, non -compet itive mechanism o f 
action. MAbs. 2016;8(3):454 -67.
Goode n et al, 2011
Gooden M, Lampen M, Jordanova ES, Leffers N, Trimbos JB, van der Burg SH, et al. HLA -E 
expressio n by gyneco logical cancers restrains tumor -infiltrating CD8+ T lymphocy tes. Proc 
Natl Acad Sci  USA. 2011;108(26):10656-61.
Guo et al, 2015
Guo ZY, Lv YG, Wang L, Shi SJ, Yang F, Zeng GX, et al. Predict ive value of HLA -G and 
HLA -E in the prognosis of co lorectal  cancer pati ents. Cellular Immuno l. 2015;293(1):10 -6.
MedImmune Protocol Amendment 4 D9108C00001 (COAST)
Durvalumab and novel oncology therapies 27Jul2021 ; Final
CONFIDENTIAL AND PROPRIETARY 79of 105 Template 18.0Hay et al, 2016
Hay CM, Sul t E, Huang Q, Mulgrew K, Fuhrmann SR, McGlinchey  KA, et al . Targeting 
CD73 the tumor microenvironment with MEDI9447. Oncoimmuno logy. 2016;5(8):e1208875.
Iannone et al, 2015
Iannone F, Porzia A, Peruzzi G, Birarelli P, Milana B, Sacco L, et al. Effect of surgery  on 
pancreat ic tumor -dependent lymphocyte asset: modulat ion of natural killer cell frequency and 
cytotoxi c function. Pancreas. 2015;44(3):386 -93.
Imfinzi® US PI, 2018
Imfinzi Package Insert. Wilmington, DE: AstraZeneca Pharmaceut icals LP; February  2018.
Inoue et al, 2017
Inoue Y, Yoshimura K, Kurabe N, Kahyo T, Kawase A, Tanahashi M, et al. Prognosti c 
impact of CD73 and A2A adenosine receptor expressio n in non-small -cell lung cancer. 
Oncotarget. 2017;8(5):8738- 51. 
Juneja et al, 2017
Juneja VR, McGuire KA, Manguso RT, LaFleur MW, Collins N, Haining WN, et al. PD -L1 
on tum or cells is sufficient for immune evasion in immunogenic tumors and inhibit s CD8 
Tcell cytotoxicit y. J Exp Med. 2017;214(4):895 -904.
Keir et al, 2008
Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD -1 and its ligands in tolerance and immunit y. 
Annu Rev Immuno l. 2008;26:677- 704. 
Kelly et al, 2008
Kelly K, Chansky  K, Gasper LE, Albain KS, Jett J, Ung YC, et al. Phase III trial o f 
maintenance gefit inib or placebo after concurrent chemoradiotherapy  and docetax el 
conso lidation in inoperable Stage III non -small-cell lung cancer:SWOG S0023. J Clin Onco l. 
2008;26(15):2450 -6.
Klein et al, 2007
Klein JP, Logan B, Harhoff M, Andersen PK. Analyzing survival curves at a fixed point in 
time. Stat Med. 2007;26(24):4505 -19.
Keytruda® US PI, 2018
Keytruda Package Insert. Whitehouse Station, NJ: Merck Sharp & Dohme Corp., a subsidiary 
of Merck and Co., Inc; August 2018.
Lee and Liu, 2008
Lee JJ, Liu DD. A predict ive probabilit y design for phase II cancer clinical trials. Clin Trials. 
2008;5(2):93 -106.
MedImmune Protocol Amendment 4 D9108C00001 (COAST)
Durvalumab and novel oncology therapies 27Jul2021 ; Final
CONFIDENTIAL AND PROPRIETARY 80of 105 Template 18.0López -Soto et al, 2017
López -Soto A, Gonzalez S, Smyth MJ, Galluzzi L. Control of metastasis by NK cells. Cancer 
Cell. 2017;32(2):135 -54.
Malladi et al, 2016
Malladi S, Macalinao DG, Jin X, He L, Basnet H, Zou Y, et al. Metastati c latency  and 
immune evasio n through autocrine inhibit ion of WNT. Cell. 2016;165(1):45 -60.
Mamessier et al, 2011
Mamessier E, Sylvain A, Thibult ML, Houvenaeghel G, Jacquemier J, Castellano R, et al. 
Hum an breast cancer cells enhance self -tolerance by  promoting evasio n from NK cell 
antitumor immuni ty. J Clin Invest. 2011;121(9):3609-22.
Ohaegbulam et al, 2015
Ohaegbulam KC, Assal A, Lazar -Molnar E, Yao Y, Zang X. Human cancer immunotherapy 
with antibodies to the PD -1 and PD -L1 pathway . Trends Mol  Med. 2015 ;21(1):24 -33.
Opdivo® US PI, 2018
Opdivo Package Insert. Princeton, NJ: Bristol -Myers Squibb Co mpany; August 2018.
Pardoll, 2012
Pardoll DM. The blockade of immune checkpo ints in cancer immunotherapy . Nat Rev Cancer. 
2012;12(4):252 -64.
Pasero et al, 2015
Pasero C, Gravis G, Granjeaud S, Guerin M, Thomassin -Piana J, Rocchi  P, et al . Highly 
effect ive NK cells are associated with good prognosis in pat ients with metastati c prostate 
cancer. Oncotarget. 2015;6(16):14360-73.
Peng et al, 2014
Peng YP, Zhang JJ, Li ang W, Tu M, Lu ZP, Wei JS, et al. Elevat ion of MMP -9 and IDO 
induced by  pancreatic cancer cells mediates natural killer cell dysfunct ion. BMC Cancer. 
2014;14:738.
Platonova et al, 2011
Platonova S, Cherfils -Vicini  J, Dam otte D, Crozet L, Vieillard V, Vali dire P, et al . Profound 
coordinated alterations of intratumoral NK cell phenoty pe and funct ion in lung carcino ma. 
Cancer Res. 2011;71(16):5412 -22.
Plathow et al, 2011
Plathow C, Ascho ff P, Lichy MP, Eschmann S, Hehr T, Brink I, et al. Positron emissio n 
tomography /com puted tom ography  and whol e-body magnet ic resonance imaging in staging of 
advanced nonsmall cell lung cancer –initial results. Invest Radio l. 2008;43(5):290 -7.
MedImmune Protocol Amendment 4 D9108C00001 (COAST)
Durvalumab and novel oncology therapies 27Jul2021 ; Final
CONFIDENTIAL AND PROPRIETARY 81of 105 Template 18.0Segal et al, 2018
Segal  NH, Nai doo J, Curi gliano G, Patel S, Sahebjam S, Papadopoulos K, et al. First -in-
human dose escalat ion of monalizumab plus durvalumab with expansio n in patients with 
metastati c microsatellite -stable co lorectal  cancer. Poster presented at: American Societ y of 
Clinical Onco logy; June 01- 05, 2018; Chicago, IL ( Abstract #3540) .
Seymour et al, 2017
Seymour L, Bogaerts J, Perrone A, Ford R, Schwartz LH, Mandrekar S, et al. iRECIST: 
guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 
2017;18(3):e143 -e52.
Sheu et al, 2005
Sheu BC, Chi ou SH, Lin HH, Chow SN, Huang SC, Ho NH, Hsu SM. Up -regulat ion of 
inhibitory  natural  killer receptors CD94/NKG2a wit h suppressed intracellular perforin 
expressio n of tumor -infiltrating CD8+ T lymphocytes in human cervical carcino ma. Cancer 
Res. 2005;65(7): 2921 -9.
Tarle et al, 1993
Tarle M, Kraljić I, Kastelan M. Comparison between NK cell act ivity and prostate cancer 
stage and grade in untreated patients: correlat ion wit h tum or markers and horm onal serotest 
data. Urol Res. 1993;21(1):17 -21.
Tecentriq ® US PI, 2018
Tecentri q Package Insert. San Francisco, CA: Genentech, Inc, a member of the Roche Group; 
July 2018.
Torre et al, 2015
Torre LA, Bray  F, Siegel  RL, Ferlay  J, Lortet -Tieulent J, Jemal A. Global Cancer Statist ics, 
2012. CA Cancer J Clin. 2015;65(2) :87-108.
Turcotte et al, 2015
Turcotte M, Spring K, Pommey S, Chouinard G, Cousineau I, George J, et al. CD73 is 
associ ated wi th poor prognosis in high -grade serous ovarian cancer. Cancer Res. 
2015;75(21):4494 -503. 
Versluis et al, 2017
Versl uis MAC, Marchal  S, Pl at A, de Bock GH, van Hall, T, de Bruyn M, et al. The 
prognosti c benefit of tum our-infiltrat ing Natural Killer cells in endo metrial cancer i s 
dependent on concurrent overexpressio n of human leucocy te anti gen-E in the tumour 
microenvironment. Eur J Cancer. 2017;86:285 -95.
Vijayan et al, 2017
Vijayan D, Young A, Teng MWL, Smy th MJ. Targeting immunosuppressive adenosine in 
cancer. Nat Rev Cancer. 2017;17(12):709 -24.
MedImmune Protocol Amendment 4 D9108C00001 (COAST)
Durvalumab and novel oncology therapies 27Jul2021 ; Final
CONFIDENTIAL AND PROPRIETARY 82of 105 Template 18.0Zeestraten et al, 2014
Zeestraten EC, Reimers MS, Saadatmand S, Goossens- Beumer IJ, Dekker JW, Liefers GJ, et 
al. Combined analysis o f HLA class I, HLA -E and HLA -G predi cts prognosi s in co lon cancer 
patients. Br J Cancer. 2014;110(2):459-68.
Zou and Chen, 2008
Zou W, Chen L. Inhibitory  B7-family molecules in the tumour microenvironment. N at Rev
Immunol.2008;8(6):467 -77.
Zou et al, 2016
Zou W, Wolchok JD, Chen L. PD- L1 (B7- H1) and PD -1 pathway  blockade f or cancer 
therapy : Mechanisms, response bio markers, and combinat ions. Sci Transl Med. 
2016;8(328):328rv4. 
MedImmune Protocol Amendment 4 D9108C00001 (COAST)
Durvalumab and novel oncology therapies 27Jul2021 ; Final
CONFIDENTIAL AND PROPRIETARY 83of 105 Template 18.09 CHANGES TO THE PROTO COL
9.1 Proto col Amendment 4
Text revi sions resul ting fro m this amendment are incorporated in the body  of Protocol  
Amendment 4. All subjects have completed their treatment period as specified by the protocol 
and no subjects are currently  receiving any  study  treatm ent. The primary reason for this 
amendment i s to cl arify the frequency and length for collect ion of overall survival data.
Substant ial changes to the protocol are summarized below:
1Title page: Replaced  with  as Medical Monitor.
2Secti on 3.1.1 (Overview): Clarified that all subjects, including those who have experi -
enced PD, will be fo llowed f or survival unt il the end of the study .
3Secti on 4.1.6 (Di scont inuat ion of Invest igational Product), Section 4.2.2 (Follow -up Pe-
riod), Tabl e 6 (Schedul e of Follow-up Procedures: Subjects Who Completed Study  Treat-
ment and Maintain DC, Subjects Who Discont inued Study Treatment Due to Other Rea-
son Not Related to PD, and Subjects Who Experienced Unconfirmed PD and are Eligible 
for a Confirmat ion Scan), and S ection 4.2.3 (End of Study ): Clarified that survival status 
will be co llected for all subjects until 60 months post Cycle 1 Day 1, at time points de-
tailed in Table 6. Further, subjects may be contacted for survival status every  12 m onths 
beyo nd 60 m onths p ost Cy cle 1 Day  1, unt il the end of the ent ire study , unless consent is 
withdrawn.
Non-substantial changes to the protocol are as fo llows:
1Protocol  Synopsi s: Updated to align with the body  of the protocol.
2Secti on 3.1.3 (Management of Study  Medicat ion Rel ated Toxi cities): A reference to the 
website hosting the toxicit y management guidelines for durvalumab was deleted as the 
website has been decommissio ned.
3Secti on 4.1.1 (Number of Subjects) and Section 4.8.2 (Sample Size): Clarified that the re-
cruitment es timate of 60 subjects per experimental treatment arm is approximate.
4Secti on 4.2.3 (End of Study ), Table 7 (Schedule of Procedures for End of Study  Visi t): 
Added a footnote to clarify that concomitant medications, AEs and SAEs will be col-
lected at this vis it only .
5Secti on 4.5.1.8 (Reporting Product Complaints): Updated the con tact inform ation for re-
porti ng product complaints.
9.2 Protocol Amendment 3
Text revi sions resul ting fro m this amendment are incorporated in the body  of Protocol  
Amendment 3. The primary reason for the amendment is to increase the window from the sub-
ject’s last cCRT to randomizat ion into the study .
PPD
PPD
MedImmune Protocol Amendment 4 D9108C00001 (COAST)
Durvalumab and novel oncology therapies 27Jul2021 ; Final
CONFIDENTIAL AND PROPRIETARY 84of 105 Template 18.0Substant ial changes to the protocol are summarized below.
1Protocol  synopsis; Section 3.1.1 (Overview), including Figure 1 (Study  Flow Di agram);
and Sect ion 4.1.2 (Inclusio n Cri teria), Cri terion 5: The window from the subject’s last 
cCRT to randomizat ion was increased from 28 days to 42 day s to align wit h the PACIFIC 
study  design and to provide sites more flexibilit y in identifying and enrolling subjects.
2Secti on 4.1.3 (Excl usion Criteria): Added criterion (new Criterion 5) excluding subjects 
with prior exposure to any  anti-PD-1, anti -PD-L1, or anti -CTLA -4 antibody  for the 
treatm ent of NSCLC to avoid confounding factors affect ing safety and efficac y 
assessments for this study . 
Non-substantial changes to the protocol are summarized below.
1Table 5 (Schedule of Screening and Treatment Period Procedures): 
(a)Added assessment for ECOG performance status for Cycle 5 through Cy cle 13. This 
assessment was i nadvertent ly omitted in the ori ginal  protocol . ECOG perform ance 
status is to be assessed throughout the study , as noted in Table 6 (Schedule of 
Follow-up Procedures) throughout the fo llow-up peri od and Table 7 (Schedule of 
Procedures for End of Study  Visi t).
(b)Footnote “e” revised to align with changes to required TSH tests described in 
Secti on4.3.3, Other Safety  Tests. 
2Table 6 (Schedule of Fo llow-up Procedures: Subjects Who Completed Study  Treatm ent 
and Maintain DC, Subjects Who Discont inued Study Treatmen t Due to Other Reason Not 
Related to PD, and Subjects Who Experienced Unconfirmed PD and are Eligible for a 
Confirmation Scan): 
(a)Clarified that di sease assessments conducted as part of fo llow-up procedures 
≤ 12 months from  Cycle 1 Day  1 can be conducted wi thin 7 days of the visit, in 
alignment with window for this assessment during the treatment period. 
(b)Footnote “a” revised to align with changes to required TSH tests described in 
Secti on4.3.3, Other Safety  Tests.
3Secti on 4.3.3 (Clinical Laboratory  Tests), Other Safet y Tests: Thy roid functi on tests were 
revised permitt ing sites to only conduct T3 or T4 tests when TSH is abnormal for 
flexibilit y to accommodate country  or inst itutional gui delines regarding thy roidal 
abnorm ality screening. Addi tionally, i t was clarified that free T3/free T4 are preferred 
over total T3/total T4 tests.
4Secti on 4.5.1.8 (Reporting Product Complaints): Updated the telephone informat ion in 
alignment with current contact.
5Protocol  synopsis and Section 4.8.1 (General Considerat ions): M odified the definit ion of 
the ITT Popul ation to align wi th the Sponsor’s current standard definit ion.
6Appendix D (Act ions Required in Cases of Increases in Liver Biochemistry  and 
Evaluat ion of Hy’s Law): Removed references as not cited in the protocol.
MedImmune Protocol Amendment 4 D9108C00001 (COAST)
Durvalumab and novel oncology therapies 27Jul2021 ; Final
CONFIDENTIAL AND PROPRIETARY 85of 105 Template 18.09.3 Protocol Amendment 2
The primary  reasons for the am endment were alignment of monalizumab informat ion with the 
new manufacturing process (Process C), updating the process for ident ifying and reporting po-
tential Hy’s Law and Hy’s Law cases, and adding an inclu sion criterion to ensure all subjects 
have at least 1 previously irradiated tumor lesio n that can be measured by RECIST v1.1. No 
subjects were enrolled in experimental Arm B (durvalumab plus monalizumab) prior to Proto-
col Amendment 2. 
All revisio ns to the protocol are noted below:
1Secti on 1.5 (Rati onale for Conducting the Study ): Included rati onale for use of ORR to 
assess ant itumor activit y 
2Secti on 4.1.2 (Incl usion Criterion): Added criterion to clarify that subjects must have at 
least 1 previously  irradiated tumor lesio n measurable by RECIST v1.1, consistent with 
the RECIST v1.1 guidelines
3Secti on 4.5.1 (Identit y of Invest igational Product), Table 8 (Identificat ion of 
Invest igational Product): Updated with new monalizumab manufacturing process 
inform ation, and added study  drug storage information.
4Secti on 4.5.1.3 (Durvalumab Dose Preparation and Administration): Revised to align wit h 
updated preferred durvalumab language, including removal of requirement that 
IVadministration filter be in -line. 
5Secti on 4.5.1.4 (Ol eclumab Dose Preparation and Administration): Revised to align with 
updated preferred oleclumab language, including removal of requirement that 
IVadministration filter be in -line.
6Secti on 4.5.1.5 (Monalizumab Dose Preparation and Administration ): Updated wi th new 
monalizumab manufacturing process informat ion.
7Secti on 5.4.6 (Potential Hy’s Law and Hy’s Law): Revised sect ion heading to include 
potenti al Hy’s Law and added requirement to report these cases as SAEs.
8Secti on 7.1 (Subj ect Data Protect ion): Revised to align with preferred MedImmune 
standard l anguage.
9Appendix D (Act ions Required in Cases of Increases in Liver Biochemistry  and 
Evaluat ion of Hy’s Law): Updated to align with revised MedImmune requirements. 
9.4 Protocol Amendment 1
The protoc ol was revised to incorporate the fo llowing US Food and Drug Administration re-
quests:
1Figure 1 (Study  Flow Diagram ): Rem oved placeholders for new combinat ion 
experimental arms (A and X) that could be added via a protocol amendment.
2Table 5 (Schedule of Scr eening and Treatment Period Procedures): Additional PK and 
ADA samples will be collected at Cy cle 11.
MedImmune Protocol Amendment 4 D9108C00001 (COAST)
Durvalumab and novel oncology therapies 27Jul2021 ; Final
CONFIDENTIAL AND PROPRIETARY 86of 105 Template 18.03Table 6 (Schedule of Fo llow-up Procedures: Subjects Who Completed Study  Treatm ent 
and Maintain DC, Subjects Who Discont inued Study Treatment Due to Other Reason Not 
Related to PD, and Subjects Who Experienced Unconfirmed PD and are Eligible for a 
Confirmation Scan): PK and ADA samples will be collected at 10 months post Cycle 1 
Day 1 (for follow -up during the first 12 months) and on Month 15 (for follow -up > 12 to 
≤ 24 months).
4Secti on 4.3.4 (Pharm acokinetic Evaluat ion and Methods): Revised to ident ify each novel 
agent to be included in the PK evaluat ion.
5Secti on 4.3.5 (Immunogenicit y Evaluat ion and Methods): Revised to ident ify each 
novel/bio logic agent to be included in the ADA evaluat ion.
6Secti on 4.3.8 (Estimate of Volume of Blood to be Collected): Updated to align with 
additional blood sam ples collected for PK and ADA assessments.
7Secti on 4.8.2 (Sample Size): Added detail for sample size determination.
MedImmune Protocol Amendment 4 D9108C00001 (COAST)
Durvalumab and novel oncology therapies 27Jul2021 ; Final
CONFIDENTIAL AND PROPRIETARY 87of 105 Template 18.0Appendix AContraception Guidance
Females of Childbearing Potential
Females of childbearing potential must use at least one of the highly effect ive methods of con-
tracepti on described in Table A1while on study  and f or 180 day s after the final dose of inves-
tigational product. It is strongly reco mmended for the male partner of a female subject to also 
use m ale condom  plus spermicide throughout this period. In addit ion, female subjects must 
refrain fro m egg cell donat ion and breast feeding while on study  and f or 180 days after the fi-
nal dose of invest igational product.
Females of childbear ing potential are defined as those who are not surgically sterile (ie, bilat-
eral tubal  ligat ion, bilateral oophorectomy, or hy sterectomy) or postmenopausal. The defini-
tion of  postm enopausal  status in this study  include:
Women < 50 y ears of age if they have been amenorrhoeic for ≥ 12 months in the absence 
of any exogenous hormonal treatment, and their levels o f luteinizing hormone and 
follicle -stimulat ing horm one are in the post -menopausal range for the inst itution or 
underwent surgical sterilizat ion (bilate ral oophorectomy  or hysterectomy ).
Women ≥ 50 y ears are consi dered post -menopausal if they have been amenorrhoeic for 
≥12 m onths in the absence of any exogenous hormo nal treatment, or underwent surgical 
sterilizat ion (ie, bilateral  oophorectomy, bilateral salpingectomy or hy sterectomy).
Non-sterilized Male Subjects
Non-sterilized male subjects must use a male condom with spermicide fro m screening to 
180days after the final dose of study  treatm ent as an effective method of contraception. It is 
strongly  recommended for the female partner of a male subject to also use a highly effect ive 
method of contraception throughout this period, as described in Table A1. In addi tion, m ale 
subjects must refrain fro m sperm  donati on while on study  and f or 180 days after the final dose 
of investigational product. 
MedImmune Protocol Amendment 4 D9108C00001 (COAST)
Durvalumab and novel oncology therapies 27Jul2021 ; Final
CONFIDENTIAL AND PROPRIETARY 88of 105 Template 18.0Table A1 Highly Effective Metho ds of Contraception
Barrier Methods Hormonal Methods
• Intrauterine device
• Intrauterine hormone -releasing 
system (UIS) a
• Bilateral tubal occlusion
• Vasectomized partner b
• Sexual abstinencec• Combined estrogen and progestogen containing 
hormonal contraception: oral (combined pill), injectable 
or transdermal (patch)
• Progestogen -only  hormonal contraception associated 
with inhibition of ovulation d: injectable, implantable or 
intravaginal
aThis is also considered a hormonal method
bWith appropriate post-vasectomy documentation of surgical success (absence of sperm in ejaculate).
cSexual abstinence is considered a highly effective method only if defined as refraining from 
heterosexual intercourse during the entire period of the study and if it is the p referred and usual 
lifesty le of the subject.
dProgestogen -only  hormonal contraception, where inhibition of ovulation is not the primary mode of 
action (eg, minipill), is not accepted as a highly effective method.
MedImmune Protocol Amendment 4 D9108C00001 (COAST)
Durvalumab and novel oncology therapies 27Jul2021 ; Final
CONFIDENTIAL AND PROPRIETARY 89of 105 Template 18.0Appendix BAdditional Safety Guidance
Further Guidance on the Definition of a Serious Adverse Event
Life threatening
‘Life -threatening’ means that the subject was at immediate risk of death from AE as it 
occurred or it is suspected that use or continued use of the product would result in the 
subject’s death. ‘Life -threatening’ does not m ean that had an AE occurred in a more severe 
form it might have caused death (eg, hepatit is that resolved wit hout hepatic failure).
Hospitalization
Outpati ent treatm ent in an emergency room is not in itself an SAE, although the reasons for it 
may be (eg, bronchospasm, laryngeal edema). Hospital admissio ns and/or surgical operations 
planned before or during a study  are not consi dered AEs if the illness or disea se existed before 
the subject was enro lled in the study, provided that it did not deteriorate in an unexpected way 
during the study .
Important Medical Event or Medical Intervent ion
Medical and scientific judgment should be exercised in deciding whether a c ase is serious in 
situations where important m edical events may  not be immediately life threatening or result in 
death, hospi talizat ion, disabilit y or incapaci ty but may jeopardize the subject or may require 
medical intervention to prevent one or more outc omes listed in the definit ion of serious. These 
shoul d usually be considered as serious.
Simply stopping the suspect drug does not mean that it is an important medical event; medical 
judgment must be used.
Examples of such events are:
Angioedema not severe enough to require intubation but requiring IV hydrocortisone 
treatm ent
Hepatotoxicit y caused by paracetamo l (acetaminophen) overdose requiring treatment with 
N-acetylcysteine
Intensive treatment in an emergency room or at home for allergic bronchospasm
Blood dy scrasias (eg, neutropenia or anemia requiring blood transfusio n) or convulsio ns 
that do not result in hospitalizat ion
Development of drug dependency or drug abuse
Assessment of Severity
Assessment of severit y is one of the responsibilit ies of the in vestigator in the evaluation o f 
AEs and SAEs. Severit y will be graded according to the NCI CTCAE v5.0 as provided in 
below. The determinat ion of severit y for all other events not listed in the NCI CTCAE v5.0 
MedImmune Protocol Amendment 4 D9108C00001 (COAST)
Durvalumab and novel oncology therapies 27Jul2021 ; Final
CONFIDENTIAL AND PROPRIETARY 90of 105 Template 18.0shoul d be made by the invest igator based upon me dical judgment and the severit y categori es 
of Grade 1 to 5 as defined below.
Grade 1 An event of mild intensit y that is usually transient and may  
requi re only  minimal treatm ent or therapeuti c intervent ion. The 
event does not generally interfere with usual activities o f daily 
living.
Grade 2 An event of moderate intensit y that i s usually alleviated with 
additional specific therapeuti c interventi on. The event interferes 
with usual  activi ties of  daily living, causing discomfort but 
poses no significant or perm anent ri sk of harm  to the subject.
Grade 3 A severe event that requires intensive therapeutic intervent ion. 
The event interrupts usual activit ies of daily living, or 
significant ly affects the clinical status of the subject.
Grade 4 An event, and/or its imm ediate sequel ae, that i s associ ated wi th 
an imminent risk of death.
Grade 5 Death as a result of an event.
Assessment of Relationship
The invest igator is required to provide an assessment of relat ionship of AEs and SAEs to the 
investigat ional product. The fo llowing factors shoul d be considered when deciding if there is a 
“reasonable possibilit y” that an AE may have been caused by the investigational product:
Time Course. Exposure to suspect investigat ional product. Has the subject actually  
received the suspect investigational product? Did the AE occur in a reasonable temporal 
relationship to the administration of the suspect investigational product?
Consistency wit h known invest igational product profile. Was the AE consistent with the 
previous knowledge of the suspect invest igational product (pharmaco logy and toxi cology) 
or products of the same pharmaco logical class? OR could the AE be ant icipated fro m its 
pharmaco logical properti es? 
De-challenge experience. Did the AE resolve or improve on stopping or r educing the dose 
of the suspect invest igational product?
No al ternative cause. The AE cannot be reasonably explained by another etio logy such as 
the underlying disease, other drugs, or other host or environmental factors.
Re-challenge experience. Did the A E reoccur if the suspected invest igational product was 
reintroduced after having been stopped? MedImmune would not normally recommend or 
support a re -challenge.
Laboratory  tests. A specific laboratory  invest igation (if performed) has confirmed the 
relationship?
MedImmune Protocol Amendment 4 D9108C00001 (COAST)
Durvalumab and novel oncology therapies 27Jul2021 ; Final
CONFIDENTIAL AND PROPRIETARY 91of 105 Template 18.0In difficult cases, other factors could be considered such as:
Is this a recognized feature of overdose of the investigat ional product?
Is there a known mechanism?
Relationship to Protocol Procedures
The invest igator is also required to provide an assessment of relat ionship of SAEs to protocol 
procedures on the SAE Report Form. This includes nontreatment -emergent SAEs (ie, SAEs 
that occur prior to the administration o f investigational product) as well as treatment -emergent 
SAEs. A protocol -related SAE may occur as a result of a procedure or intervent ion required 
during the study  (eg, bl ood collect ion, washout of an exist ing medicat ion). The fo llowing 
guidelines shoul d be used by  investi gators to assess the relat ionship of SAEs to the protocol:
Protocol  related: The event occurred due to a procedure/intervention that was described 
in the protocol for which there is no alternat ive et iology  present in the 
subject’s medical record.
Not protocol related: The event is related to an etio logy other than the procedure/ 
intervent ion that was described in the protocol (the alternative et iology 
must be documented in the study  subject’s m edical record).
MedImmune Protocol Amendment 4 D9108C00001 (COAST)
Durvalumab and novel oncology therapies 27Jul2021 ; Final
CONFIDENTIAL AND PROPRIETARY 92of 105 Template 18.0Appendix CNational Institute of Allergy and Infectious Diseases and 
Food Allergy a nd Anaphylaxis Network Guidance for 
Anaphylaxis Diagnosis
National Inst itute of Allergy and Infectious Diseases and Food Allergy and Anaphylaxis 
Network define anaphylaxis as a serious allergic reaction that is rapid in on set and may cause 
death. They recognize 3 categories of anaphylaxis, with criteria designated to capture from 80% of 
cases (category 1) to > 95% of all cases of anaphylaxis (for all 3 categories).
1Acute onset of an illness (minutes to several hours) with invo lvement of the skin, mucosal 
tissue, or both (eg, generalized hives, pruritus or flushing, swo llen lips -tongue -uvula) 
AND AT LEAST ONE OF THE FOLLOWING: 
(a)Respiratory  com promise (eg, dyspnea, whe eze-bronchospasm, stridor, reduced peak 
expiratory  flow (PEF), hy poxemia)
(b)Reduced blood pressure (BP) or associated symptoms of end -organ dysfunct ion 
(eg,hypotonia [collapse], syncope, incont inence)
2Two or more of the following that occur rapidly after ex posure to a likely allergen for that 
patient (minutes to several hours): 
(a)Involvement of the skin -mucosal t issue (eg, generalized hives, itch -flush, swollen 
lips-tongue-uvula)
(b)Respiratory  com promise (eg, dyspnea, wheeze- bronchospasm, stridor, reduced PEF, 
hypoxemia)
(c)Reduced BP or associated symptoms (eg, hy potonia [coll apse], syncope, 
incont inence)
(d)Persi stent gastrointestinal symptoms (eg, crampy  abdominal  pain, vomi ting)
3Reduced BP after exposure to known allergen for that patient (minutes to several hours ): 
(a)Infants and children: low systolic BP (age specific) or greater than 30% decrease in 
systolic BP
(b)Adults: systolic BP of less than 90 mm Hg or greater than 30% decrease fro m that 
person’s baseline
For addi tional information, pl ease refer to: Sam pson HA , Muñoz -Furlong A, Cam pbell RL, 
Adkinson FN Jr, Bock SA, Branum A, et al. Second symposium on the definit ion and 
management of anaphylaxis: Summary  report. Second Nati onal Institute of Allergy and 
Infectious Disease/Food Allergy  and Anaphylaxis Network sym posium. J Allergy  Clin 
Immunol. 2006;117:391 -7.
MedImmune Protocol Amendment 4 D9108C00001 (COAST)
Durvalumab and novel oncology therapies 27Jul2021 ; Final
CONFIDENTIAL AND PROPRIETARY 93of 105 Template 18.0Appendix DActions Required in Cases of Increases in Liver Biochemistry 
and Evaluation of Hy’s Law
D 1 Introduction
This appendix describes the process t o be fo llowed in order to ident ify and appropriately 
report potential Hy’s Law cases and Hy’s Law cases. It is not intended to be a comprehensive 
guide to the management of elevated liver biochemistries. Specific guidance on managing 
liver abnormalit ies ca n be found in the Toxicit y Management Guidelines (see Section 3.1.3 ).
During the course of the study , the invest igator will remain vigilant for inc reases in liver 
biochemistry . The invest igator is responsible for determining whether a subject meets 
potenti al Hy’s Law cri teria at any  point during the study .
All sources of l aboratory  data are appropri ate for the determinat ion of potenti al Hy’s Law and 
Hy’s Law events; this includes samples taken at scheduled study  visits and other visi ts 
including all local laboratory  evaluat ions even if collected outside of the study  visit s.
The invest igator will also review AE data (for example, for AEs that may indic ate el evati ons 
in liver bio chemistry ) for possible potenti al Hy’s Law events.
The invest igator participates, together with MedImmune clinical pro ject representatives, in 
review and assessment of cases meet ing potential Hy’s Law criteria to agree whether Hy ’s 
Law cri teria are m et. Hy’s Law criteria are met if there is no alternat ive explanat ion for the 
elevations in liver biochemistry  other than drug -induced liver injury (DILI) caused by the 
investigat ional product. 
The invest igator is responsible for recor ding data pertaining to potential Hy’s Law/Hy’s Law 
cases and for reporting AEs and SAEs according to the outcome of the review and assessment 
in line wit h standard safety  reporting processes.
D 2 Definitions
D2.1 Potential Hy’s Law
AST or ALT ≥ 3 × ULN together with TBL ≥ 2 × ULN at any po int during the study  
following the start of investigational product irrespective of an increase in ALP.
D2.2 Hy’s Law
AST or ALT ≥ 3 × ULN together with TBL ≥ 2 × ULN, where no other reason, other than 
the invest igational product, can be found to explain the combinat ion of increases; eg, elevated 
ALP indicat ing cholestasis, viral hepat itis, or another drug.
MedImmune Protocol Amendment 4 D9108C00001 (COAST)
Durvalumab and novel oncology therapies 27Jul2021 ; Final
CONFIDENTIAL AND PROPRIETARY 94of 105 Template 18.0For potential Hy’s Law and Hy’s Law, the elevation in transaminases must precede or be 
coincident with (ie, on the same day ) the elevation in TBL, but there is no specified t imeframe 
within which the elevat ions in transaminases and TBL must occur.
D 3 Identification of Potential Hy’s Law Cases
In order to i dentify  cases of potential  Hy’s Law, i t is important to perform a comprehensive
review of laboratory  data for any  subject who m eets any of the fo llowing i dentificat ion criteria 
in isolation or in co mbinat ion:
ALT ≥ 3 × ULN
AST ≥ 3 × ULN
TBL ≥ 2 × ULN
The invest igator will, without delay, review each new laboratory report and if the 
ident ificat ion criteria are met will:
Notify  the sponsor study  representative
Determine whether the subject meets potential Hy’s Law criteria (see Section D 2) by 
reviewing laboratory  reports from  all previ ous visits
Prom ptly enter the laboratory  data into the l aboratory  eCRF
D 4 Follow -up
D4.1 Potential Hy’s Law Criteria Not Met
If the subject does not meet potential Hy’s Law criteria the invest igator will:
Inform  the study  representative that the subject has not met potential Hy’s Law criteria.
Perform  follow-up on subsequent laboratory  resul ts according to the guidance provided in 
the study  protocol .
D4.2 Potential Hy’s Law Criteria Met
If the subject does meet potential Hy’s Law criteria the invest igator will:
Notify  the sponsor study  representative who will then inform the study  team
Within 1 day of potential Hy’s Law criteria being met, the invest igator will report the 
case as an SAE of Potential Hy’s Law; serious cri teria ‘Important m edical event’ and 
causalit y assessment ‘yes/related’ according to clinical study  protocol  process for SAE 
reporting
MedImmune Protocol Amendment 4 D9108C00001 (COAST)
Durvalumab and novel oncology therapies 27Jul2021 ; Final
CONFIDENTIAL AND PROPRIETARY 95of 105 Template 18.0The m edical  monitor contacts the invest igator, to provide guidance, discuss and agree on an 
approach for the st udy subjects’ fo llow-up (including further laboratory  testing) and the 
continuous review of data. 
Subsequent to this contact the invest igator will:
Moni tor the subject until liver biochemistry  parameters and appropriate clinical 
symptoms and signs return to norm al or baseline levels, or as l ong as m edically indicated. 
Com plete f ollow -up SAE Form  as requi red.
Invest igate the etio logy of the event and perform diagnostic investigat ions as discussed 
with the m edical m onitor. 
Com plete the rel evant Case Report Form  (CRF) Modul es as inform ation beco mes 
available
D 5 Review and Assessment of Potential Hy’s Law Cases
The instructions in this sect ion shoul d be fo llowed for all  cases where potenti al Hy’s Law 
criteria are met.
As soon as possible after the biochemistry  abnormalit y was ini tially detected, the m edical 
monitor will  contact the invest igator in order to review available data and agree on whether 
there is an alternat ive explanat ion for meeting potent ial Hy’s Law cri teria other than DILI 
caused by  the invest igational product, to ensure timely analysis and reporting to health author-
ities per local requirements from the date potential Hy’s Law criteria were met . The m edical 
monitor and gl obal safety physician will also be involved in this review together with other
subject matter experts as appropriate.
According to the outcome of the review and assessment, the invest igator will fo llow the 
instructi ons bel ow.
Where there is an agreed alternative explanation for the ALT or AST and TBL elevat ions, 
a determination of whether the alternat ive explanatio n is an AE will be made and 
subsequent ly whether the AE meets the criteria for an SAE:
If the alternat ive explanat ion is notan AE, record the alternative explanat ion on the 
appropriate CRF
If the alternat ive explanat ion is an AE/SAE, update the previously submitted potential 
Hy’s Law SAE and AE CRFs accordingly wit h the new information (reassessing event 
term; causalit y and seri ousness cri teria) fo llowing the spons or’s standard processes
If it is agreed that there is no explanat ion that would explain the ALT or AST and TBL 
elevations other than the invest igational product:
MedImmune Protocol Amendment 4 D9108C00001 (COAST)
Durvalumab and novel oncology therapies 27Jul2021 ; Final
CONFIDENTIAL AND PROPRIETARY 96of 105 Template 18.0Send the updated SAE (report term ‘Hy’s Law’) according to the sponsor’s standard 
processes.
The ‘Medically  Important’ seri ous cri terion shoul d be used if no other serious criteria 
apply
As there is no alternat ive explanation for the Hy’s Law case, a causalit y assessment 
of ‘related’ should be assigned
If, there i s an unavo idable delay of over 15 calendar day s in obtaining the informat ion neces-
sary to assess whether or not the case meets the criteria for Hy’s Law, then it is assumed that 
there is no alternat ive explanation unt il such time as an informed decisio n can be made:
Provi de any further update to the previously  submitted SAE of Potenti al Hy’s Law (report 
term now ‘Hy’s Law case’), ensuring causalit y assessment are related to the 
investigat ional product and seriousness criteria is medically important, according to the 
clinical study  protoc ol process for SAE reporting
Continue fo llow-up and review according to agreed plan. Once the necessary  
supplementary  informat ion is obtained, repeat the review and assessment to determine 
whether Hy’s Law criteria are still met. Update the previously subm itted potenti al Hy’s 
Law SAE report fo llowing clinical study  protocol  process for SAE reporti ng, according to 
the outcom e of the review and am end the reported term if an alternat ive explanat ion for 
the liver biochemistry  elevati ons is determined
D 6 Actions R equired for Repeat Episodes of Potential Hy’s Law
This sect ion is applicable when a subject meets potent ial Hy’s Law criteria on study  treatm ent 
and has already met potential Hy’s Law criteria at a previous on study  treatment vi sit.
The requi rement to cond uct fo llow-up, revi ew, and assessment of a repeat occurrence(s) of 
potenti al Hy’s Law is based on the nature of the alternat ive cause ident ified for the previous 
occurrence. 
The invest igator should determine the cause for the previous occurrence of potent ial Hy’s Law 
criteria being met and answer the fo llowing quest ion:
Was the alternat ive cause for the previous occurrence o f potenti al Hy’s Law cri teria being 
met found to be the disease under study  eg, chronic or progressing malignant disease, 
severe infec tion, or liver di sease?
If No: follow the process described in Sect ion D4.2, for reporting potential Hy’s Law as an 
SAE.
MedImmune Protocol Amendment 4 D9108C00001 (COAST)
Durvalumab and novel oncology therapies 27Jul2021 ; Final
CONFIDENTIAL AND PROPRIETARY 97of 105 Template 18.0If Yes:
Determine if the re has been a significant change in the subject’s condit ion compared with 
when potential Hy’s Law criteria were previously met:
If there is no significant change no action is required
If there is a significant change fo llow the process described in Section D4.2, for reporting 
potenti al Hy’s Law as an SAE
A ‘significant’ change in the subject’s condit ion refers to a clinically  relevant change in any of 
the individual liver biochemistry  parameters (ALT, AST, or TBL) in isolat ion or in co mbina-
tion, or a clinically  relevant change in associated symptoms. The determinat ion of whether 
there has been a significant change will be at the discretion of the inv estigator; this may be in 
consultation wit h the m edical m onitor if  there is any  uncertaint y.
D 7 Laboratory Tests
To evaluate the underlying et iology of potenti al Hy’s Law cases, relevant laboratory  tests will  
be perform ed as outlined in Sect ion 4.3.3 . Addi tional laboratory  assessments m ay be per-
formed as clinically indicated.
MedImmune Protocol Amendment 4 D9108C00001 (COAST)
Durvalumab and novel oncology therapies 27Jul2021 ; Final
CONFIDENTIAL AND PROPRIETARY 98of 105 Template 18.0Appendix EGenetic Research
Rationale and Objectives
MedImmune intends to collect and store DNA for genet ic research to explore how genetic 
variat ions may affect clinical parameters, risk and prognosis o f diseases, and the response to 
medicat ions.Genet ic research may lead to better understanding of diseases , better di agnosis of 
diseases or other improvements in healt h care and to the discovery  of new diagnosti cs, treat-
ments or medicat ions. 
In addit ion, collect ion of DNA samples from populat ions wit h well described clinical charac-
teristics may lead to improv ements in the design and interpretation of clinical trials and, possi-
bly, to genetically  guided treatment strategies.
Genetic Research Plan and Procedures
Selection of Genetic Research Population
Study Selection Record
All subjects will be asked to participate in this genetic research. Participat ion is voluntary and 
if a subject declines to participate there will be no penalt y or l oss of benefit. The subject will 
not be excluded from any aspect of the main study .
Inclusion Criteria
For inclusio n in this gen etic research, subjects must fulfil all o f the inclusio n criteria described 
in the main body  of the Clinical Study  Protocol  and:
Provi de inform ed consent for the genetic sampling and analyses.
Exclusion Criteria
Exclusio n from this genet ic research may be for any  of the excl usion criteria specified in the 
main study  or any  of the fo llowing:
Previous allogeneic bone marrow transplant
Non-leukocyte depleted whole blood transfusio n in 120 days of genetic sample collection
Discontinuation of Subjects from Thi s Genetic Research
Specific reasons for discont inuing a subject from this genet ic research are:
Withdrawal o f consent for genet ic research: Subjects may withdraw fro m this genetic research 
at any  time, independent of any decisio n concerning participat ion in other aspects of the main 
study . Vol untary  discont inuat ion will not prejudice further treatment. Procedures for with-
drawal  of informed consent are outlined in Sect ion 4.1.8 of the protocol.
MedImmune Protocol Amendment 4 D9108C00001 (COAST)
Durvalumab and novel oncology therapies 27Jul2021 ; Final
CONFIDENTIAL AND PROPRIETARY 99of 105 Template 18.0Collection of Samples for Genetic Research
The blood sample for genet ic research will be obtained fro m the subjects at screening. 
Although DNA is stable, early  sample collect ion is preferred to avoid introducing bias through 
excluding subjects who may wit hdraw due to an AE, such subjects would be important to 
include in any genet ic analysis. If for any reason the sample is not drawn at screening, it may 
be taken at any  visit until  the l ast study  visit. Only  one sample shoul d be collected per subject 
for genet ics during the study . Sam ples will  be collected, labelled, stored and shipped as 
detailed in the Laboratory  Manual.
Coding and Storage of DNA Samples
The processes adopted for the coding and storage of samples for genet ic analysis are 
important to maintain subject confidentialit y. Samples will  be stored for a m aximum  of 
15years or as per local regulations , from the date of last subject l ast vi sit, after whi ch they 
will be destroy ed. DNA i s a fini te resource tha t is used up during analyses. Samples will be 
stored and used until no further analyses are possible or the maximum storage time has been 
reached.
An addit ional second code will be assigned to the blood sample either before or at the time of 
DNA extraction replacing the informat ion on the sample tube. Thereafter, the sample will be 
ident ifiable by the second, unique number only. This number is used to ident ify the sample 
and corresponding data at the MedImmune genet ics laboratori es, or at the desi gnated 
organizat ion. No personal details ident ifying the individual will be available to any  person 
(MedImmune emplo yee or desi gnated organizat ions working with the DNA).
The link between the subject enrollment/randomization code and the second number will be 
mainta ined and stored in a secure environment, with restricted access at MedImmune or 
designated organizat ions. The link will be used to ident ify the relevant DNA samples for 
analysis, facilitate correlat ion of genoty pic resul ts wi th clinical  data, all ow regulat ory audi t 
and to trace samples for destruction in the case of withdrawal o f consent.
Ethical and Regulatory Requirements
The principles for ethical and regulatory  requi rements for the study , incl uding this genet ics 
research component, are outlined in Secti on 7 of the protocol.
Informed Consent
The genetic component of this study  is opti onal, and the subject may participate in other 
components of the m ain study  without parti cipat ing in the genet ic component. To participate 
in the genet ic co mponent of the study the subject must sign and date both the consent form for 
the main study  and the genet ic co mponent of the study . Copi es of  both si gned and dated 
consent forms must be given to the subject and the originals filed at the study  center. The 
Principal Invest igator(s) is responsible for ensuring that consent is given freely and that the 
MedImmune Protocol Amendment 4 D9108C00001 (COAST)
Durvalumab and novel oncology therapies 27Jul2021 ; Final
CONFIDENTIAL AND PROPRIETARY 100of 105 Template 18.0subject understands that they  may freely  discontinue from  the genet icaspect of the study  at 
any time.
Subject Data Protection
MedImmune will not provide individual genoty pe resul ts to subjects, any  insurance com pany, 
any emplo yer, their family members, or their general physician unless required to do so by 
law.
Extra preca utions are taken to preserve confident iality and prevent genetic data being linked to 
the identi ty of the subject. In except ional circumstances, however, certain individuals might 
see both the genetic data and the personal ident ifiers of a subject. For exa mple, in the case of a 
medical emergency, a MedImmune Physician or an invest igator might know a subject’s 
ident ity and also have access to his or her genet ic data. Also, Regulatory  authori ties may  
requi re access to the relevant files, though the subject’s medical informat ion and the genet ic 
files woul d rem ain physically  separate.
Data Management
Any genoty pe data generated in this study  will be stored at a secure system at MedImmune 
and/or designated organizations to analyze the samples.
The results from this genet ic research may be reported in a separate report fro m the CSR or 
published in scient ific journals.
MedImmune and its designated organizations may share summary results (such as genet ic 
differences fro m groups of individuals with a disease) fro m this genetic research with other 
researchers, such as hospitals, academic organizat ions or health insurance co mpanies. This 
can be done by placing the results in scient ific databases, where they can be combined wit h 
the resul ts of similar studies to learn eve n more about healt h and disease. The researchers can 
only use this inform ation for healt h-related research purposes. Researchers may see summary 
resul ts, but they  will not be able to see individual subject data or any  personal  identifiers. 
Some or all  of the clinical datasets from the main study  may be merged wi th the genet ic data 
in a suitable secure environment separate from the clinical database.
Statistical Methods and Determination of Sample Size
The number of subjects who will agree to participate in the genet ic research is unknown. It is 
therefore not possible to establish whether sufficient data will be collected to allow a formal 
statist ical evaluat ion or whether only descript ive statist ics will be generated. A Statist ical 
Analysis Plan will be pre pared where appropriate.
MedImmune Protocol Amendment 4 D9108C00001 (COAST)
Durvalumab and novel oncology therapies 27Jul2021 ; Final
CONFIDENTIAL AND PROPRIETARY 101of 105 Template 18.0Appendix FResponse Evaluation Criteria in Solid Tumors Version 1.1 
F 1 Measurability of Tumor Lesions
Tumor lesi ons will  be categori zed as fo llows:
Measurable Lesions -Must b e accurately measured in at least one dimensio n (longest 
diameter in the plane of measurement is to be recorded) with a minimum size of: 
10mm by CT scan (irrespect ive of scanner type) and MRI (no less than double the 
slice thi ckness and a minimum o f 10 m m). 
10mm caliper measurement by  clinical  examination (when superficial).
Malignant lymph nodes are considered pathologically enlarged and measurable, a 
lymph node must be ≥ 15 mm in short axis when assessed by  CT scan (CT scan slice 
thickness recommended to be no greater than 5 mm).
Nonmeasurable Lesions -Nonmeasurable lesio ns are defined as all other lesio ns (or 
sites of  disease), including small lesio ns (longest diameter < 10 mm or pathological 
lymph nodes with ≥ 10 to < 15 mm short axis). Lesions cons idered truly  nonmeasurable 
include the fo llowing: l eptom eningeal disease, ascites, pleural/pericardial effusio n, 
inflammatory  breast disease, lymphangit ic involvement of skin or lung, and abdo minal 
masses/abdo minal organo megaly identified by physical exami nation that is not 
measurable by reproducible imaging techniques.
Target Lesions -At baseline, all lesions up to a maximum o f 5 lesions total  (and a 
maximum o f 2lesions per organ) representative of all invo lved organs should be 
ident ified as target lesions. It may be the case that, on occasion, the largest lesio n does not 
lend itself to reproducible measurement in which circumstance the next largest lesio n 
which can be measured reproducibly  should be selected.
Non-target Lesions -It is possible to record mult iple non -target l esions invo lving the 
same organ as a single item (eg, “mult iple enlarged pelvic lymph nodes” or “mult iple 
liver m etastases”). 
New Lesions -Though only  certain new l esion measurements will be included in the 
tumor burden, all new lesions that can be accurately measured should be recorded. Up to 
5 addi tional target l esions (maximum  of 2 addi tional lesions per organ) may be added to 
the tumor burden at each postbaseline assessment to facilitate the exploratory  iRECIST 
analysis. Other new lesio ns will be included into the non -tumor burden.
MedImmune Protocol Amendment 4 D9108C00001 (COAST)
Durvalumab and novel oncology therapies 27Jul2021 ; Final
CONFIDENTIAL AND PROPRIETARY 102of 105 Template 18.0F 2 RECIST v1.1 Response Criteria
Evaluation of Target Lesions
CR -Disappearance of all target lesio ns. Any pathological lymph nodes (whether target 
or non -target) m ust have reduct ion in short axis to < 10 mm (the sum may not be “0” if 
there are target nodes). 
PR-At least a 30% decrease in the sum o f the diameters of target lesio ns, taking as 
reference the baseline sum diameters.
PD -At least a 20% increase in the sum of diamete rs of target lesions, taking as reference 
the smallest sum  on study  (this includes the baseline sum if that is the smallest on study ). 
In addit ion to the relat ive increase of 20%, the sum must also demonstrate an abso lute 
increase of at least 5 mm. (Note: the appearance of one or more new lesio ns is also 
considered PD.)
SD-Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for 
PD, taking as reference the smallest sum of diameters while on study .
Evaluation of Non -target Les ions
CR-Disappearance of all non -target l esions and norm alizat ion of tumor marker level. 
All lymph nodes m ust be non -patho logical in size (< 10 mm short axis). 
Non-CR/Non -PD-Persistence o f 1or more non -target lesio n(s) and/or maintenance of 
tumor marker level above the norm al limits.
PD-Unequivocal progression o f exist ing non-target l esions will  be defined as the overall 
level of substant ial worsening in non -target disease such that, even in presence of SD or 
PR in target disease, the overall tumor burden has increased sufficient ly to merit 
discontinuat ion of therapy  (see Secti on4.1.6 ). In the absence of measurable disease, 
change in non -measu rable disease comparable in magnitude to the increase would be 
requi red to decl are PD for measurable disease. Examples include an increase in a pleural 
effusio n from ‘trace’ to ‘large,’ an increase in lymphangit ic disease fro m localized to 
widespread.
Appearance of New Lesions
The appearance of new lesio ns is considered PD according to RECIST v1.1. Considering the 
unique response kinet ics that have been observed with immunotherapy, new lesio ns can 
nonetheless derive clinical benefit.
Evaluation of Overall Response
For the overall response based on RECIST v1.1, confirmat ion of CR and PR is required by a 
repeat, consecut ive assessment no less than 4 weeks from  the date of first documentation. If a 
subject discontinues the study  due to PD and begins another tr eatment, a confirmatory scan is 
not required.
MedImmune Protocol Amendment 4 D9108C00001 (COAST)
Durvalumab and novel oncology therapies 27Jul2021 ; Final
CONFIDENTIAL AND PROPRIETARY 103of 105 Template 18.0Table F1provi des overall responses for all possible combinat ions of tumor responses in target 
and non -target lesio ns wit h or without the appearance o f new lesio ns.
Table F1 Evaluation of Overall Response Using RECIST v1.1
Target Lesions Non-target Lesions New Lesions Overall Response
Complete responseComplete response (or no non -
target lesion)No Complete response
No target lesiona Complete response No Complete response
Complete response Not evaluablebNo Partial response
Complete responseNon-complete response /
non-progressive diseaseNo Partial response
Partial responseNon-progressive disease and
not evaluable (or no non -target 
lesion) bNo Partial response
Stable diseaseNon-progressive disease and
not evaluable (or no non -target 
lesion) bNo Stable disease
Not all evaluated Non-progressive disease No Not evaluable
No target lesion aNot all evaluated No Not evaluable
No target lesion a Non-complete response /
non-progressive diseaseNoNon-complete response /
non-progressive disease
Progressive disease Any Yes/No Progressive disease
Any Progressive disease Yes/No Progressive disease
Any Any Yes Progressive disease
No target lesion aUnequivocal progressive disease Yes/No Progressive disease
No target lesion aAny Yes Progressive disease
RECIST v1.1 = Response Evaluated Criteria in Solid Tumors version 1.1.
aDefined as no target lesion at baseline.
bNot evaluable is defined as either when no or only a subset of lesion measurements are made at an 
assessment.
Reference: Eisenhauer et al, 2009
SIGNATURE PAGE
This is a representation of an electronic record that was signed
electronically and this page is the manifestation of the electronic signature
Document Name: d9108c00001-csp-amendment-4
Document Title: d9108c00001-csp-amendment-4(COAST)
Document ID: Doc ID-004111051
Version Label: 2.0 CURRENT LATEST APPROVED
Server Date
(dd-MMM-yyyy HH:mm ‘UTC’Z)Signed by Meaning of Signature
27-Jul-2021 17:47 UTC Content Approval
27-Jul-2021 12:10 UTC Content Approval
27-Jul-2021 15:18 UTC Content Approval
Notes: (1) Document details as stored in ANGEL, an AstraZeneca document management system.
PPD
PPD
PPD